EX-99.1 2 d386634dex991.htm EX-99.1 EX-99.1

LOGO


Exhibit 99.1

The Company is a life insurance company established in Beijing, China on 30 June 2003 according to the Company Law and the Insurance Law of the People’s Republic of China. The Company was successfully listed on the New York Stock Exchange1, the Hong Kong Stock Exchange and the Shanghai Stock Exchange on 17 and 18 December 2003, and 9 January 2007, respectively. The Company’s registered capital is RMB28,264,705,000.

The Company is a leading life insurance company in China and possesses an extensive distribution network comprising exclusive agents, direct sales representatives, and dedicated and non-dedicated agencies. The Company is one of the largest institutional investors in China, and becomes one of the largest insurance asset management companies in China through its controlling shareholding in China Life Asset Management Company Limited. The Company also has controlling shareholding in China Life Pension Company Limited.

Our products and services include individual life insurance, group life insurance, and accident and health insurance. The Company is a leading provider of individual and group life insurance, annuity products and accident and health insurance in China. As at 30 June 2022, the Company had approximately 317 million long-term individual and group life insurance policies, annuity contracts, and long-term health insurance policies in force. We also provide both individual and group accident and short-term health insurance policies and services.

 

1 

The Company has filed a Form 25 with the United States Securities and Exchange Commission on 22 August 2022 to delist its American depositary shares from the New York Stock Exchange. After 1 September 2022, the American depositary shares of the Company will no longer be listed and traded on the New York Stock Exchange. For details, please refer to “Information on Delisting of American Depositary Shares” in the section headed “Significant Events” of this report.


LOGO


LOGO

 

2


FINANCIAL SUMMARY

MAJOR FINANCIAL DATA AND INDICATORS1

 

                   RMB million  
     As at 30 June
2022
     As at 31 December
2021
     Increase/Decrease from
the end of 2021
 

Total assets

     5,173,524        4,891,085        5.8

Including: Investment assets2

     4,977,082        4,716,401        5.5

Equity holders’ equity

     479,850        478,585        0.3

Equity per share3 (RMB per share)

     16.98        16.93        0.3

Gearing ratio4 (%)

     90.56        90.05       
An increase of 0.51
percentage point
 
 
     January to June
2022
     January to June
2021
     Increase/
Decrease from
the corresponding
period in 2021
 

Total revenues

     516,670        537,153        -3.8

Including: Net premiums earned

     419,636        422,642        -0.7

Profit before income tax

     24,991        46,095        -45.8

Net profit attributable to equity holders of the Company

     25,416        40,968        -38.0

Earnings per share (basic and diluted)3 (RMB per share)

     0.90        1.45        -38.0

Weighted average ROE (%)

     5.20        8.72       
A decrease of 3.52
percentage points
 
 

Net cash inflow/(outflow) from operating activities

     242,684        198,320        22.4

Net cash inflow/(outflow) from operating activities per share3 (RMB per share)

     8.59        7.02        22.4

 

Notes:

 

1.

The interim financial results of the Company are unaudited. The financial data of January to June 2021 for this report have been restated due to a business combination under the common control in 2021. For details, please refer to Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements in this report.

2.

Investment assets = Cash and cash equivalents + Securities at fair value through profit or loss + Available-for-sale securities + Held-to-maturity securities + Term deposits + Securities purchased under agreements to resell + Loans + Statutory deposits-restricted + Investment properties + Investments in associates and joint ventures

3.

In calculating the percentage changes of “Equity per share”, “Earnings per share (basic and diluted)” and “Net cash inflow/(outflow) from operating activities per share”, the tail differences of the basic figures have been taken into account.

4.

Gearing ratio = Total liabilities/Total assets

 

3


MAJOR ITEMS OF THE CONSOLIDATED FINANCIAL STATEMENTS AND THE REASONS FOR CHANGE

 

                         RMB million

Major Items of the

Consolidated Statement of

Financial Position

   As at
30 June
2022
     As at
31 December
2021
     Change    

Main Reasons for Change

Term deposits

     510,832        529,488        -3.5  

Held-to-maturity securities

     1,565,158        1,533,753        2.0  

Available-for-sale securities

     1,618,290        1,429,287        13.2   An increase in the allocation of equity assets in available-for-sale securities

Securities at fair value through profit or loss

     201,601        206,771        -2.5  

Securities purchased under agreements to resell

     44,943        12,915        248.0   The needs for liquidity management

Cash and cash equivalents

     94,127        60,440        55.7   The needs for liquidity management

Loans

     653,033        666,087        -2.0  

Investment properties

     13,144        13,374        -1.7  

Investments in associates and joint ventures

     269,621        257,953        4.5   New investments in associates and joint ventures and an increase in the equity of associates and joint ventures

Insurance contracts

     3,763,217        3,419,899        10.0   The accumulation of insurance liabilities from new policies and renewals

Investment contracts

     348,375        313,594        11.1   An increase in the scale of universal insurance accounts

Securities sold under agreements to repurchase

     175,450        239,446        -26.7   The needs for liquidity management

Annuity and other insurance balances payable

     60,339        56,818        6.2   An increase in maturities payable

Interest-bearing loans and other borrowingsNote

     18,965        18,686        1.5   The fluctuation of exchange rate

Equity holders’ equity

     479,850        478,585        0.3   Due to the combined impact of total comprehensive income and profit distribution during the Reporting Period

 

Note:

Interest-bearing loans and other borrowings included a three-year bank loan of EUR330 million with a maturity date on 8 September 2023, a five-year bank loan of GBP275 million with a maturity date on 25 June 2024, a five-year bank loan of USD860 million with a maturity date on 16 September 2024, a six-month bank loan of EUR127 million with a maturity date on 13 July 2022, which is automatically renewed upon maturity pursuant to the terms of the agreement, and a six-month bank loan of EUR78 million with a maturity date on 5 July 2022, which is automatically renewed upon maturity pursuant to the terms of the agreement. All of the above are fixed rate bank loans. Interest-bearing loans and other borrowings also included a five-year bank loan of USD970 million with a maturity date on 27 September 2024, and an eighteen-month bank loan of EUR100 million with a maturity date on 8 September 2023, both of which are floating rate bank loans.

 

4


                         RMB million

Major Items of the

Consolidated Statement of

Comprehensive Income

   January
to June
2022
     January
to June
2021
     Change    

Main Reasons for Change

Net premiums earned

     419,636        422,642        -0.7  

Life insurance business

     355,898        356,304        -0.1  

Health insurance business

     56,145        58,085        -3.3  

Accident insurance business

     7,593        8,253        -8.0   Due to the adjustment of business structure

Investment income

     91,196        82,046        11.2   An increase in interest income from debt-type investments

Net realised gains on financial assets

     6,662        22,571        -70.5   A decrease in spread income of stocks in available-for-sale securities

Net fair value gains through profit or loss

     (5,129      5,303        N/A     Due to the market value fluctuation of securities at fair value through profit or loss and investment operations

Net gains on investments of associates and joint ventures

     5,757        7,683        -25.1   A decrease in the profits of certain associates

Other income

     4,305        4,591        -6.2   A decrease in the management fee of pension products of the subsidiary

Insurance benefits and claims expenses

     415,698        408,540        1.8   An increase in the change of insurance contract liabilities

Investment contract benefits

     6,631        5,333        24.3   An increase in the scale of universal insurance accounts

Policyholder dividends resulting from participation in profits

     11,837        15,483        -23.5   A decrease in investment income from the participating accounts

Underwriting and policy acquisition costs

     35,305        42,132        -16.2   A decrease in the size of sales force and the adjustment of business structure

Finance costs

     2,610        2,193        19.0   An increase in interest paid for securities sold under agreements to repurchase

Administrative expenses

     18,052        18,142        -0.5  

Income tax

     (1,183      4,372        N/A     Due to the combined impact of income tax payable and deferred income tax

Net profit attributable to equity holders of the Company

     25,416        40,968        -38.0   A decrease in investment income due to the increasing volatilities in equity market

 

5


LOGO

 

2022 is an important year for China to embark on a new journey toward the second centennial goal of fully building a modern socialist country. Being committed to the new concept of development at a new stage, China Life made its contributions to the new development landscape and continued to pursue its high-quality development, aiming to stride forward on the journey of building a world-class life insurance company.

Looking back, the first half of 2022 witnessed complicated and challenging international environment, and multiple and sporadic outbreaks of the COVID-19 pandemic in China. The domestic economy faced greater difficulties and challenges with adverse impact of unexpected factors, and the life insurance industry was still at a stage of profound adjustments. China Life steadfastly pushed forward its development with Chinese characteristics, coordinated pandemic prevention and control as well as business

development in high efficiency, and calmly tackled different challenges, as a result of which the Company further enhanced its comprehensive strengths with its market leading position remaining solidified.

In the first half of 2022, we adhered to the due role of insurance in protection and properly steered our development direction. In pursuit of the original aspiration of “providing insurance for the people”, and adhering to the people-centered development philosophy and keeping the “National Priorities” in mind, we gave full play to the functions of insurance in economic compensation, financing, wealth management and social management, took initiatives to serve and stabilize the overall economy, made tremendous efforts to support pandemic prevention and control, and launched various preferential measures to assist enterprises in difficulty. We proactively played our leading role in the industry, and got deeply engaged in

 

 

6


building a multi-tiered social security system, with an aim to protect people’s good life. Our insurance programs for new urban residents were kicked off, the pilot programs of the exclusive pension insurance were promoted nationwide, and the coverage of inclusive insurance was continuously expanded. We insisted on the role of the financial industry in serving the real economy, gave full play to the advantages of the long-term and stable nature of insurance funds to serve major national strategies and to facilitate the circulation of domestic economy. As at the end of the Reporting Period, our investments in real economy reached RMB3.3 trillion and that in regional development strategy amounted to RMB2.2 trillion. We promoted dual carbon initiatives in all aspects, recording an increase of 31% in green investments year on year. In the meantime, we proactively pushed forward rural revitalization by carrying out a number of highly recognized assistance programs in relation to healthcare, industry development and consumption boosting.

In the first half of 2022, we upheld the guideline of making progress while maintaining stability and further solidified our market leading position. Despite multiple challenges brought by industry transformation as well as abrupt unforeseen factors, we firmly pursued the high-quality development, prioritized business value, and adopted various measures and policies, which further enhanced our ability in addressing uncertainties, and our overall business operations achieved steady progress with good momentum. In the first half of 2022, premiums from new policies rose by over 4% year on year, further stabilizing our business foundation, and both of our premium scale and business value continued to lead the industry, well demonstrating our role of the “cornerstone” in stabilizing the overall development of the industry. We further strengthened the asset-liability

coordination and interaction, consistently optimized our investment allocation, and strived to seize the medium- to long-term investment opportunities, thus realizing a gross investment yield of 4.21% amid the significant volatilities of the equity market. As at the end of the Reporting Period, our solvency ratios were at a relatively high level with the core capital and overall capital remaining highly adequate.

In the first half of 2022, we firmly advanced reforms and innovation to further enhance our driving forces for development. We proactively adapted to the new requirements in a new era, took active moves to resolve new issues and explore new business fields, consistently deepened supply-side structural reforms of the insurance industry, and accelerated the upgrade of our business model. With the promotion of digital transformation in greater depth, our capability in delivery of products and services continued to be enhanced. We proceeded further with the construction of the sales system, the sales deployment of “Yi Ti Duo Yuan” turned more sophisticated, and our sales force became more professional and specialized. Being customer-centric, we kept a close eye on the latest market demands, expanded the scope of insurance coverage and enriched the supply of insurance products and services centering on healthcare and elderly care, etc. We facilitated the deployment of “Inclusive Healthcare” and “Integrated Aged-care” initiatives, and accelerated the cultivation of the “insurance + services” model, so as to satisfy the needs of people for diversified protection in their full life span. Furthermore, we attached great importance to the protection of customers’ rights and interests and consistently built up our “convenient, quality and caring” service brand, with an aim to enhance service efficiency and quality.

 

 

7


In the first half of 2022, we firmly held on to the bottom line of risk prevention to further strengthen our capability in risk prevention and control. To coordinate development and security, we promoted the compliance culture, adhered to sound and prudent business operation, and reinforced the asset-liability management with a systematic concept and strengthened bottom-line thinking. In strict compliance with regulatory requirements, we actively implemented the C-ROSS (Phase II) Regulation, improved the risk management and control mechanism, optimized the enterprise-wide risk management system, and promoted the application of technologies, so that our risk control measures were further optimized and our risk prevention capability continued to be enhanced. In the integrated risk rating for insurance industry conducted by the CBIRC, we have maintained the rating of Class A for 16 consecutive quarters.

At present, there are increasing uncertainties for the domestic economy, the shrinking demand is intertwined with disrupted supply, structural contradictions overlap with cyclical problems, and the life insurance industry begins to stabilize as a whole. In the long run, with great advantages in national system and governance, and the long-term positive fundamentals of domestic economy remaining intact, our country has the most promising market in the world in terms of domestic demands and the obvious advantages of the massive market. Particularly, with the implementation of national strategies of proactively responding to population aging as well as Healthy China initiative in great depth, there will be a broader development space in sectors such as pension insurance and health insurance, etc., thus the long-term positive development foundation of the industry will remain unchanged, and the industry will still be at an important stage full of strategic opportunities.

Facing both opportunities and challenges, and shouldering profound responsibilities, we will set sail and forge ahead with firm determination. The life insurance industry is an indispensable and important pillar of the modern financial system and multi-tiered social security system. As a leader in the industry, China Life will focus on serving the overall interests of national development and maintain strategic consistency to push forward the implementation of the “14th Five-Year Plan”. By sticking to the original role of insurance and advancing reforms and innovation with steadfast efforts, we will take digital transformation as an important driving force and further leverage the advantages of synergy effects of integrated finance, so as to lead the industry in pursuing the high-quality development.

By Order of the Board

 

LOGO

Bai Tao

Chairman

25 August 2022

 

 

8


MANAGEMENT DISCUSSION AND ANALYSIS

The Company prioritized stability while pursuing progress, adhered to the original function of insurance, constantly deepened supply-side reforms, and coordinated the pandemic control and high-quality development. As a result, its overall business operations registered a steady performance with sound momentum, its business scale and value continued to lead the industry, the quality and efficiency of its operations and services were consistently improved, and its comprehensive strengths were steadily enhanced with its leading position in the industry further solidified.

 

LOGO

 

9


REVIEW OF BUSINESS OPERATIONS IN THE FIRST HALF OF 2022

In the first half of 2022, facing the increasingly complicated and challenging international environment, as well as multiple and sporadic outbreaks of the COVID-19 pandemic in China, the domestic economy was under new and growing downward pressure. The growth of insurance premiums further slowed down due to the profound adjustments in the life insurance industry, the decelerated release of insurance demands and a decline of sales force. During the Reporting Period, despite exceptionally complicated and difficult circumstances, the Company prioritized stability while pursuing progress, adhered to the original function of insurance, constantly deepened supply-side reforms, and coordinated the pandemic control and high-quality development. As a result, its overall business operations registered a steady performance with sound momentum, its business scale and value continued to lead the industry, the quality and efficiency of its operations and services were consistently improved, and its comprehensive strengths were steadily enhanced with its leading position in the industry further solidified.

The Company continued to deepen reforms and innovation and promoted transformation and upgrade in key areas, injecting new driving forces for its high-quality development. The individual agent business sector consistently pushed forward the transformation of sales force to be high-quality, professional and efficient by focusing on its quality improvement. The diversified business sector consistently optimized its business mode, with its capability in specialized business operations continuing to increase. For the investment sector, the achievements of market-oriented reforms were continuously consolidated. Adhering to the top-level allocation strategy, the Company further improved the structure of asset allocation, and the long-term investment deployment was optimized. The technology sector facilitated the integration of internal and external data and digital collaboration, and fully enhanced its capability in digital connectivity within and outside the Company by deepening the construction of its digital platform. The operation sector innovatively promoted the implementation of a nationwide integrated model of intelligent centralization and sharing for business operations, consistently reinforced the protection of consumers’ rights and interests, built up its service brand, and further enhanced service efficiency and customer experience, with a view to providing customers with “convenient, quality and caring” operations and services.

 

 

Key Performance Indicators for the First Half of 2022

 

            RMB million  
     January to June
2022
     January to June
2021
 

Gross written premiums

     439,969        442,299  

Premiums from new policies

     139,358        133,914  

Including: First-year regular premiums

     79,838        80,674  

First-year regular premiums with a payment duration of ten years or longer

     30,226        28,940  

Renewal premiums

     300,611        308,385  

Gross investment income

     98,542        117,638  

Net profit attributable to equity holders of the Company

     25,416        40,968  

Value of half year’s sales

     25,745        29,867  

Including: Individual agent business sector

     24,185        28,969  

Policy Persistency Rate (14 months)1 (%)

     85.10        81.20  

Policy Persistency Rate (26 months)1 (%)

     76.50        81.60  

Surrender Rate2 (%)

     0.51        0.67  
     As at 30 June
2022
     As at 31 December
2021
 

Embedded value

     1,250,877        1,203,008  

Number of long-term in-force policies (hundred million)

     3.17        3.23  

 

 

Notes:

 

  1.

The Persistency Rate for long-term individual life insurance policy is an important operating performance indicator for life insurance companies. It measures the ratio of in-force policies in a pool of policies after a certain period of time. It refers to the proportion of policies that are still effective during the designated month in the pool of policies whose issue date was 14 or 26 months ago.

  2.

Surrender Rate = Surrender payment/(Liability of long-term insurance contracts at the beginning of the period + Premiums of long-term insurance contracts)

 

10


LOGO

LOGO

 

 

In the first half of 2022, the industry entered into a stage of profound adjustments. The Company prioritized business value and demonstrated greater resilience in its business development, with its business scale and value continuing to lead the market. During the Reporting Period, the Company’s gross written premiums amounted to RMB439,969 million, generally remaining stable as compared to the corresponding period last year, and its industry leadership was further enhanced. The Company’s business value continued to take the lead in the industry. Particularly, as at the end of the Reporting Period, the embedded value of the Company reached RMB1,250,877 million, an increase of 4.0% from the end of 2021; in the first half of 2022, the value of half year’s sales was RMB25,745 million, a decrease of 13.8% year on year. The key performance indicators of the Company saw stable progress. Premiums from new policies were RMB139,358 million, an increase of 4.1% year on year. The first-year regular premiums were RMB79,838 million, a decrease of 1.0% year on year. In particular, first-year regular premiums with a payment duration of ten years or longer were RMB30,226 million, an increase of 4.4% year on year. Due to the impact of maturity of premium payment

terms of certain insurance products, renewal premiums were RMB300,611 million, a decrease of 2.5% year on year. During the Reporting Period, the surrender rate was 0.51%, a decrease of 0.16 percentage point year on year.

As at the end of the Reporting Period, the total assets of the Company surpassed RMB5 trillion to RMB5,173,524 million, increasing by 5.8% from the end of 2021. Adhering to its strategic consistency and with an emphasis on the asset-liability interaction, the Company consistently implemented its medium- to long-term strategic plan of asset allocation, continued to optimize its allocation to core investment assets, and actively seized the long-term allocation opportunities during the equity market corrections. Due to the impact of the short-term volatilities in equity market, the Company registered a gross investment income of RMB98,542 million, a decrease of 16.2% year on year, and the gross investment yield was 4.21%, down by 148 basis points from the corresponding period of 2021. Net profit attributable to equity holders of the Company was RMB25,416 million, a decrease of 38.0% year on year.

 

 

11


BUSINESS ANALYSIS

Figures of Gross Written Premiums

Gross Written Premiums Categorized by Business

 

                   RMB million  
     January to June
2022
     January to June
2021
     Change  

Life Insurance Business

     356,528        356,897        -0.1

First-year business

     83,519        74,339        12.3

First-year regular

     76,874        73,471        4.6

Single

     6,645        868        665.6

Renewal business

     273,009        282,558        -3.4

Health Insurance Business

     75,284        76,372        -1.4

First-year business

     47,954        50,829        -5.7

First-year regular

     2,961        7,198        -58.9

Single

     44,993        43,631        3.1

Renewal business

     27,330        25,543        7.0

Accident Insurance Business

     8,157        9,030        -9.7

First-year business

     7,885        8,746        -9.8

First-year regular

     3        5        -40.0

Single

     7,882        8,741        -9.8

Renewal business

     272        284        -4.2
  

 

 

    

 

 

    

 

 

 

Total

     439,969        442,299        -0.5
  

 

 

    

 

 

    

 

 

 

 

  Note:

  Single premiums in the above table included premiums from short-term insurance business.

During the Reporting Period, gross written premiums from the life insurance business of the Company were RMB356,528 million, a year-on-year decrease of 0.1%. Gross written premiums from the health insurance business were RMB75,284 million, a year-on-year decrease of 1.4%. Gross written premiums from the accident insurance business were RMB8,157 million, a year-on-year decrease of 9.7%.

 

12


Gross Written Premiums Categorized by Channel

 

            RMB million  
     January to June
2022
     January to
June 2021
 

Individual Agent Business Sector1

     352,487        363,822  

First-year business of long-term insurance

     69,042        68,755  

First-year regular

     68,957        68,648  

Single

     85        107  

Renewal business

     274,016        285,006  

Short-term insurance business

     9,429        10,061  

Bancassurance Channel

     42,609        34,441  

First-year business of long-term insurance

     16,709        11,996  

First-year regular

     10,864        11,993  

Single

     5,845        3  

Renewal business

     25,707        22,261  

Short-term insurance business

     193        184  

Group Insurance Channel

     16,759        16,690  

First-year business of long-term insurance

     732        799  

First-year regular

     16        33  

Single

     716        766  

Renewal business

     862        1,070  

Short-term insurance business

     15,165        14,821  

Other Channels2

     28,114        27,346  

First-year business of long-term insurance

     8        16  

First-year regular

     1        –    

Single

     7        16  

Renewal business

     26        48  

Short-term insurance business

     28,080        27,282  
  

 

 

    

 

 

 

Total

     439,969        442,299  
  

 

 

    

 

 

 

 

Notes:

 

  1.

Premiums of individual agent business sector included premiums of the general sales team and the upsales team.

  2.

Premiums of other channels mainly included premiums of government-sponsored health insurance business and online sales, etc.

 

Insurance Business

Analysis of Insurance Business

In the first half of 2022, there were severe complexities and uncertainties for the development of the industry, which posed greater challenges to the development of the Company’s insurance business. The Company kept a close eye on the change of the market demands, maintained strategic consistency, and adjusted its development tactics in a timely manner. It focused on the basic operational units, strived to consolidate its foundation through specialized operation, standardized management, market-oriented mechanism and technological support, and unswervingly pursued the high-quality development of its businesses, thereby solidifying its market leading advantages further. As at the end of the Reporting Period, the number of total sales force of the Company was 810,000.

Individual Agent Business Sector

The individual agent business sector strived to make progress while maintaining stability, consistently deepened business restructuring, and saw stable progress of business development. During the Reporting Period, gross written premiums from the sector were RMB352,487 million, a decrease of 3.1% year on year. Renewal premiums amounted to RMB274,016 million, a decrease of 3.9% year on year. First-year regular premiums were RMB68,957 million, an increase of 0.5% year on year. In particular, first-year regular premiums with a payment duration of ten years or longer were RMB30,212 million, an increase of 4.7% year on year, and its proportion in the first-year regular premiums rose by 1.76 percentage points year on year. In the first half of 2022, the value of half year’s sales of the sector was RMB24,185 million, a decrease of 16.5% year on year, and new business margin by annual premium equivalent was 30.4%, a decrease of 6.1 percentage points year on year.

 

 

13


During the Reporting Period, the Company continued to drive business through productive agents, upheld the sales force strategy of “stabilizing headcount while seeking for higher productivity”, and the size of its sales force was generally stabilized with enhanced quality. As at the end of the Reporting Period, the number of agents of the sector was 746,000, including 476,000 agents from the general sales team and 270,000 agents from the upsales team, and the proportion of the number of high-performance agents remained stable. In the first half of 2022, the individual agent business sector actively responded to multiple challenges from the regular pandemic prevention and control as well as the change of the market environment, focused on the basic operational units and adopted various measures to stimulate the vitality of its sales teams. The Company rolled out the “Zhongxin Project” specifically for building up a specialized and professional agent team. It also upgraded its fundamental agent force management rule, focusing on newly recruited agents, agent managers and high-performance agents, and further enhanced its business quality management. Meanwhile, the Company pushed forward technology-empowered sales and team management in great depth. Through the digital platforms such as “China Life e-learning” and intelligent training system, the Company strengthened online training and risk compliance education to revitalize its sales teams in an orderly manner, with a view to pushing forward their high-quality development.

Diversified Business Sector

By concentrating on specialized operation, quality and efficiency enhancement, as well as transformation and

innovation, the diversified business sector coordinated well with the individual agent business sector and actively developed the bancassurance business, group insurance, and health insurance businesses. The bancassurance channel further promoted and implemented its business mode transformation and the operation modes of group insurance and health insurance were optimized for steady advancement.

Bancassurance Channel The bancassurance channel actively deepened its cooperation with banks, steadily enhanced its business scale and value, and gradually strengthened its capability of sustainable development. During the Reporting Period, gross written premiums from the channel amounted to RMB42,609 million, an increase of 23.7% year on year. First-year regular premiums were RMB10,864 million, a decrease of 9.4% year on year. In particular, first-year regular premiums with a payment duration of five years or longer were RMB3,511 million. Renewal premiums amounted to RMB25,707 million (a year-on-year increase of 15.5%), accounting for 60.33% of gross written premiums from the channel. The bancassurance channel constantly enhanced the professional and technological capability of its account manager team, the quality of which was steadily improved. As at the end of the Reporting Period, the number of account managers of the bancassurance channel was 23,000, the quarterly average active managers remained stable, and the productivity per manager increased continuously.

 

 

LOGO

LOGO

 

 

14


Group Insurance Channel With high-quality development as the guiding principle, the group insurance channel coordinated business scale and profitability and pushed forward stable development in all business lines. During the Reporting Period, gross written premiums from the channel were RMB16,759 million, an increase of 0.4% year on year. Short-term insurance premiums from the channel were RMB15,165 million, an increase of 2.3% year on year. As at the end of the Reporting Period, the number of direct sales representatives was 41,000, in which the proportion of high-performance personnel rose by 6 percentage points from the end of 2021.

 

LOGO

Other Channels In the first half of 2022, gross written premiums from other channels were RMB28,114 million, an increase of 2.8% year on year. The Company proactively participated in a variety of government-sponsored health insurance businesses. As at the end of the Reporting Period, the Company carried out over 200 supplementary major medical expenses insurance programs, covering nearly 350 million people. It also undertook over 300 health care entrusted programs, providing services to more than 100 million people; over 60 long-term care insurance programs in 17 provinces and cities, covering nearly 26 million people; and more than 170 supplementary medical insurance programs in 26 provinces and

cities, covering over 58 million people. The Company actively participated in the construction of a multi-tiered social security system and implemented nearly 70 city-customized commercial medical insurance projects in 21 provinces and cities accumulatively, covering more than 18 million people.

In recent years, the Company has greatly developed the online insurance business and provided customers with quality service experience through online-to-offline sales and online direct sales. During the Reporting Period, the Company’s online insurance business grew rapidly. Total premiums2 under the CBIRC caliber were RMB38,872 million, an increase of 121.5% year on year, reaching a new record high. By adhering to the objective of “enhancing and optimizing the OTO business, actively expanding the public domain traffic business, and achieving a breakthrough in exclusive online insurance business”, the Company consistently optimized its online organization and business system featuring centralized operation and unified management, and offered a variety of products that were tailored for different scenarios and customers. Going forward, the Company will take active actions to develop online exclusive life insurance business, with a view to providing customers with more convenient online insurance services.

 

 

2 

Including premiums from online insurance business acquired by different sales channels of the Company.

 

15


Integrated Financial Sector

Being customer-centric, the Company fully leveraged the resource advantages of the fellow members of CLIC and actively engaged in the construction of a “Life Insurance plus” integrated financial ecosystem, turning the integrated financial advantages into a driving force for the high-quality development of the Company. In the first half of 2022, premiums of CLP&C cross-sold by the Company were RMB11,058 million, with the number of insurance policies increasing by 18.8% year on year. Through the cross-sale of property insurance products, the Company diversified its client base and facilitated its sales team to meet sales targets, maintain its size and secure a higher commission income. Additional first-year receipts of enterprise annuity funds and pension products of Pension Company cross-sold by the Company through collaboration were RMB11,078 million. The Company entrusted CGB to sell its bancassurance products, with the first-year regular premiums recording a relatively stable growth. Meanwhile, in order to satisfy the diverse needs of its customers, the Company worked with CGB and CLP&C to carry out various operation activities to provide customers with a series of quality financial and insurance service solutions.

By integrating online and offline as well as internal and external healthcare resources, the Company improved its health management and service capabilities and actively participated in Healthy China initiative. China Life Inclusive Healthcare Service Platform continued to diversify its services while upgrading its system functions. As at the end of the Reporting Period, more than a hundred types of services were available on the platform, and the accumulated registered users of the platform rose by over 13% from the end of 2021, remaining the leadership of the industry. The Company implemented the national strategy of proactively responding to population aging, continued to establish the China Life elderly care system, fully leveraged the advantage of the long-term nature of insurance funds, and deployed towards multi-level elderly care services such as residential elderly care services and community-based elderly care services through the China Life Integrated Aged Care Fund. In the first half of 2022, the China Life Integrated Aged Care Fund accelerated the consolidation of health resources and continued to proceed with pension and retirement projects in strategic regions such as Beijing-Tianjin-Hebei, the Yangtze River Economic Belt, and the Guangdong-Hong Kong-Macao Greater Bay Area.

Analysis of Insurance Products

Playing an important role in serving national strategies of Healthy China initiative and proactively responding to population aging, the Company adhered to the customer-centric product development concept, vigorously enhanced its capability in product innovation, and consistently improved its diversified product supply system. In the first half of 2022, for the purpose of serving the strategy of Healthy China initiative, the Company strengthened innovation in insurance liabilities with respect to diseases, medical health and care, and launched several series of critical illness insurance products and medical insurance products, to provide better health protection for customers with diversified demands. It introduced exclusive accident protection products for flexible employees and new urban residents to increase the accessibility and convenience of insurance services to flexible employment groups. The Company also took active actions to serve the national strategy of proactively responding to population aging, diversified the series of insurance products for the seniors, and took an initiative to launch the insurance products tailored to the seniors. It actively engaged in the development of the third-pillar pension insurance and initiated nationwide promotion of the exclusive pension products.

In the first half of 2022, the Company newly developed and upgraded a total of 42 products, including two life insurance products, ten health insurance products, 29 accident insurance products, and one annuity insurance product. Out of these products, 39 were protection-oriented insurance products, and three were long-term savings insurance products.

 

 

16


Insurance Contracts

 

                   RMB million  
     As at 30
June 2022
     As at 31
December 2021
     Change  

Life insurance

     3,487,177        3,180,931        9.6

Health insurance

     266,090        228,899        16.2

Accident insurance

     9,950        10,069        -1.2
  

 

 

    

 

 

    

 

 

 

Total of insurance contracts

     3,763,217        3,419,899        10.0
  

 

 

    

 

 

    

 

 

 

Including: Residual marginNote

     834,995        835,400        -0.1

 

Note:

The residual margin is a component of insurance contract reserve, which results in no Day 1 gain at the initial recognition of an insurance contract. The residual margin is set to zero if it is negative.

 

As at the end of the Reporting Period, the reserves of insurance contracts of the Company were RMB3,763,217 million, up by 10.0% from RMB3,419,899 million as at the end of 2021, primarily due to the accumulation of insurance

liabilities from new policies and renewals. As at the date of the statement of financial position, the reserves of various insurance contracts of the Company passed the liability adequacy test.

 

 

Analysis of Claims and Policyholder Benefits

 

                   RMB million  
     January to
June 2022
     January to
June 2021
     Change  

Insurance benefits and claims expenses

     415,698        408,540        1.8

Life insurance business

     369,167        361,737        2.1

Health insurance business

     44,318        42,972        3.1

Accident insurance business

     2,213        3,831        -42.2

Investment contract benefits

     6,631        5,333        24.3

Policyholder dividends resulting from participation in profits

     11,837        15,483        -23.5

 

During the Reporting Period, insurance benefits and claims expenses rose by 1.8% year on year due to an increase in the change of insurance contract liabilities. In particular, insurance benefits and claims expenses of life insurance business rose by 2.1% year on year. Insurance benefits and claims expenses of health insurance business rose by 3.1% year on year. Insurance benefits and claims expenses

of accident insurance business declined by 42.2% year on year. Investment contract benefits rose by 24.3% year on year due to an increase in the scale of universal insurance accounts. Policyholder dividends resulting from participation in profits declined by 23.5% year on year due to a decrease in investment income from the participating accounts.

 

 

17


Analysis of Underwriting and Policy Acquisition Costs and Other Expenses

 

                   RMB million  
     January to
June 2022
     January to
June 2021
     Change  

Underwriting and policy acquisition costs

     35,305        42,132        -16.2

Finance costs

     2,610        2,193        19.0

Administrative expenses

     18,052        18,142        -0.5

Other expenses

     6,429        6,057        6.1

Statutory insurance fund contribution

     874        861        1.5

 

During the Reporting Period, underwriting and policy acquisition costs declined by 16.2% year on year due to a decrease in the size of sales force and the adjustment of business structure. Finance costs rose by 19.0% year on year due to an increase in interest paid for securities sold under agreements to repurchase. Administrative expenses declined by 0.5% year on year.

Investment Business

In the first half of 2022, domestic bond yields were at historic lows and the interest rate pivot fell remarkably from 2021, which created a mounting pressure on the allocation of fixed-income assets. Due to the effects of various factors such as the Russia-Ukraine conflict, accelerated tightening of monetary policy by the Federal Reserve and the prevalence of the pandemic in China, the A-share market plummeted rapidly and such decrease was subsequently narrowed after the easing of the pandemic and the gradual rollout of domestic policies for stabilization of growth. The dramatic change of market situation posed greater challenges to investment management. In this circumstance, the Company

adhered to its strategic consistency, firmly served the major national strategies and supported real economy, and consistently implemented its medium- to long-term strategic plan of asset allocation. It seized opportunities for making allocations, and adopted multiple measures concurrently to stabilize investment income. Firstly, the Company continued to optimize its allocation to core investment assets and flexibly adjusted allocation and the type of fixed-income assets in response to the fluctuations in interest rates and the supply of assets, with a view to stabilizing coupon income and asset durations. Secondly, the Company seized the long-term allocation opportunities during the equity market corrections and invested prudently, adjusting equity positions towards neutral weight. Thirdly, the Company strengthened the innovation in alternative investment models for the establishment and optimization of pyramid-shaped alternative investment portfolios with non-standard debt-type products as the foundation, supplemented by equity investment plans and equity investment funds, with an aim to stabilize the long-term expected returns of investment portfolios.

 

 

18


Investment Portfolios

As at the end of the Reporting Period, the Company’s investment assets categorized by investment object are set out as below:

 

                  RMB million  

Investment category

   As at 30 June 2022     As at 31 December 2021  
   Amount      Percentage     Amount      Percentage  

Fixed-maturity financial assets

     3,698,665        74.32     3,672,262        77.86

Term deposits

     510,832        10.26     529,488        11.23

Bonds

     2,339,610        47.02     2,273,425        48.20

Debt-type financial products1

     442,638        8.89     443,784        9.41

Other fixed-maturity investments 2

     405,585        8.15     425,565        9.02

Equity financial assets

     856,582        17.21     699,457        14.83

Common stocks

     433,203        8.71     302,090        6.41

Funds3

     126,044        2.53     112,689        2.39

Other equity investments4

     297,335        5.97     284,678        6.03

Investment properties

     13,144        0.26     13,374        0.28

Cash and others5

     139,070        2.79     73,355        1.56

Investments in associates and joint ventures

     269,621        5.42     257,953        5.47
  

 

 

    

 

 

   

 

 

    

 

 

 

Total

     4,977,082        100.00     4,716,401        100.00
  

 

 

    

 

 

   

 

 

    

 

 

 

 

Notes:

 

1.

Debt-type financial products included debt investment schemes, trust schemes, project asset-backed plans, credit asset-backed securities, specialized asset management plans, and asset management products, etc.

2.

Other fixed-maturity investments included policy loans, statutory deposits-restricted, and interbank certificates of deposits, etc.

3.

Funds included equity funds, bond funds and money market funds, etc. In particular, the balances of money market funds as at 30 June 2022 and 31 December 2021 were RMB3,274 million and RMB1,961 million, respectively.

4.

Other equity investments included private equity funds, unlisted equities, preference shares and equity investment plans, etc.

5.

Cash and others included cash, cash at banks, short-term deposits, and securities purchased under agreements to resell, etc.

 

As at the end of the Reporting Period, the Company’s investment assets reached RMB4,977,082 million, an increase of 5.5% from the end of 2021. Among the major types of investments, the percentage of investment in bonds changed to 47.02% from 48.20% as at the end of 2021, the percentage of term deposits changed to 10.26% from

11.23% as at the end of 2021, the percentage of investment in debt-type financial products changed to 8.89% from 9.41% as at the end of 2021, and the percentage of investment in stocks and funds (excluding money market funds) increased to 11.17% from 8.75% as at the end of 2021.

 

 

19


Investment Income

 

     RMB million  
     January to
June 2022
    January to
June 2021
 

Gross investment income

     98,542       117,638  

Net investment income

     97,009       89,764  

Net income from fixed-maturity investments

     77,278       70,928  

Net income from equity investments

     13,028       10,512  

Net income from investment properties

     56       35  

Investment income from cash and others

     890       606  

Share of profit of associates and joint ventures

     5,757       7,683  

Net realised gains on financial assets

     6,662       22,571  

Net fair value gains through profit or loss

     (5,129     5,303  

Disposal gains and impairment losses of associates and joint ventures

     –         –    

Net investment yield1

     4.15     4.33

Gross investment yield2

     4.21     5.69

 

Notes:

 

1.

Net investment yield = (Net investment income – Interest paid for securities sold under agreements to repurchase)/((Investment assets at the end of the previous year – Securities sold under agreements to repurchase at the end of the previous year + Investment assets at the end of the period – Securities sold under agreements to repurchase at the end of the period)/2)/181×365

2.

Gross investment yield = (Gross investment income – Interest paid for securities sold under agreements to repurchase)/((Investment assets at the end of the previous year – Securities sold under agreements to repurchase at the end of the previous year + Investment assets at the end of the period – Securities sold under agreements to repurchase at the end of the period)/2)/181×365

 

In the first half of 2022, the Company’s net investment income was RMB97,009 million, rising by 8.1% year on year, an increase of RMB7,245 million from the corresponding period of 2021. Affected by the decline in interest rate, the Company recorded the net investment yield of 4.15% in the first half of 2022, down by 18 basis points from the corresponding period of 2021. Due to the effects of volatilities in equity market and a year-on-year decrease in spread income from equity investment products, the gross investment income of the Company were RMB98,542 million in the first half of 2022, down by 16.2% year on year, a decrease of RMB19,096 million from the corresponding period of 2021. Gross investment yield was 4.21%, down by 148 basis points from the corresponding period of 2021. The comprehensive investment yield3 taking into account the current net fair value changes of available-for-sale securities recognized in other comprehensive income was 3.75%, down by 186 basis points from the corresponding period of 2021.

Credit Risk Management

The Company’s credit asset investments mainly included credit bonds and debt-type financial products, which concentrated on sectors such as banking, transportation, non-banking finance, public utilities, and energy, and the financing entities were primarily large central-owned enterprises and state-owned enterprises. As at the end of

the Reporting Period, over 97% of the credit bonds and over 99% of the debt-type financial products held by the Company were rated AAA by external rating institutions. In general, the asset quality of the Company’s credit investment products was in good condition, and the credit risks were well controlled.

The Company insisted on a prudent investment philosophy and carried out comprehensive risk management to prevent various investment risks. Based on a disciplined and scientific internal rating system and a multi-dimensional management mechanism of risk limits, the Company scrutinized credit profiles of targets and risk exposure concentration before investment in a prudent manner and carried out ongoing tracking after investment, effectively managing the credit risks through early identification, early warning, and early disposal. Under a market environment where credit default events occurred frequently, no credit default event occurred for the Company in the first half of 2022.

Major Investments

During the Reporting Period, there was no material equity investment or non-equity investment of the Company that was subject to disclosure requirements.

 

 

 

 

3 

Comprehensive investment yield = (Gross investment income – Interest paid for securities sold under agreements to repurchase + Current net fair value changes of available-for-sale securities recognized in other comprehensive income)/((Investment assets at the end of the previous year – Securities sold under agreements to repurchase at the end of the previous year + Investment assets at the end of the period – Securities sold under agreements to repurchase at the end of the period)/2)/181×365

 

20


ANALYSIS OF SPECIFIC ITEMS

Profit before Income Tax

 

                   RMB million  
     January to
June 2022
     January to
June 2021
     Change  

Profit before income tax

     24,991        46,095        -45.8

Life insurance business

     9,376        26,605        -64.8

Health insurance business

     6,127        6,057        1.2

Accident insurance business

     1,939        890        117.9

Other businesses

     7,549        12,543        -39.8

 

During the Reporting Period, profit before income tax from the life insurance business decreased by 64.8% year on year due to a decrease in investment income affected by significant volatilities in equity market. Profit before income tax from the health insurance business rose by 1.2% year on year, generally remained stable year on year. Profit before income tax from the accident insurance business rose by 117.9% year on year due to business quality improvement. Profit before income tax from other businesses decreased by 39.8% year on year due to a decrease in the profits of certain associates.

Analysis of Cash Flows

Liquidity Sources

The Company’s cash inflows mainly come from insurance premiums, income from non-insurance contracts, interest income, dividend and bonus, and proceeds from sale and maturity of investment assets. The primary liquidity risks with respect to these cash inflows are the risk of surrender by contract holders and policyholders, as well as the risks of default by debtors, interest rate fluctuations and other market volatilities. The Company closely monitors and manages these risks.

The Company’s cash and bank deposits can provide it with a source of liquidity to meet normal cash outflows. As at the end of the Reporting Period, the balance of cash and cash equivalents was RMB94,127 million. In addition, the vast majority of its term deposits in banks allow it to withdraw funds on deposits, subject to a penalty interest charge. As at the end of the Reporting Period, the amount of term deposits was RMB510,832 million.

The Company’s investment portfolio also provides it with a source of liquidity to meet unexpected cash outflows. The Company is also subject to market liquidity risk due to the large size of its investments in some of the markets in which it invests. In some circumstances, some of its holdings of investment securities may be large enough to have an influence on the market value. These factors may adversely affect its ability to sell these investments or sell them at a fair price.

Liquidity Uses

The Company’s principal cash outflows primarily relate to the payables for the liabilities associated with its various life insurance, annuity, accident insurance and health insurance products, operating expenses, income taxes and dividends that may be declared and paid to its equity holders. Cash outflows arising from the Company’s insurance activities primarily relate to benefit payments under these insurance products, as well as payments for policy surrenders, withdrawals and policy loans.

The Company believes that its sources of liquidity are sufficient to meet its current cash requirements.

 

 

21


Consolidated Cash Flows

The Company has established a cash flow testing system, and conducts regular tests to monitor the cash inflows and outflows under various scenarios and adjusts the asset portfolio accordingly to ensure sufficient sources of liquidity.

 

                         RMB million
     January
to June
2022
     January
to June
2021
     Change    

Main Reasons for Change

Net cash inflow/(outflow) from operating activities

     242,684        198,320        22.4   An increase in the scale of investment contracts

Net cash inflow/(outflow) from investing activities

     (136,691      (226,724      -39.7   The needs for investment management

Net cash inflow/(outflow) from financing activities

     (72,511      53,584        N/A     The needs for liquidity management

Foreign exchange gains/(losses) on cash and cash equivalents

     205        (38      N/A    

Net increase in cash and cash equivalents

     33,687        25,142        34.0  

 

Solvency Ratio

An insurance company shall have the capital commensurate with its risks and business scale. According to the nature and capacity of loss absorption by capital, the capital of an insurance company is classified into the core capital and the supplementary capital. The core solvency ratio is the

ratio of core capital to minimum capital, which reflects the adequacy of the core capital of an insurance company. The comprehensive solvency ratio is the ratio of the sum of core capital and supplementary capital to minimum capital, which reflects the overall capital adequacy of an insurance company. The following table shows the Company’s solvency ratios as at the end of the Reporting Period:

 

 

     RMB million  
     As at 30
June 2022
(unaudited)
    As at 31
March 2022
(unaudited)
 

Core capital

     798,141       769,197  

Actual capital

     1,112,129       1,079,754  

Minimum capital

     472,120       436,083  

Core solvency ratio

     169.05     176.39

Comprehensive solvency ratio

     235.56     247.60

 

Pursuant to the requirements of the CBIRC, the Company started to implement the “Solvency Regulatory Rules II for Insurance Companies” from the solvency quarterly report for the first quarter of 2022. As at the end of the Reporting Period, the comprehensive solvency ratio and the core solvency ratio of the Company were 235.56% and 169.05%, respectively. Due to the impacts of various factors such as the continuous growth of investment assets, decline of

discount rate in solvency reserve and dividends payment, the solvency ratios slightly decreased from the end of the first quarter of 2022, continuing to stay relatively high.

Sale of Material Assets and Equity

During the Reporting Period, there was no sale of material assets and equity of the Company.

 

 

22


Major Subsidiaries and Associates of the Company

 

                                    RMB million

Company Name

  

Major Business Scope

   Registered
Capital
    

Shareholding

   Total Assets      Net Assets     

Net Profit

China Life Asset Management Company Limited

   Management and utilization of proprietary funds; acting as agent or trustee for asset management business; consulting business relevant to the above businesses; other asset management business permitted by applicable PRC laws and regulations      4,000    60%      17,549        14,661      1,433

China Life Pension Company Limited

   Group pension insurance and annuity; individual pension insurance and annuity; short-term health insurance; accident insurance; reinsurance of the above insurance businesses; business for the use of insurance funds that are permitted by applicable PRC laws and regulations; pension insurance asset management product business; management of funds in RMB or foreign currency as entrusted by entrusting parties for the retirement benefit purpose; other businesses permitted by the CBIRC      3,400     

70.74% is held by the Company,

and 3.53% is

held by AMC

     8,804        6,136      607

China Life Property and Casualty Insurance Company Limited

   Property loss insurance; liability insurance; credit insurance and bond insurance; short-term health insurance and accident insurance; reinsurance of the above insurance businesses; business for the use of insurance funds that are permitted by applicable PRC laws and regulations; other businesses permitted by the CBIRC      18,800      40%      130,013        26,197      1,177

China Guangfa Bank Co., Ltd.

   Taking public deposits; granting short-term, mid-term and long-term loans; handling settlements in and out of China; honoring bills and offering discounting services; issuing financial bonds; issuing, paying for and underwriting government bonds as an agent; sales and purchases of negotiable securities such as government bonds and financial bonds; engaging in inter-bank borrowings; providing letters of credit service and guarantee; engaging in bank card business; acting as payment and receipt agent and insurance agent; providing safe deposit box services; taking deposits and granting loans in foreign currency; foreign currency remittance; foreign currency exchange; international settlements; foreign exchange settlements and sales; inter-bank foreign currency borrowings; honoring bills of exchange and offering discounting services in foreign currency; granting foreign currency loans; granting foreign currency guarantees; sales and purchases of negotiable securities other than shares in a foreign currency for itself and as an agent; issuing negotiable securities other than shares in a foreign currency for itself and as an agent; sales and purchases of foreign exchange on its own account and on behalf of its customers; issuing and making payments for foreign credit card as an agent; offshore financial operations; assets and credit verification, consultation and notarization businesses; other businesses approved by the CBIRC and other relevant authorities      21,790      43.686%      3,388,627        259,966      9,316

 

Note:     For details, please refer to Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements in this report.

Structured Entities Controlled by the Company

The details of structured entities controlled by the Company are set out in Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements in this report.

Changes in Accounting Estimates

The changes in accounting estimates of the Company during the Reporting Period are set out in Note 3 in the Notes to the Interim Condensed Consolidated Financial Statements in this report.

Analysis of Core Competitiveness

During the Reporting Period, there was no material change in the Company’s core competitiveness.

 

23


TECHNOLOGY EMPOWERMENT, OPERATIONS AND SERVICES, RISK CONTROL AND MANAGEMENT

Technology Empowerment

In the first half of 2022, the Company further proceeded with digital transformation, accelerated technological innovation, applied digital technologies in all aspects to empower value creation, deepened the integration of technologies with business operations, and facilitated its high-quality development by digital driving force.

Technological innovation was pushed forward to a new level. With a new proprietary distributed open cloud architecture as the foundation for the digital transformation and development of the Company, the storage utilization efficiency was tripled with lower costs, making remarkable achievements in green and low-carbon emissions. It has also been leading the industry for two consecutive years in terms of innovation in the IT applications, and continued to be the market leader in the innovative development of InsurTech field.

Intelligent application was deepened with further expansion. The Company made breakthroughs in human-machine collaboration by building an AI-powered “Digital Workforce”. Various intelligent robots, such as “smart consultants”, “intelligent underwriting” and “intelligent customer service”, were developed by the Company, offering self-service responses of over 200,000 times per day. Big data services were expanded on an ongoing basis, and big data empowerment scenarios grew by nearly 94% from the same period last year, which consistently enriched the intelligent insurance-related scenarios.

Digital connectivity was open and extended. With support of the digital platform and being driven by diversified scenarios, the Company further enhanced its coordination capability, fostering efficient collaboration within the Company and establishing an internet-based social ecosystem externally, and released 3,498 services cumulatively and connected to 1,092 ecological applications of various types, which widely extended to both online and offline operations, as well as inside and outside the Company, and provided customers with a full range of insurance digital services.

Operations and Services

In the first half of 2022, being customer-centric, the Company adhered to the operational service objectives of “efficiency first, technology-driven, value increase and first-class customer experience” and innovatively promoted the implementation of a nationwide integrated model of intelligent centralization and sharing for operations to accelerate the integration of services with sales, with a view to providing customers with “convenient, quality and caring” services.

Green development, online services increased substantially. As the online platform further expanded its capacity, the number of registered users and monthly active users of China Life App grew by 20.2% and 7.2% year on year, respectively. Paperless services were widely applied. The number of online out-bound messages increased by 7.2% year on year, the paperless application rate of long-term individual insurance reached 99.9%, the volume of electronic return visits for new policies surged to 97.5%, online service rate of policy administration rose by 6.1 percentage points from the high level in the corresponding period last year, and online Customer Service Agent services rose by 167.3% year on year.

Innovative models, operational efficiency enhanced significantly. The Company put into practice the model of intelligent centralization and sharing for operations and made new breakthroughs in digital application, as a result of which the processing efficiency of policy administration for individual insurance rose by 20% as compared with that prior to the sharing for operations. The intelligent approval rates of policy administration and claims settlement remained at a high level. The underwriting process was upgraded intelligently, which improved the operation efficiency of new policies of long-term individual insurance by 5.3% year on year and the intelligent approval rate of underwriting to 94.2%.

 

 

24


Honoured commitment, creating a “convenient and caring” claims settlement brand. The Company demonstrated its corporate responsibility to make claims settlement much faster than before. To be in line with the Catalogue of Drugs for National Medical Insurance, the Company carried out the dynamic adjustment of detailed data, achieving an average efficiency of 0.46 day for claims settlement and a claims acceptance rate of 99.5%. A variety of convenient claims payment methods introduced by the Company were highly recognized by customers. “Direct Claims Payment” provided claims payments to 2.28 million customers. “Claims Settlement for Critical Illness within One Day” made claims payment of RMB3,580 million. “Door-to-door Claims” services were provided to more than 60,000 customers with difficulties.

Improved experience, offering diversified ecological services. The Company paid close attention to the differentiated needs of customers and expanded the scope of its diversified services. It promoted a number of value-added services, such as “700 Healthy Walk”, “Little Painters of China Life” and “Customer Festival”, etc., themed on “healthy exercise, parent-child education and enjoying life”, bringing the number of customers served to rise by 5.8% year on year. The Company also provided caring services to the elderly customers, such as the priority access to the 95519 customer service line and the exclusive services of the senior-friendly version of China Life App, which were well received by the seniors, and the total number of the users of such services amounted to nearly 13 million.

Risk Control and Management

During the Reporting Period, the Company consistently strengthened its internal control and risk management in strict compliance with the laws and regulations of its listed jurisdictions, as well as the regulatory requirements of the industry. The Company has established a risk preference management system with the statement on risk preference as the carrier, and the risk tolerance and limit indicators as the focus, integrated risk preference requirements into various lines of its business operation and management, and significantly enhanced its capability in risk management. In the first quarter of 2022, the CBIRC adopted a new indicator system under the C-ROSS (Phase II) Regulation for the integrated risk rating for insurance industry for the first time. The Company benchmarked against the new regulations for active implementation and has maintained the rating of Class A for 16 consecutive quarters.

The Company actively conducted various tasks on risk screening and governance and identified hidden risks in a timely manner, so as to enhance its capability to address risks in all aspects. The Company fully implemented the C-ROSS (Phase II) Regulation of the CBIRC, and constantly optimized the enterprise-wide risk management system of C-ROSS. The system of investment risk management and control was continuously improved, and a framework for the whole-chain investment risk analysis was established. The Company strengthened the system for sales risk management and control, actively conducted sales risk pre-warning and investigation, cultivated integrity culture among sales agents, and introduced the credit rating system for the agents, etc. The Company fully implemented the regulatory requirements on anti-money laundering, and performed all of its anti-money laundering obligations, which further improved the effectiveness of its anti-money laundering risk management and control.

By attaching great importance to the protection of consumers’ rights and interests, the Company integrated the protection of consumers’ rights and interests into every aspect of its corporate governance and business operation and management, consistently pushed forward the effective operation of the closed-loop management mechanism for consumers’ rights and interests protection, adopted stringent information confidentiality measures to ensure personal information security of consumers, improved the systems for the management of customer complaints and risk management and control, reinforced the concept of integrity and compliance in sales and services, and consistently increased the sense of fulfillment, happiness and security of its consumers.

The Company carried out the activities of the “Year of Regulation Compliance” in great depth, continued to optimize its system of internal rules and policies, reinforced compliance monitoring and inspection, organized the promotion of law and compliance education, strengthened compliance assessments, endeavored to enhance the effectiveness of compliance management, and constantly improved its capability of compliance risk prevention and control.

 

 

25


The Company consistently strengthened the supervision through audits to facilitate its high-quality development. It implemented special audits and audit investigations on the key issue areas where regulators and the management of the Company had concerns. It carried out the audits of economic responsibility and the audits of senior management, strengthened the application of audit results comprehensively, and fully exerted the role of internal audit to offer support to the decision making for the supervision, appraisal and employment of the managers. It consistently stepped up efforts in supervising rectification and liability attribution for any problems identified in audits, fully proceeded with the mechanism for audit supervision and rectification as well as the mechanism for handover and follow-up of issues, and further optimized closed-loop internal audits, in a bid to enhance the efficiency and effects of audits.

The Company paid great attention and took active actions to implement the Data Security Law of the PRC for the purpose of protecting the legitimate rights and interests of customers. It optimized its data governance structure, refined the responsibilities of divisions at all levels for data management, further optimized the long-term mechanism for data management, and improved the data management rules. The Company assessed the sophistication of data management capability against the national benchmarks, categorized and classified corporate data, defined the targets to be protected for data security and the key areas for protection, unified all requirements for the strategy on classified protection of data, achieved the classified security protection for the full life cycle such as the collection, transmission and storage of data, established a 3-dimensional data security protection system based on classified protection, and consistently strengthened the management and control of data security, in order to ensure that the data was manageable and controllable.

PERFORMANCE OF THE CORPORATE SOCIAL RESPONSIBILITY

By setting its strategic goal as “building a world-class and responsible life insurance company” in corporate social responsibility and upholding the philosophy of “people-centered, caring for life, creating value and serving the society”, the Company consistently enhanced its environmental, social and governance performance to contribute to the sustainable development of the society.

Leveraging the advantage of insurance protection to proactively integrate business operations into the national development

The Company fully leveraged the advantage of its principal insurance business to serve the new development landscape, with a view to contributing to the high-quality social and economic development. As at 30 June 2022, the Company carried out more than 200 supplementary major medical expenses insurance programs, providing services to nearly 350 million urban and rural residents, and implemented nearly 70 city-customized commercial medical insurance programs in 21 provinces and cities accumulatively. In order to satisfy the demands of the seniors for diversified insurance protection, the Company insured over 40 million seniors through the group insurance channel, offering an insurance coverage of approximately RMB2.09 trillion. The Company enriched insurance services available for the new urban residents, offering a total of 12 insurance products. It also gave full play to the advantages of long-term and stable nature of insurance funds to serve the national strategies and to support the development of the real economy. As at 30 June 2022, investments in the real economy amounted to RMB3.3 trillion.

Promoting green finance to realize the dual carbon goals

By integrating an overall environmental goal of “ensuring a healthy and friendly environment for the accomplishment of carbon neutrality” into its development philosophy, the Company actively carried out a variety of economic activities with both environmental and social benefits, and improved the ESG risk management mechanism, so as to apply its green development strategy thoroughly in such aspects as green sales, green insurance, green investment, green operations, green office and green lifestyle. The Company continued to practice the ESG investment concept and deeply explored the investment opportunities arisen in the sectors of energy conservation and environmental protection, green upgrade of infrastructures, and green services. As at 30 June 2022, green investments of the existing projects were over RMB400 billion. The Company stepped up its efforts in expanding corporate clients from the green industry and consistently broadened the scope of insurance protection, with an aim to diversify the liabilities of insurance protection. It continued to push forward the whole process of green operations, as a result of which the rate of paperless notification services rose by 24.5 percentage points year on year, and the online policy administration services recorded a saving of 791 tonnes of papers. The Company has generally achieved the full coverage of paperless insurance application for long-term individual insurance business, which maintained the leading position in the industry.

 

 

26


Committing to public welfare and charitable campaigns to perform its corporate responsibility

The Company actively devoted itself to public welfare and charitable campaigns by offering insurance protection in form of donation and paying attention to the growth of teenagers, so as to demonstrate its efforts in assuming corporate responsibility with practical actions. During the Reporting Period, the Company offered by way of donation the insurance protection with a total insurance coverage of approximately RMB277 billion for the medical staff and workers in the frontline of pandemic prevention and control, and made a donation of RMB7 million to Shanghai and Jilin Province through China Life Foundation in support of their pandemic prevention and control. The Company continued to carry out the “Green Life” healthcare assistance program to provide illness and medical protection to the minors of the low income families and those with economic difficulties due to illness. As at 30 June 2022, the Company offered insurance protection of approximately RMB4,000 million to nearly 300,000 children. It vigorously offered assistance to rural children in terms of the aesthetic education and consistently carried out the “Bringing Art to the Countryside” charitable project, which benefited dozens of rural primary schools in more than 10 provinces.

Consolidating the achievements of poverty alleviation and effectively coordinating rural revitalization

In the first half of 2022, the Company strengthened its corporate responsibility, coordinated joint forces from all fronts to offer assistance, fully upgraded the “Poverty Alleviation Insurance” series, made innovation in assistance measures, and expanded the coverage for assistance, so as to enhance the effectiveness of assistance initiatives. The Company dispatched 995 cadres staying at villages for assistance to undertake projects in 1,138 assistance localities. Through the active implementation of the preferential policy in relation to the supplementary major medical expenses insurance for people with difficulties, the Company made claims payment of more than RMB700 million to over 750,000 people with difficulties in the first half of 2022. It further enriched the exclusive products of “rural revitalization” series and expanded the protection coverage of the products and services, and such exclusive products were promoted in 28 provinces, regions and cities. In the first half of 2022, the Company devoted assistance funds of RMB6.37 million. Its rural revitalization related insurance business covered over 21 million rural residents, and the related investments amounted to nearly RMB80 billion accumulatively.

FUTURE PROSPECT

Industry Landscape and Development Trends

Despite the current complicated and severe international environment, multiple and sporadic outbreaks of the pandemic in China and growing pressure of economic downturn, the domestic economy remains resilient with strong potentials, and the long-term positive economic fundamentals remain unchanged. The macro-economic recovery, consistent promotion of national strategies of Healthy China initiative and proactively responding to population aging, etc. will bring about new development opportunities for the life insurance industry. With the further promotion of common prosperity, the size of China’s middle class will continue to grow, meaning more effective demands for the life insurance market. The market players sped up their reform and transformation, and accelerated InsurTech empowerment in various aspects, such as sales, operations, and risk control, etc., which will provide a powerful intrinsic impetus to the industry. The CBIRC has rolled out a series of measures to optimize the regulatory system and mechanism for health insurance, regulate the development of the third-pillar pension insurance, promote the financial sector to better serve the real economy, and deepen financial supply-side structural reforms, which offer a favorable environment for the high-quality development of the insurance industry.

Development Strategies and Business Plans of the Company

In the second half of 2022, the Company will uphold the guideline of making progress while maintaining stability, adhere to the original function of insurance, consistently deepen supply-side reforms, give full play to the protection role of insurance, and strive to achieve steady business development. The Company will deepen reform and transformation with firm determination, strengthen the protection of consumers’ rights and interests in all aspects, and continue to pursue the high-quality development of the Company by enhancing its capability of value creation, digital operations, innovation of insurance products and services as well as risk prevention and control.

 

 

27


Potential Risks

Externally, the risk of stagflation in the world economy is rising, major economies have tended to tighten their policies, and the external instabilities and uncertainties have increased significantly; and domestically, the impact of the pandemic is lingering, shrinking demand is intertwined with disrupted supply, structural problems combines with cyclical problems, and the foundation for steady economic recovery is not yet consolidated, which also pose challenges to the steady development of the insurance industry. In the circumstances of pandemic and the transformation of the industry, operating environment and customer demands witness changes, and the industry has entered into a stage of profound adjustments. The Company will take a variety of measures to actively respond to such risks and challenges. It will adhere to the principle of making progress while maintaining stability, continue to push forward in-depth reform and transformation, and strive to improve the quality of its business operation and management. In respect of the capital market, as the interest rate is at a low level, credit risk is relatively high, and equity

market volatility is dominant, premium assets satisfying the requirements for investment allocation have become scare, and the Company are under double pressures of the continuous downturn of investment yield of fixed-income assets and the increasing fluctuation in the overall income of investment portfolios. The Company will continue to prioritize asset-liability management, constantly strengthen its professional research on investment, further optimize its asset allocation mix, and flexibly adjust its investment tactics to respond to market changes. Furthermore, the Company will continuously focus on and enhance the analysis of the related complex risk factors and vigorously pursue its high-quality development.

The Company believes that it will have sufficient capital to meet its insurance business expenditures and new general investment needs in the second half of 2022. At the same time, the Company will make corresponding financing arrangements based on capital market conditions if it plans to implement any business development strategies in the future.

 

 

28


LOGO

 

BACKGROUND

China Life Insurance Company Limited prepares financial statements to public investors in accordance with the relevant accounting standards. An alternative measure of the value and profitability of a life insurance company can be provided by the embedded value method. Embedded value is an actuarially determined estimate of the economic value of the life insurance business of an insurance company based on a particular set of assumptions about future experience, excluding the economic value of future new business. In addition, the value of half year’s sales represents an actuarially determined estimate of the economic value arising from new life insurance business issued in half year based on a particular set of assumptions about future experience.

China Life Insurance Company Limited believes that reporting the Company’s embedded value and value of half year’s sales provides useful information to investors in two respects. First, the value of the Company’s in-force business represents the total amount of shareholders’ interest in distributable earnings, in present value terms, which can be expected to emerge over time, in accordance with the assumptions used. Second, the value of half year’s sales provides an indication of the value created for investors by new business activity based on the assumptions used and hence the potential of the business. However, the

information on embedded value and value of half year’s sales should not be viewed as a substitute of financial measures under the relevant accounting basis. Investors should not make investment decisions based solely on embedded value information and the value of half year’s sales.

It is important to note that actuarial standards with respect to the calculation of embedded value are still evolving. There is still no universal standard which defines the form, calculation methodology or presentation format of the embedded value of an insurance company. Hence, differences in definition, methodology, assumptions, accounting basis and disclosures may cause inconsistency when comparing the results of different companies.

Also, the calculation of embedded value and value of half year’s sales involves substantial technical complexity and estimates can vary materially as key assumptions are changed. Therefore, special care is advised when interpreting embedded value results.

The values shown below do not consider the future financial impact of transactions between the Company and CLIC, CLI, AMC, Pension Company, CLP&C, and etc.

 

 

29


DEFINITIONS OF EMBEDDED VALUE AND VALUE OF HALF YEAR’S SALES

The embedded value of a life insurer is defined as the sum of the adjusted net worth and the value of in-force business allowing for the cost of required capital.

“Adjusted net worth” is equal to the sum of:

 

  Net assets, defined as assets less corresponding policy liabilities and other liabilities valued; and

 

  Net-of-tax adjustments for relevant differences between the market value and the book value of assets, together with relevant net-of-tax adjustments to certain liabilities.

The market value of assets can fluctuate significantly over time due to the impact of the prevailing market environment. Hence the adjusted net worth can fluctuate significantly between valuation dates.

The “value of in-force business” and the “value of half year’s sales” are defined here as the discounted value of the projected stream of future shareholders’ interest in distributable earnings for existing in-force business at the valuation date and for half year’s sales in the 6 months immediately preceding the valuation date.

The value of in-force business and the value of half year’s sales have been determined using a traditional deterministic discounted cash flow methodology. This methodology makes implicit allowance for the cost of investment guarantees and policyholder options, asset/liability mismatch risk, credit risk, the risk of operating experience’s fluctuation and the economic cost of capital through the use of a risk-adjusted discount rate.

PREPARATION AND REVIEW

The embedded value and the value of half year’s sales were prepared by China Life Insurance Company Limited in accordance with the “CAA Standards of Actuarial Practice: Appraisal of Embedded Value” issued by the China Association of Actuaries (“CAA”) in November 2016. Deloitte Consulting (Shanghai) Co., Ltd. performed a review of China Life’s embedded value. The review statement is contained in the “Independent Actuaries Review Opinion Report on Embedded Value of China Life Insurance Company Limited” section.

ASSUMPTIONS

The valuation assumptions used as at 30 June 2022 are consistent with those used as at 31 December 2021.

 

 

30


SUMMARY OF RESULTS

The embedded value as at 30 June 2022 and the corresponding results as at 31 December 2021 are shown below:

 

Components of Embedded Value

          RMB million  

ITEM

        30 June
2022
     31 December
2021
 

A

  

Adjusted Net Worth

     703,520        674,317  

B

  

Value of In-Force Business before Cost of Required Capital

     620,064        593,137  

C

  

Cost of Required Capital

     (72,706      (64,446

D

  

Value of In-Force Business after Cost of Required Capital (B + C)

     547,357        528,691  

E

  

Embedded Value (A + D)

     1,250,877        1,203,008  

 

Note:    Numbers may not be additive due to rounding.

The value of half year’s sales for the 6 months ended 30 June 2022 and for the corresponding period of last year is shown below:

 

Components of Value of Half Year’s Sales           RMB million  

ITEM

        30 June
2022
     30 June
2021
 

A

  

Value of Half Year’s Sales before Cost of Required Capital

     30,440        33,512  

B

  

Cost of Required Capital

     (4,695      (3,645

C

  

Value of Half Year’s Sales after Cost of Required Capital (A + B)

     25,745        29,867  
  

Including: Value of Half Year’s Sales of Individual Agent Business Sector

     24,185        28,969  

The new business margin of half year’s sales of individual agent business sector for the 6 months ended 30 June 2022 is shown below:

 

New Business Margin of Half Year’s Sales of Individual Agent Business Sector             
     30 June
2022
    30 June
2021
 

By First Year Premium

     28.5     36.2

By Annual Premium Equivalent

     30.4     36.5

 

Note:    First Year Premium is the written premium used for calculation of the value of half year’s sales and Annual Premium Equivalent is calculated as the sum of 100 percent of first year regular premiums and 10 percent of single premiums.

 

31


MOVEMENT ANALYSIS

The following analysis tracks the movement of the embedded value from the start to the end of the Reporting Period:

 

Analysis of Embedded Value Movement in the First Half Year of 2022    RMB million  

ITEM

      

A Embedded Value at the Start of Year

     1,203,008  

B Expected Return on Embedded Value

     44,091  

C Value of New Business in the Period

     25,745  

D Operating Experience Variance

     3,881  

E Investment Experience Variance

     (17,240

F Methodology and Model Changes

     388  

G Market Value and Other Adjustments

     8,479  

H Exchange Gains or Losses

     473  

I Shareholder Dividend Distribution and Capital Changes

     (18,372

J Others

     423  

K Embedded Value as at 30 June 2022 (sum A through J)

     1,250,877  

 

Notes: 1. Numbers may not be additive due to rounding.

           2. Items B through J are explained below:

 

  B

Reflects expected impact of covered business, and the expected return on investments supporting the 2022 opening net worth.

  C

Value of half year’s sales for the 6 months ended 30 June 2022.

  D

Reflects the difference between actual operating experience in the first half year of 2022 (including mortality, morbidity, lapse, and expenses etc.) and the assumptions.

  E

Compares actual with expected investment returns during the first half year of 2022.

  F

Reflects the effects of appraisal methodology and model enhancement.

  G

Change in the market value adjustment from the beginning of year 2022 to 30 June 2022 and other adjustments.

  H

Reflects the gains or losses due to changes in exchange rate.

  I

Reflects dividends distributed to shareholders during the first half year of 2022.

  J

Other miscellaneous items.

 

32


SENSITIVITY RESULTS

Sensitivity tests were performed using a range of alternative assumptions. In each of the sensitivity tests, only the assumption referred to was changed, with all other assumptions remaining unchanged. The results are summarized below:

 

Sensitivity Results      RMB million  
     Value of In-Force
Business after Cost of
Required Capital
     Value of Half year’s
Sales after Cost of
Required Capital
 

Base case scenario

     547,357        25,745  

1. Risk discount rate +50bps

     522,588        24,539  

2. Risk discount rate -50bps

     573,917        27,038  

3. Investment return +50bps

     656,451        31,719  

4. Investment return -50bps

     438,714        19,781  

5. 10% increase in expenses

     540,810        23,847  

6. 10% decrease in expenses

     553,905        27,643  

7. 10% increase in mortality rate for non-annuity products and 10% decrease in mortality rate for annuity products

     543,731        25,285  

8. 10% decrease in mortality rate for non-annuity products and 10% increase in mortality rate for annuity products

     550,960        26,207  

9. 10% increase in lapse rates

     547,206        25,325  

10. 10% decrease in lapse rates

     547,509        26,186  

11. 10% increase in morbidity rates

     538,989        24,772  

12. 10% decrease in morbidity rates

     555,902        26,719  

13. Allowing for diversification in calculation of VIF

     594,744        –    

 

33


INDEPENDENT ACTUARIES REVIEW OPINION REPORT ON EMBEDDED VALUE OF CHINA LIFE INSURANCE COMPANY LIMITED

China Life Insurance Company Limited (“China Life”) has prepared embedded value results as at 30 June 2022 (“EV Results”). The disclosure of these EV Results, together with a description of the methodology and assumptions that have been used, are shown in the Embedded Value section.

China Life has retained Deloitte Consulting (Shanghai) Co., Ltd. to review its EV Results. The task is undertaken by Deloitte Actuarial and Insurance Solutions of Deloitte Consulting (Shanghai) Co., Ltd. (“Deloitte Consulting” or “we”).

Scope of Work

Our scope of work covered:

 

  a review of the methodology used to develop the embedded value and value of half year’s sales as at 30 June 2022, in accordance with the “CAA Standards of Actuarial Practice: Appraisal of Embedded Value”, issued by the China Association of Actuaries (“CAA”);

 

  a review of the economic and operating assumptions used to develop embedded value and value of half year’s sales as at 30 June 2022; and

 

  a review of China Life’s EV Results, including embedded value, value of half year’s sales, analysis of embedded value movement from 31 December 2021 to 30 June 2022, and the sensitivity results of value of in-force business and value of half year’s sales.

Basis of Opinion, Reliance and Limitation

We carried out our review work based on “CAA Standards of Actuarial Practice: Appraisal of Embedded Value”, issued by CAA. In carrying out our review, we have relied on the completeness and accuracy of audited and unaudited data and information provided by China Life.

The determination of embedded value is based on a range of assumptions on future operations and investment performance. The future actual experiences are affected by internal and external factors, many of which are not entirely controlled by China Life. Hence the future actual experiences may deviate from these assumptions.

This report is addressed solely to China Life in accordance with the terms of our engagement letter. To the fullest extent permitted by applicable law, we do not accept or assume any responsibility, duty of care or liability to anyone other than China Life for or in connection with our review work, the opinions we have formed, or for any statements set forth in this report.

Opinion

Based on the scope of work above, we have concluded that:

 

  The embedded value methodology used by China Life is in line with the “CAA Standards of Actuarial Practice: Appraisal of Embedded Value” issued by CAA. This method is commonly used by life and health insurance companies in China;

 

  The economic assumptions used by China Life have taken into account the current investment market conditions and the investment strategy of China Life;

 

  The operating assumptions used by China Life have taken into account the past experience and the expectation of future experience; and

 

  The embedded value results are consistent with its methodology and assumptions used. The overall result is reasonable.

For and on behalf of Deloitte Consulting (Shanghai) Co., Ltd.

Eric Lu    Yu Jiang

25 August 2022

 

 

34


LOGO

 

INFORMATION ON DELISTING OF AMERICAN DEPOSITARY SHARES

As considered and approved by the sixteenth meeting of the seventh session of the Board of Directors of the Company, after taking into account a number of considerations, including the limited trading volume of its American depositary shares (“ADSs”) relative to the worldwide trading volume of its H Shares, and the considerable administrative costs of maintaining the listing of the ADSs on the New York Stock Exchange (the “NYSE”), the registration of the ADSs and the underlying H Shares under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) and complying with the periodic reporting requirements and related obligations of the Exchange Act, the Company

has filed a Form 25 with the United States Securities and Exchange Commission on 22 August 2022 to delist its ADSs from the NYSE under the Exchange Act. The last day of trading of the ADSs on the NYSE is 1 September 2022. After that date, the ADSs of the Company will no longer be listed and traded on the NYSE. For details, please refer to the announcement published by the Company on the website of the HKSE on 12 August 2022.

MATERIAL LITIGATIONS OR ARBITRATIONS

During the Reporting Period, the Company was not involved in any material litigation or arbitration.

 

 

35


MAJOR CONNECTED TRANSACTIONS

Continuing Connected Transactions

During the Reporting Period, the following continuing connected transactions were carried out by the Company pursuant to Rule 14A.76(2) of the Rules Governing the Listing of Securities on the HKSE (the “Listing Rules”), including the asset management agreement between the Company and AMC, the insurance sales framework agreement between the Company and CLP&C, the framework agreement between the Company and Chongqing International Trust Inc. (“Chongqing Trust”), and the framework agreement between the Company and China Life Capital. These continuing connected transactions were subject to the reporting, announcement and annual review requirements but were exempt from the independent shareholders’ approval requirement under the Listing Rules. CLIC, the controlling shareholder of the Company, holds 60% of the equity interest in CLP&C and 100% of the equity interest in China Life Capital. Therefore, each of CLIC, CLP&C and China Life Capital constitutes a connected person of the Company. AMC is held as to 60% and 40% by the Company and CLIC, respectively, and is therefore a connected subsidiary of the Company. Chongqing Trust is an associate of CLIC and CLP&C by virtue of its acting as the trustee of a trust scheme of which CLP&C is a beneficiary, and is therefore also a connected person of the Company pursuant to Rule 14A.13(2) of the Listing Rules.

During the Reporting Period, the continuing connected transactions carried out by the Company that were subject to the reporting, announcement, annual review and independent shareholders’ approval requirements under Chapter 14A of the Listing Rules included the framework agreements entered into by AMP with the Company, CLIC, CLP&C and CLI, respectively, and the agreement for entrusted investment and management and operating services with respect to alternative investments with insurance funds between the Company and CLI. Such agreements and the transactions thereunder have been approved by the independent shareholders of the Company. CLIC holds 100% of the equity interest in CLI. Therefore, CLI is a connected person of the Company. AMP is a subsidiary of AMC, and is therefore a connected subsidiary of the Company.

During the Reporting Period, the Company also carried out certain continuing connected transactions, including the policy management agreement between the Company and CLIC, and the asset management agreement between CLIC and AMC, which were exempt from the reporting, announcement, annual review and independent shareholders’ approval requirements under Chapter 14A of the Listing Rules.

The Company has complied with the disclosure requirements under Chapter 14A of the Listing Rules in respect of the above continuing connected transactions. When conducting the above continuing connected transactions during the Reporting Period, the Company has followed the pricing policies and guidelines formulated at the time when such transactions were entered into.

Policy Management Agreement

The Company and CLIC entered into the 2022-2024 policy management agreement on 31 December 2021, with a term from 1 January 2022 to 31 December 2024. Pursuant to the agreement, the Company will continue to accept CLIC’s entrustment to provide policy administration services relating to the non-transferred policies. The Company acted as a service provider under the agreement and did not acquire any rights or assume any obligations as an insurer under the non-transferred policies. For details as to the method of calculation of the service fee, please refer to Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements. The annual cap in respect of the service fee to be paid by CLIC to the Company for each of the three years ending 31 December 2024 is RMB491 million.

For the first half of 2022, the service fee paid by CLIC to the Company amounted to RMB210.62 million.

 

 

36


Asset Management Agreements

Asset Management Agreement between the Company and AMC

The Company and AMC entered into the 2020-2022 asset management agreement on 1 July 2020, with a term from 1 July 2020 to 31 December 2022. Pursuant to the 2020-2022 asset management agreement, AMC agreed to invest and manage assets entrusted to it by the Company, on a discretionary basis, within the scope granted by the Company and in accordance with the requirements of applicable laws and regulations, regulatory requirements and the investment guidelines given by the Company. In consideration of AMC’s services in respect of investing and managing various categories of assets entrusted to it by the Company under the agreement, the Company agreed to pay AMC a service fee. For details as to the method of calculation of the service fee, please refer to Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements. The annual caps for the three years ending 31 December 2022 are RMB3,000 million, RMB4,000 million and RMB5,000 million, respectively.

For the first half of 2022, the Company paid AMC a service fee of RMB1,425.67 million.

Asset Management Agreement between CLIC and AMC

CLIC and AMC entered into the 2020-2022 asset management agreement on 1 July 2020, with a term from 1 July 2020 to 31 December 2022. Pursuant to the 2020-2022 asset management agreement, AMC agreed to invest and manage assets entrusted to it by CLIC, on a discretionary basis, subject to the investment guidelines and instructions given by CLIC. In consideration of AMC’s services in respect of investing and managing assets entrusted to it by CLIC under the agreement, CLIC agreed to pay AMC a service fee. For details as to the method of calculation of the service fee, please refer to Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements. The annual cap for each of the three years ending 31 December 2022 is RMB500 million.

For the first half of 2022, CLIC paid AMC a service fee of RMB69.58 million.

Agreement for Entrusted Investment and Management and Operating Services with respect to Alternative Investments with Insurance Funds between the Company and CLI

As approved by the Extraordinary General Meeting 2021 of the Company, the Company and CLI entered into the 2022-2024 agreement for entrusted investment and management and operating services with respect to alternative investments with insurance funds on 27 December 2021. Such agreement took effect from 1 January 2022, with a term of two years ending on 31 December 2023. Unless a party serves the other party a written notice for non-renewal prior to 90 working days before the expiry date of the agreement, the agreement will be automatically renewed for one year from the expiry date thereof. Pursuant to the agreement, the Company will entrust CLI to perform services including the entrusted investment and management and the entrusted operation with respect to alternative investments. For the entrusted investment and management, it covers the equity/real estate direct investments, equity/real estate funds, non-standard financial products and quasi-securitization financial products already entrusted by the Company to CLI for investment and management under the existing projects, as well as the non-standard financial products and quasi-securitization financial products entrusted for investment under the new projects. CLI will continue to invest and manage assets entrusted to it by the Company, on a discretionary basis, within the scope of utilization of insurance funds as specified by the regulatory authorities and in accordance with the requirements of applicable laws and regulations and the investment guidelines of the Company, and the Company will pay CLI the investment management service fee, product management fee, real estate operation management service fee and performance award in respect of the investment and management services provided by CLI to the Company. For the entrusted operation, CLI will provide the operating services to the Company with respect to the equity/real estate funds invested by the Company at its own discretion and within the scope prescribed in the agreement, and the Company will pay CLI the entrusted operating fee in this regard. For details as to the method of calculation of the fees for the investment and management services (including the investment management service fee, product management fee, real estate operation management service fee and performance reward) and the entrusted operation fee in relation to the operating services, please refer to Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements.

 

 

37


For each of the three years ending 31 December 2024, the annual cap on the contractual amount of assets newly entrusted by the Company to CLI for investment and management is RMB65,000 million or its equivalent in foreign currency, and the annual cap on the fees for the investment and management services payable by the Company to CLI (including the investment management service fee, product management fee, real estate operation management service fee and performance reward) and the entrusted operation fee in relation to the operating services is RMB2,000 million or its equivalent in foreign currency.

For the first half of 2022, the fees for the investment and management services (including the investment management service fee, product management fee, real estate operation management service fee and performance reward) and the entrusted operation fee in relation to the operating services paid by the Company to CLI amounted to RMB289.97 million, and the contractual amount of assets newly entrusted by the Company to CLI for investment and management was RMB17,880 million.

Cooperation Framework Agreement for Investment Management with Insurance Funds between the Company and China Life Capital

The Company and China Life Capital entered into the 2020-2022 framework agreement on 31 December 2019, with a term from 1 January 2020 to 31 December 2022. Pursuant to the agreement, the Company will continue to subscribe in the capacity of the limited partner for the fund products of which China Life Capital or any of its subsidiaries serves (individually and jointly with third parties) as the general partner, and/or the fund products of which China Life Capital serves as the manager (including the fund manager and co-manager). For each of the three years ending 31 December 2022, the annual cap for the subscription by the Company in the capacity of the limited partner of the fund products of which China Life Capital or any of its subsidiaries serves as the general partner is RMB5,000 million, and the annual cap for the management fee charged by China Life Capital as the general partner or the manager of the fund products is RMB200 million.

For the first half of 2022, the amount of subscription by the Company in the capacity of the limited partner of the fund products of which China Life Capital or any of its subsidiaries serves as the general partner was RMB0 million, and the management fee charged by China Life Capital as the general partner or the manager of the fund products was RMB71.02 million.

Insurance Sales Framework Agreement

The Company and CLP&C entered into the 2021 insurance sales framework agreement on 20 February 2021, with a term of two years from 8 March 2021 to 7 March 2023. Unless a party serves the other party a written notice for non-renewal within 30 days before the expiration of the 2021 insurance sales framework agreement, the agreement will be automatically extended for one year to 7 March 2024 from the expiration thereof. Pursuant to the agreement, CLP&C will entrust the Company to act as an agent to sell selected insurance products within the authorized regions, and pay an agency service fee to the Company in consideration of the services provided. For details as to the method of calculation of the agency service fee, please refer to Note 18 in the Notes to the Interim Condensed Consolidated Financial Statements. The annual caps for the three years ending 31 December 2023 are RMB3,500 million, RMB3,830 million and RMB4,240 million, respectively.

For the first half of 2022, CLP&C paid the Company an agency service fee of RMB718.05 million.

 

 

38


Framework Agreements with AMP

Framework Agreement between the Company and AMP

As approved by the First Extraordinary General Meeting 2019 of the Company, the Company and AMP entered into the 2020-2022 framework agreement on 31 December 2019, with a term of three years from 1 January 2020 to 31 December 2022. Pursuant to the agreement, the Company and AMP will continue to conduct certain daily transactions, including the subscription and redemption of fund products, sales agency services, asset management for specific clients and other daily transactions permitted by laws and regulations. Pricing of the transactions under the agreement shall be determined by the parties through arm’s length negotiations with reference to industry practices. For the three years ending 31 December 2022, the annual cap of the subscription price and corresponding subscription fee for the subscription of fund products is RMB72,600 million; the annual cap of the redemption price and corresponding redemption fee for the redemption of fund products is RMB72,600 million; the annual caps of the sales commission fee and client maintenance fee payable by AMP are RMB700 million, RMB800 million and RMB900 million, respectively; the annual caps of the management fee (including the performance-based fee) payable by the Company for the asset management for specific clients are RMB300 million, RMB400 million and RMB500 million, respectively; and the annual cap of the fees for other daily transactions is RMB100 million.

For the first half of 2022, the subscription price and corresponding subscription fee for the subscription of fund products were RMB455.00 million, the redemption price and corresponding redemption fee for the redemption of fund products were RMB5,379.38 million, the management fee (including the performance-based fee) paid by the Company for the asset management for specific clients was RMB0 million, and the fees for other daily transactions were RMB1.53 million.

Framework Agreement between CLIC and AMP

As approved by the First Extraordinary General Meeting 2019 of the Company, CLIC and AMP entered into the 2020-2022 framework agreement on 6 September 2019, with a term of three years from 1 January 2020 to 31 December 2022. Pursuant to the agreement, CLIC and AMP

will continue to conduct certain daily transactions, including the subscription and redemption of fund products and private asset management. Pricing of the transactions under the agreement shall be determined by the parties through arm’s length negotiations with reference to industry practices. For each of the three years ending 31 December 2022, the annual cap of the subscription price and corresponding subscription fee for the subscription of fund products is RMB10,000 million; the annual cap of the redemption price and corresponding redemption fee for the redemption of fund products is RMB10,000 million; and the annual cap of the management fee (including the performance-based fee) payable by CLIC for the private asset management is RMB100 million.

For the first half of 2022, the subscription price and corresponding subscription fee for the subscription of fund products were RMB0 million, the redemption price and corresponding redemption fee for the redemption of fund products were RMB324.64 million, and the management fee (including the performance-based fee) paid by CLIC for the private asset management was RMB0 million.

Framework Agreement between CLP&C and AMP

As approved by the First Extraordinary General Meeting 2019 of the Company, CLP&C and AMP entered into the 2020-2022 framework agreement on 3 December 2019, with a term of three years from 1 January 2020 to 31 December 2022. Pursuant to the agreement, CLP&C and AMP will continue to conduct certain daily transactions, including the subscription and redemption of fund products, asset management for specific clients and other daily transactions permitted by laws and regulations. Pricing of the transactions under the agreement shall be determined by the parties through arm’s length negotiations with reference to industry practices. For each of the three years ending 31 December 2022, the annual cap of the subscription price for the fund products is RMB10,000 million; the annual cap of the redemption price for the fund products is RMB10,000 million; the annual cap of the subscription fee for the fund products is RMB100 million; the annual cap of the redemption fee for the fund products is RMB100 million; the annual cap of the management fee (including the performance-based fee) payable by CLP&C for the asset management for specific clients is RMB100 million; and the annual cap of the fees for other daily transactions is RMB100 million.

 

 

39


For the first half of 2022, the subscription price for the fund products was RMB0 million, the redemption price for the fund products was RMB0 million, the subscription fee for the fund products was RMB0 million, the redemption fee for the fund products was RMB0 million, the management fee (including the performance-based fee) paid by CLP&C for the asset management for specific clients was RMB0 million, and the fees for other daily transactions were RMB0.11 million.

Framework Agreement between CLI and AMP

As approved by the First Extraordinary General Meeting 2019 of the Company, CLI and AMP entered into the 2020-2022 framework agreement on 17 February 2020, with a term of three years from 1 January 2020 to 31 December 2022. Pursuant to the agreement, CLI and AMP will continue to conduct certain daily transactions, including the subscription and redemption of fund products, asset management for specific clients, advisory services and other daily transactions permitted by laws and regulations. Pricing of the transactions under the agreement shall be determined by the parties through arm’s length negotiations with reference to industry practices. For each of the three years ending 31 December 2022, the annual cap of the subscription price and corresponding subscription fee for the subscription of fund products is RMB10,000 million; the annual cap of the redemption price and corresponding redemption fee for the redemption of fund products is RMB10,000 million; the annual cap of the management fee (including the performance-based fee) payable by CLI and its subsidiaries for the asset management for specific clients is RMB150 million; the annual cap of the management fee (including the performance-based fee) payable by the subsidiaries of AMP for the asset management for specific clients is RMB150 million; the annual cap of the advisory fee payable by CLI and its subsidiaries for the advisory services is RMB150 million; the annual cap of the advisory fee payable by AMP and its subsidiaries for the advisory services is RMB150 million; and the annual cap of the fees for other daily transactions is RMB150 million.

For the first half of 2022, the subscription price and corresponding subscription fee for the subscription of fund products were RMB187.44 million, the redemption price and corresponding redemption fee for the redemption of fund products were RMB387.49 million, the management fee (including the performance-based fee) paid by CLI and its subsidiaries for the asset management for specific clients was RMB0 million, the management fee (including the performance-based fee) paid by the subsidiaries of AMP for the asset management for specific clients was RMB0 million; the advisory fee paid by CLI and its subsidiaries for the advisory services was RMB0 million; the advisory fee paid by AMP and its subsidiaries for the advisory services was RMB0 million, and the fees for other daily transactions were RMB0 million.

Framework Agreement between the Company and Chongqing Trust

The Company and Chongqing Trust entered into the 2020-2022 framework agreement on 27 December 2019, with a term of three years from 1 January 2020 to 31 December 2022. Pursuant to the agreement, the Company and Chongqing Trust will continue to conduct the subscription and redemption of trust products and other daily transactions permitted by laws and regulations. Pricing of the transactions under the agreement shall be determined by the parties through arm’s length negotiations with reference to industry practices. For each of the three years ending 31 December 2022, the annual cap of the total amount of subscription and redemption of the trust products is RMB30,000 million; the annual cap of the trustee’s remuneration is RMB500 million; and the annual cap of the fees for other daily transactions is RMB100 million.

For the first half of 2022, the total amount of subscription and redemption of the trust products was RMB1.95 million, the trustee’s remuneration was RMB8.26 million, and the fees for other daily transactions were RMB0 million.

 

 

40


Other Major Connected Transaction

As approved at the seventh meeting of the seventh session of the Board of Directors, the Company and CLP&C entered into a capital injection contract on 31 March 2022, and CLIC is also scheduled to enter into the capital injection contract with CLP&C, pursuant to which the Company and CLIC will make capital injections of RMB3.6 billion and RMB5.4 billion, respectively, to CLP&C. Upon completion of the transaction, the registered capital of CLP&C will be increased from RMB18.8 billion to RMB27.8 billion, and will continue to be held as to 40% and 60% by the Company and CLIC, respectively.

Each of CLIC and CLP&C is a connected person of the Company. The above transaction constituted a one-off connected transaction of the Company that was subject to the reporting and announcement requirements but was exempt from the independent shareholders’ approval requirement under Rule 14A.76(2) of the Listing Rules.

The Company has complied with the disclosure requirement under Chapter 14A of the Listing Rules in respect of the above one-off connected transaction.

Statement on Claims, Debt Transactions and Guarantees of a Non-operating Nature with Related Parties

During the Reporting Period, the Company was not involved in claims, debt transactions or guarantees of a non-operating nature with related parties.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S SECURITIES

During the Reporting Period, the Company and its subsidiaries did not purchase, sell or redeem any of the Company’s listed securities.

MATERIAL CONTRACTS AND THEIR PERFORMANCE

During the Reporting Period, the Company neither acted as trustee, contractor or lessee of other companies’ assets, nor entrusted, contracted or leased its assets to other companies, the profit or loss from which accounted for 10% or more of the Company’s total profits for the Reporting Period, nor were there any such matters that occurred in previous periods but subsisted during the Reporting Period.

The Company neither gave external guarantees nor provided guarantees to its holding subsidiaries during the Reporting Period.

Entrusted investment management during the Reporting Period or any investment management occurred in previous periods but subsisted during the Reporting Period: Investment is one of the principal businesses of the Company. The Company mainly adopts the mode of entrusted investment for management of its investment assets, and has established a diversified framework of entrusted investment management with China Life’s internal managers playing the key role and the external managers offering effective supports. The internal managers include AMC and its subsidiaries, CLI and its subsidiaries and Pension Company. The external managers comprise both domestic and overseas managers, including fund companies, securities companies and other professional investment management institutions. The Company selected different investment managers based on the purpose of allocation of various types of investments, their risk features and the expertise of different managers, so as to establish a great variety of investment portfolios and improve the efficiency of insurance fund utilization. The Company entered into entrusted investment management agreements with all managers and supervised the managers’ daily investment performance through the measures such as investment guidelines, asset entrustment and performance appraisals. The Company also adopted risk control measures in respect of specific investments based on the characteristics of different managers and investment products.

Except as otherwise disclosed in this report, the Company had no other material contracts during the Reporting Period.

 

 

41


PENSION PLAN

Full-time employees of the Company are covered by various government-sponsored pension plans, under which the employees are entitled to a monthly pension based on certain formulae. These government agencies are responsible for the pension liability to these employees upon retirement. The Company contributes on a monthly basis to these pension plans. All contributions made under the government-sponsored pension plans described above are fully attributable to employees at the time of the payment and the Company is unable to forfeit any amounts contributed by it to such plans. In addition to the government-sponsored pension plans, the Company established an employee annuity fund plan pursuant to the relevant laws and regulations in the PRC, whereby the Company is required to contribute to the plan at fixed rates of the employees’ salary costs. Contributions made by the Company under the annuity fund plan that is forfeited in respect of those employees who resign from their positions prior to the full vesting of the contributions will be recorded in the public account of the annuity fund and shall not be used to offset any contributions to be made by the Company in the future. All funds in the public account will be attributed to the employees whose accounts are in normal status after the approval procedures are completed as required. Under these plans, the Company has no legal or constructive obligation for retirement benefit beyond the contributions made.

H SHARE STOCK APPRECIATION RIGHTS

No H Share stock appreciation rights of the Company were granted or exercised in the first half of 2022. The Company will deal with such rights and related matters in accordance with relevant PRC governmental policies.

UNDERTAKINGS OF THE COMPANY, SHAREHOLDERS, EFFECTIVE CONTROLLERS, ACQUIRERS, DIRECTORS, SUPERVISORS, SENIOR MANAGEMENT OR OTHER RELATED PARTIES WHICH ARE EITHER GIVEN OR EFFECTIVE DURING THE REPORTING PERIOD

Prior to the listing of the Company’s A Shares (30 November 2006), land use rights were injected by CLIC into the Company during its reorganization. Out of these, four pieces of land (with a total area of 10,421.12 square meters) had not had its formalities in relation to the change of ownership completed. Further, out of the properties injected into the Company, there were six properties (with a gross floor area of 8,639.76 square meters) in respect of which the formalities in relation to the change of ownership had not been completed. CLIC undertook to assist the Company in completing the above-mentioned formalities within one year of the date of listing of its A Shares, and in the event that such formalities could not be completed within such period, CLIC would bear any potential losses to the Company due to the defective ownership.

CLIC strictly followed these commitments. As at the end of the Reporting Period, save for the two properties and related land of the Company’s Shenzhen Branch, the ownership registration formalities of which had not been completed due to historical reasons, all other formalities in relation to the change of land and property ownership had been completed. The Shenzhen Branch of the Company continues to use such properties and land, and no other parties have questioned or hindered the use of such properties and land by the Company.

 

 

42


The Company’s Shenzhen Branch and the other co-owners of the properties have issued a letter to the governing department of the original owner of the properties in respect of the confirmation of ownership of the properties, requesting it to report the ownership issue to the State-owned Assets Supervision and Administration Commission of the State Council (“SASAC”), and requesting the SASAC to confirm the respective shares of each co-owner in the properties and to issue written documents in this regard to the department of land and resources of Shenzhen, so as to assist the Company and the other co-owners to complete the formalities in relation to the division of ownership of the properties.

Given that the change of ownership of the above two properties and related land use rights were directed by the co-owners, and all formalities in relation to the change of ownership were proceeded slowly due to reasons such as issues rooted in history and government approvals, CLIC, the controlling shareholder of the Company, made further commitment as follows: CLIC will assist the Company in completing, and urge the co-owners to complete, the formalities in relation to the change of ownership in respect of the above two properties and related land use rights as soon as possible. If the formalities cannot be completed due to the reasons of the co-owners, CLIC will take any other legally practicable measures to resolve the issue and will bear any potential losses suffered by the Company as a result of the defective ownership.

AUDITORS

Following the consideration and approval by the shareholders at the 2021 Annual General Meeting on 29 June 2022, PricewaterhouseCoopers Zhong Tian LLP has been reappointed as the PRC auditor and the auditor for the Form 20-F of the Company for the year 2022, and PricewaterhouseCoopers has been reappointed as the Hong Kong auditor of the Company for the year 2022, who will hold office until the conclusion of the 2022 Annual General Meeting. The Company’s 2022 half-year financial statements prepared in accordance with the China Accounting Standards for Business Enterprises have been reviewed (not audited) by PricewaterhouseCoopers Zhong Tian LLP and the Company’s 2022 Interim Condensed Consolidated Financial

Statements prepared in accordance with the International Financial Reporting Standards have been reviewed (not audited) by PricewaterhouseCoopers.

ALLEGED VIOLATION OF LAWS AND REGULATIONS BY, PENALTIES IMPOSED ON AND RECTIFICATION OF THE COMPANY AND ITS CONTROLLING SHAREHOLDERS, EFFECTIVE CONTROLLER, DIRECTORS, SUPERVISORS OR SENIOR MANAGEMENT

During the Reporting Period, based on the information disclosed on 8 January 2022 on the website of the Central Commission for Discipline Inspection and the National Supervisory Commission, Mr. Wang Bin, the former Secretary to the Party Committee and the former Chairman of the Board of Directors of CLIC, is currently under the disciplinary review and investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission for suspected serious violation of disciplines and laws. Mr. Wang Bin is also the former Chairman of the Board and the former Executive Director of the Company. Given that Mr. Wang Bin was not able to perform his role and duties as the Chairman of the Board during the period of investigation, Mr. Yuan Changqing, a Non-Executive Director of the Company, was elected at the sixth meeting of the seventh session of the Board of Directors of the Company to assume the roles and duties of the Chairman of the Board during the period commencing from the date of passing of the Board resolution and ending on the effective date of the appointment of a new Chairman of the Board. The Board received a resignation letter from Mr. Wang Bin on 23 February 2022. As Mr. Wang Bin was unable to perform his role and duties as a Director, he had resigned from his positions as the Chairman of the Board and an Executive Director of the Company. The resignation took effect on the same day. Please refer to the announcements published by the Company on the website of the HKSE on 9 January 2022, 13 January 2022 and 23 February 2022, respectively.

 

 

43


Save for the above, during the Reporting Period, the Company was not investigated for suspected crimes according to law, and none of its controlling shareholders, effective controller, Directors, Supervisors and senior management were not subject to any compulsory measures for suspected crimes according to law. The Company or its controlling shareholders, effective controller, Directors, Supervisors and senior management were not subject to any criminal punishment, investigation by the CSRC for alleged violation of laws and regulations, administrative penalty by the CSRC, or material administrative penalty by other competent authorities, nor were they detained by the disciplinary inspection and supervison authorities for alleged serious violation of disciplines or laws or duty-related crimes which had an impact on their performance of duties. None of the Company’s Directors, Supervisors and senior management were subject to any compulsory measures by other competent authorities for alleged violation of laws and regulations which had an impact on their performance of duties.

RESTRICTION ON MAJOR ASSETS

The major assets of the Company are financial assets. During the Reporting Period, there was no major asset of the Company being seized, detained or frozen that is subject to the disclosure requirements.

 

 

44


LOGO

 

CORPORATE GOVERNANCE

In the first half of 2022, the Company adhered strictly to the regulatory requirements and listing rules of the jurisdictions where it is listed, and adopted effective measures to improve the efficiency of the Board of Directors, strengthen the communication with investors, standardize and upgrade the system and workflow of information disclosure, and increase the transparency of its business operations, so as to ensure that investors, especially small and medium investors, have an equal access to the Company’s information.

The shareholders’ general meetings, the Board of Directors and the Board of Supervisors of the Company have been functioning pursuant to their relevant procedural rules. As at 30 June 2022, the Board of Directors held eight meetings, and the Board of Supervisors held three meetings. The announcements concerning the resolutions adopted at the above meetings were published on the China Securities Journal, Securities Times and Securities Daily, as well as the website of the SSE, the HKExnews website of Hong Kong Exchanges and Clearing Limited and the website of the Company.

Shareholders’ general meetings convened during the Reporting Period are as follows:

Four proposals, including the “Proposal in relation to the Election of Mr. Bai Tao as an Executive Director of the Seventh Session of the Board of Directors of the Company”, the “Proposal in relation to the Election of Mr. Huang Yiping as an Independent Director of the Seventh Session of the Board of Directors of the Company”, the “Proposal in relation to the Election of Ms. Chen Jie as an Independent Director of the Seventh Session of the Board of Directors of the Company” and the “Proposal in relation to the ‘Outline of the 14th Five-Year Development Plan of the Company’”, were considered and approved by a combination of on-site and online voting at the First Extraordinary General Meeting 2022 held by the Company in Beijing on 27 April 2022.

 

 

45


Six proposals, including the “Proposal in relation to the Report of the Board of Directors of the Company for the Year 2021”, the “Proposal in relation to the Report of the Board of Supervisors of the Company for the Year 2021”, the “Proposal in relation to the Financial Report of the Company for the Year 2021”, the “Proposal in relation to the Profit Distribution Plan of the Company for the Year 2021”, the “Proposal in relation to the Remuneration of Directors and Supervisors of the Company” and the “Proposal in relation

to the Appointment of Auditors of the Company for the Year 2022”, were considered and approved by a combination of on-site and online voting, and the “Duty Report of the Independent Directors of the Board of Directors of the Company for the Year 2021” and the “Report on the Overall Status of Connected Transactions of the Company for the Year 2021” were received and reviewed at the 2021 Annual General Meeting held by the Company in Beijing on 29 June 2022.

 

 

Session of the meeting

  

Date of the meeting

  

Index for websites on which
resolutions were published

  

Date of publication of resolutions

First Extraordinary General Meeting 2022

   27 April 2022   

www.sse.com.cn

www.hkexnews.hk

www.e-chinalife.com

   27 April 2022

2021 Annual General Meeting

   29 June 2022   

www.sse.com.cn

www.hkexnews.hk

www.e-chinalife.com

   29 June 2022

 

The Company has applied the principles of the Corporate Governance Code (the “CG Code”) as set out in Appendix 14 to the Listing Rules. Save for code provision F.2.2, the Company has complied with all code provisions of the CG Code during the Reporting Period. Mr. Bai Tao, the Chairman of the Board of Directors of the Company, was unable to attend the 2021 Annual General Meeting of the Company as required by code provision F.2.2 due to the reason of pandemic prevention and control. Mr. Li Mingguang, an Executive Director of the Company, was elected by the Board to preside over the meeting, and communicated with shareholders in an effective manner.

The Audit Committee of the Board of Directors of the Company has reviewed the 2022 Interim Report of the Company.

IMPLEMENTATION OF PROFIT DISTRIBUTION PLAN DURING THE REPORTING PERIOD

The Company will not declare any interim dividend of ordinary shares for the Reporting Period.

According to the Profit Distribution Plan of the Company for the Year 2021 approved at the 2021 Annual General Meeting held on 29 June 2022, with the appropriation to its discretionary surplus reserve fund of RMB5,096 million (10% of the net profit for the year 2021 under the China Accounting Standards for Business Enterprises), based on a total of 28,264,705,000 shares in issue, the Company has distributed a cash dividend of RMB0.65 per share (inclusive of tax) to all shareholders of the Company, totaling approximately RMB18,372 million (inclusive of tax).

 

 

46


CHANGES IN ORDINARY SHARES AND SHAREHOLDERS INFORMATION

Changes in Share Capital

During the Reporting Period, there was no change in the total number of shares and the share capital of the Company.

Information on Shareholders

Total number of shareholders and their shareholdings

 

Total number of holders of ordinary shares as at the end of the Reporting Period    No. of A Share shareholders: 131,678
   No. of H Share shareholders: 25,256
Particulars of top ten shareholders of the Company        Unit: Shares    

 

Name of shareholder

   Nature of
shareholder
   Percentage of
shareholding
    Total number of
shares held as at
the end of the
Reporting Period
     Increase/decrease
during the
Reporting Period
     Number of shares
subject to selling
restrictions
     Number of shares
pledged or frozen
 

China Life Insurance (Group) Company

   State-owned legal person      68.37     19,323,530,000        –          –          –    

HKSCC Nominees Limited

   Overseas legal person      25.92     7,327,252,165        - 679,338        –          –    

China Securities Finance Corporation Limited

   State-owned legal person      2.51     708,240,246        –          –          –    

Central Huijin Asset Management Limited

   State-owned legal person      0.41     117,165,585        –          –          –    

Hong Kong Securities Clearing Company Limited

   Overseas legal person      0.14     39,617,818        - 17,488,953        –          –    

Guosen Securities Co., Ltd. – Founder Fubon CSI Insurance Theme Index Securities Investment Fund

   Other      0.09     24,629,550        +2,294,867        –          –    

China Universal Asset Management Co., Ltd – Industrial and Commercial Bank of China Limited – China Universal – Tianfu Bull No. 53 Asset Management Plan

   Other      0.05     15,015,845        –          –          –    

Industrial and Commercial Bank of China Limited – SSE 50 Exchange Traded Index Securities Investment Fund

   Other      0.04     11,330,504        - 2,847,000        –          –    

Li Zhuo

   Domestic natural person      0.04     10,320,933        +790,800        –          –    

China International Television Corporation

   State-owned legal person      0.04     10,000,000        –          –          –    

Notes:

1.

HKSCC Nominees Limited is a company that holds shares on behalf of the clients of the Hong Kong stock brokers and other participants of the CCASS system. The relevant regulations of the HKSE do not require such persons to declare whether their shareholdings are pledged or frozen. Hence, HKSCC Nominees Limited is unable to calculate or provide the number of shares that are pledged or frozen.

2.

China Universal Asset Management Co., Ltd – Industrial and Commercial Bank of China Limited – China Universal – Tianfu Bull No. 53 Asset Management Plan has Industrial and Commercial Bank of China Limited as its asset trustee. Industrial and Commercial Bank of China Limited – SSE 50 Exchange Traded Index Securities Investment Fund has Industrial and Commercial Bank of China Limited as its fund depositary. Save as above, the Company was not aware of any connected relationship and concerted parties as defined by the “Measures for the Administration of the Takeover of Listed Companies” among the top ten shareholders of the Company.

Change in the Controlling Shareholder and the Effective Controller

During the Reporting Period, there was no change in the controlling shareholder and the effective controller of the Company.

 

47


Interests and Short Positions in the Shares and Underlying Shares of the Company Held by Substantial Shareholders and Other Persons Under Hong Kong Laws and Regulations

So far as is known to the Directors, Supervisors and the chief executive of the Company, as at 30 June 2022, the following persons (other than the Directors, Supervisors and the chief executive of the Company) had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the Securities and Futures Ordinance (“SFO”), or which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO, or as otherwise notified to the Company and the HKSE:

 

Name of substantial shareholder

  

Capacity

   Class of shares      Number of
shares held
    Percentage of
the respective
class of shares
    Percentage of
the total number
of shares in issue
 

China Life Insurance (Group) Company

  

Beneficial owner

     A Shares        19,323,530,000 (L)      92.80     68.37

BlackRock, Inc. (Note)

  

Interest in controlled corporation

     H Shares        433,528,591 (L)      5.83     1.53
           6,876,000 (S)      0.09     0.02

The letter “L” denotes a long position. The letter “S” denotes a short position.

 

(Note):

BlackRock, Inc. was interested in a total of 433,528,591 H shares of the Company in accordance with the provisions of Part XV of the SFO. Of these shares, BlackRock Investment Management, LLC, BlackRock Financial Management, Inc., BlackRock Institutional Trust Company, National Association, BlackRock Fund Advisors, BlackRock Advisors, LLC, BlackRock Japan Co., Ltd., BlackRock Asset Management Canada Limited, BlackRock Investment Management (Australia) Limited, BlackRock Asset Management North Asia Limited, BlackRock (Netherlands) B.V., BlackRock Advisors (UK) Limited, BlackRock Asset Management Ireland Limited, BLACKROCK (Luxembourg) S.A., BlackRock Investment Management (UK) Limited, BlackRock Asset Management Deutschland AG, BlackRock Fund Managers Limited, BlackRock Life Limited, BlackRock (Singapore) Limited, BlackRock Asset Management Schweiz AG and Aperio Group, LLC were interested in 4,070,000 H shares, 6,406,000 H shares, 89,687,588 H shares, 179,380,000 H shares, 992,000 H shares, 16,236,243 H shares, 948,000 H shares, 4,137,000 H shares, 17,949,961 H shares, 16,355,543 H shares, 146,000 H shares, 63,667,627 H shares, 1,056,000 H shares, 10,167,826 H shares, 492,000 H shares, 11,139,123 H shares, 524,500 H shares, 2,534,000 H shares, 24,000 H shares and 7,615,180 H shares, respectively. All of these entities are either controlled or indirectly controlled subsidiaries of BlackRock, Inc.

 

    

BlackRock, Inc. held by way of attribution a short position as defined under Part XV of the SFO in 6,876,000 H shares (0.09%). Of these 6,876,000 H shares, 3,956,000 H shares were cash settled unlisted derivatives.

Save as disclosed above, the Directors, Supervisors and the chief executive of the Company are not aware of any other party who, as at 30 June 2022, had an interest or short position in the shares and underlying shares of the Company which was recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

 

48


DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT

Change in Shares of the Company Held by Directors, Supervisors and Senior Management

During the Reporting Period, there was no change in shares of the Company held by Directors, Supervisors and senior management.

Directors, Supervisors and Senior Management

As at the date of this report, Directors, Supervisors and senior management of the Company were as follows:

 

DIRECTORS    Executive Directors   

Bai Tao (Chairman)

Li Mingguang

Huang Xiumei

   (appointed on 31 May 2022)
   Non-executive Director    Wang Junhui   
   Independent Directors    Lam Chi Kuen    (appointed on 13 July 2022)
     

Zhai Haitao

Huang Yiping

      Chen Jie    (appointed on 13 July 2022)

SUPERVISORS

   Non-employee Representative Supervisors   

Jia Yuzeng (Chairman)

Niu Kailong

  
   Employee Representative Supervisors   

Wang Xiaoqing

Lai Jun

Hu Zhijun

   (appointed on 13 July 2022)

SENIOR

   Temporary Person in Charge of the Company    Zhao PengNote    (appointed on 2 August 2022)

MANAGEMENT

   Vice President, Chief Actuary, Board Secretary    Li Mingguang   
   Vice President, Person in Charge of Finance    Huang Xiumei   
   Vice Presidents   

Ruan Qi

Zhan Zhong

Yang Hong

  
   Assistants to the President   

Zhao Guodong

Liu Yuejin

Zhang Di (Chief Investment Officer)

Bai Kai

   (appointed on 29 April 2022)
   Compliance Officer    Xu Chongmiao   
   Person in Charge of Audit    Liu Fengji   

 

Note:

On 2 August 2022, Mr. Zhao Peng was appointed as the President of the Company at the fifteenth meeting of the seventh session of the Board of Directors of the Company and his qualification as the President of the Company is subject to the approval by the CBIRC. The Board has appointed Mr. Zhao Peng as the temporary person in charge of the Company before the approval on his qualification is obtained.

 

49


During the Reporting Period and up to the date of this report, the change of Directors, Supervisors and senior management of the Company was as follows:

As elected by the First Extraordinary General Meeting 2022 of the Company and the eleventh meeting of the seventh session of the Board of Directors convened on the same day and upon approval by the CBIRC, Mr. Bai Tao has served as the Chairman of the Board of Directors and an Executive Director of the Company since 31 May 2022.

As elected by the First Extraordinary General Meeting 2022 of the Company and upon approval by the CBIRC, Mr. Huang Yiping has served as an Independent Director of the seventh session of the Board of Directors, the Chairman of the Risk Management and Consumer Rights Protection Committee, as well as a member of each of the Strategy and Assets and Liabilities Management Committee and the Connected Transactions Control Committee of the Company since 13 July 2022; Ms. Chen Jie has served as an Independent Director of the seventh session of the Board of Directors, the Chairman of each of the Nomination and Remuneration Committee and the Connected Transactions Control Committee, as well as a member of each of the Audit Committee and the Risk Management and Consumer Rights Protection Committee of the Company since 13 July 2022.

With effect from 22 February 2022, Mr. Lam Chi Kuen was redesignated as the Chairman of the Audit Committee and a member of the Nomination and Remuneration Committee, remained as a member of the Connected Transactions Control Committee and ceased to serve as the Chairman of the Strategy and Assets and Liabilities Management Committee; Mr. Zhai Haitao was redesignated as the Chairman of the Strategy and Assets and Liabilities Management Committee and a member of the Audit Committee, remained as a member of the Connected Transactions Control Committee and ceased to serve as a member of the Nomination and Remuneration Committee.

Mr. Wang Junhui was appointed as a member of the Nomination and Remuneration Committee on 25 May 2022.

Mr. Zhao Peng was nominated as an Executive Director of the seventh session of the Board of Directors of the Company at the fifteenth meeting of the seventh session of the Board of Directors of the Company. Such proposal shall be submitted to the shareholders’ general meeting of the Company for consideration and approval and his qualification as a Director of the Company is subject to the approval by the CBIRC.

As elected by the eighth extraordinary meeting of the third session of the employee representative meeting of the Company and upon approval by the CBIRC, Ms. Hu Zhijun has served as an Employee Representative Supervisor of the seventh session of the Board of Supervisors of the Company since 13 July 2022.

Mr. Cao Weiqing was elected as an Employee Representative Supervisor of the seventh session of the Board of Supervisors of the Company at the ninth extraordinary meeting of the third session of the employee representative meeting of the Company. The qualification of Mr. Cao Weiqing as a Supervisor is subject to the approval by the CBIRC.

On 2 August 2022, Mr. Zhao Peng was appointed as the President of the Company at the fifteenth meeting of the seventh session of the Board of Directors of the Company and his qualification as the President of the Company is subject to the approval by the CBIRC. The Board has appointed Mr. Zhao Peng as the temporary person in charge of the Company before the approval on his qualification is obtained.

As Mr. Wang Bin was unable to continue to perform his role and duties as a Director, he tendered his resignation to the Board of Directors on 23 February 2022 and had resigned from his positions as the Chairman of the Board of Directors and an Executive Director of the Company. The resignation took effect on the same day.

Due to the reason of age, Mr. Yuan Changqing ceased to be a Non-executive Director of the Company from 1 June 2022.

As Mr. Tang Xin had consecutively served as an Independent Director of the Company for six years, he tendered his resignation to the Board of Directors on 6 March 2022 pursuant to the relevant PRC regulations and had resigned from his positions as an Independent Director, the Chairman of each of the Nomination and Remuneration Committee and the Connected Transactions Control Committee, and a member of each of the Audit Committee and the Risk Management and Consumer Rights Protection Committee of the Company. Since his resignation would result in the number of Independent Directors on the Board of Directors falling below the minimum number required by the relevant regulations and the Articles of Association, Mr. Tang Xin continued to perform his duties until the qualification of Ms. Chen Jie as a Director was approved by the CBIRC on 13 July 2022.

 

 

50


As Ms. Leung Oi-Sie Elsie had consecutively served as an Independent Director of the Company for nearly six years, she tendered her resignation to the Board of Directors on 18 July 2022 pursuant to the relevant PRC regulations and had resigned from her positions as an Independent Director, the Chairman of the Risk Management and Consumer Rights Protection Committee, and a member of each of the Strategy and Assets and Liabilities Management Committee and the Connected Transactions Control Committee. The resignation took effect on the same day.

Due to the adjustment of work arrangements, Mr. Su Hengxuan ceased to be the President, an Executive Director and a member of the Strategy and Assets and Liabilities Management Committee of the Company from 1 August 2022.

Due to the adjustment of work arrangements, Mr. Cao Qingyang ceased to be an Employee Representative Supervisor of the Company from 18 July 2022.

As considered by the ninth meeting of the seventh session of the Board of Directors of the Company and upon approval by the CBIRC, Mr. Bai Kai has served as an Assistant to the President of the Company since 29 April 2022.

Performance of Duties by Independent Directors

The Independent Directors of the Company diligently fulfilled their responsibilities and faithfully performed their duties by attending the First Extraordinary General Meeting 2022 and the 2021 Annual General Meeting, and meetings of the Board and the specialized Board committees, so as to examine and approve the Company’s business development, its financial management and connected transactions. They actively participated in the development of specialized Board committees and provided professional advice in respect of major decisions of the Company. The Independent Directors seriously listened to the reports from relevant personnel in order to understand the daily operations and possible operational risks of the Company in a timely manner. They expressed their opinions at Board meetings and performed their duties as Independent Directors in an effective manner.

During the Reporting Period, no Independent Director of the Company had raised any objection against the proposals and matters considered by the Board of the Company.

Disclosure of Interests of Directors, Supervisors and the Chief Executive in the Shares of the Company

As at 30 June 2022, none of the Directors, Supervisors and the chief executive of the Company had any interests or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) that were required to be recorded in the register of the Company required to be kept pursuant to Section 352 of the SFO or which had to be notified to the Company and the HKSE pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the “Model Code”) as set out in Appendix 10 to the Listing Rules.

Compliance with the Code for Securities Transactions by Directors and Supervisors of the Company

The Board has established written guidelines on no less exacting terms than the Model Code for Directors and Supervisors of the Company in respect of their dealings in the securities of the Company. After making specific inquiries to all the Directors and Supervisors of the Company, they confirmed that they had complied with the Model Code and the Company’s own guidelines during the Reporting Period.

BRANCHES AND EMPLOYEES OF THE COMPANY

As at 30 June 2022, the Company had approximately 19,000 branches4.

As at 30 June 2022, the Company had 102,195 employees in total. There was no material change in the employee remuneration policy and training program when compared with the information disclosed in the Company’s Annual Report 2021.

 

 

51


LOGO

BASIC INFORMATION OF THE COMPANY

 

Registered Name in Chinese    中國人壽保險股份有限公司(簡稱「中國人壽」)
Registered Name in English    China Life Insurance Company Limited (“China Life”)
Legal Representative    Bai Tao
Registered Office Address/ Current Office Address    16 Financial Street, Xicheng District, Beijing, P.R. China
Postal Code    100033
Telephone    86-10-63633333
Investor Relations Hotline    86-10-63631241
Customer Service Hotline    95519
Fax    86-10-66575722
Website    www.e-chinalife.com
Email    ir@e-chinalife.com
Hong Kong Office Address    16/F, Tower A, China Life Centre, One Harbour Gate, 18 Hung Luen Road, Hung Hom, Kowloon, Hong Kong
Telephone    852-29192628

 

52


CONTACT INFORMATION

 

   Board Secretary    Securities Representative

Name

   Li Mingguang    Li Yinghui

Office Address

   16 Financial Street, Xicheng District, Beijing, P.R. China    16 Financial Street, Xicheng District, Beijing, P.R. China

Telephone

   86-10-63631241    86-10-63631191

Fax

   86-10-66575112    86-10-66575112

Email

   ir@e-chinalife.com    liyh@e-chinalife.com
     

*  Ms. Li Yinghui, Securities Representative of the Company, is also the main contact person of the external Company Secretary engaged by the Company.

INFORMATION DISCLOSURE AND PLACE FOR OBTAINING THE REPORT

 

Media and Websites for the Company’s A Share Disclosure   

China Securities Journal (www.cs.com.cn)

Securities Times (www.stcn.com)

Securities Daily (www.zqrb.cn)

CSRC’s Designated Website for the Company’s Interim Report Disclosure    www.sse.com.cn

The Company’s H Share

Disclosure Websites

  

HKExnews website of Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk

The Company’s website at www.e-chinalife.com

The Company’s Interim Report

may be obtained at

   12/F, Tower A, China Life Plaza, 16 Financial Street, Xicheng District, Beijing, P.R. China

STOCK INFORMATION

 

Stock Type   

Exchanges on which the

Stocks are Listed

   Stock Short Name    Stock Code

A Share

   Shanghai Stock Exchange    China Life    601628

H Share

   The Stock Exchange of Hong Kong Limited    China Life    2628

ADR

   New York Stock Exchange       LFC

 

*

After 1 September 2022, the ADSs of the Company will no longer be listed and traded on the NYSE.

 

53


OTHER RELEVANT INFORMATION

 

H Share Registrar and Transfer Office

   Computershare Hong Kong Investors Services Limited    Address: Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong

Depositary of ADR

   Deutsche Bank    Address: 1 Columbus Circle, New York, NY 10019, United States of America

Domestic Legal Adviser

   King & Wood Mallesons   

International Legal Advisers

   Latham & Watkins LLP    Debevoise & Plimpton LLP
   Domestic Auditor    International Auditor
   PricewaterhouseCoopers Zhong Tian LLP    PricewaterhouseCoopers

Auditors of the Company

   Address: 11/F, PricewaterhouseCoopers Center, 2 Link Suqare, 202 Hubin Road, Huangpu District, Shanghai, PRC   

Address: 22/F, Prince’s Building,

Central, Hong Kong

  

Name of the Signing Auditors:

Zhou Xing, Huang Chen

  

Name of the Certified Auditor:

Yip Siu Foon, Linda

 

54


INDEX OF INFORMATION DISCLOSURE ANNOUNCEMENTS

 

Serial
No.    

 

Items

   Date of
disclosure
 
1  

Announcement

     2022/1/9  
2  

Announcement on Election of Director to Act as Chairman

     2022/1/13  
3  

Announcement of Premium Income

     2022/1/14  
4  

Election of Language and Means of Receipt of Corporate Communication

     2022/1/17  
5  

Reply Form

     2022/1/17  
6  

Announcement – Connected Transaction – Capital Injection to CLP&C

     2022/1/20  
7  

Announcement – Forfeiture of Unclaimed Dividends

     2022/1/25  
8  

Announcement of Premium Income

     2022/2/16  
9  

Announcement – Change of Composition of the Special Committees of the Board

     2022/2/22  
10  

Announcement – Resignation of Chairman of the Board

     2022/2/23  
11  

Announcement – Resignation of Independent Director

     2022/3/7  
12  

Announcement – Nomination of Directors

     2022/3/8  
13  

Notice of Board Meeting

     2022/3/10  
14   Election of Mr. Bai Tao as an Executive Director of the Seventh Session of the Board of Directors, Election of Mr. Huang Yiping as an Independent Director of the Seventh Session of the Board of Directors, Election of Ms. Chen Jie as an Independent Director of the Seventh Session of the Board of Directors, Outline of the “14th Five-Year Development Plan” of the Company and Notice of the First Extraordinary General Meeting 2022      2022/3/10  
15   Form of Proxy of Holders of H Shares for use at the First Extraordinary General Meeting 2022 of the Company to be held on Wednesday, 27 April 2022      2022/3/10  
16  

Notice of the First Extraordinary General Meeting 2022

     2022/3/10  
17  

Reply Slip of Holders of H Shares

     2022/3/10  
18  

Notification Letter and Change Request Form to Registered Shareholders

     2022/3/10  
19  

Notification Letter and Request Form to Non-Registered Shareholders

     2022/3/10  
20  

Announcement of Premium Income

     2022/3/11  
21  

Voluntary Announcement – Convening of 2021 Annual Results Briefing

     2022/3/16  
22  

Announcement of Results for the Year Ended 31 December 2021

     2022/3/24  
23  

China Life Insurance Company Limited 2021 Environmental, Social and Governance & Social Responsibility Report

     2022/3/24  
24  

Summary of Solvency Quarterly Report of Insurance Company (Fourth Quarter of 2021)

     2022/3/24  
25   Overseas Regulatory Announcement – China Life Insurance Company Limited – Announcement on Changes in Accounting Estimates      2022/3/24  
26  

Announcement – Election of Employee Representative Supervisor

     2022/4/1  
27  

Annual Report 2021

     2022/4/13  
28  

Notice of Board Meeting

     2022/4/13  

 

55


Serial
No.    

 

Items

   Date of
disclosure
 
29  

Announcement of Premium Income

     2022/4/13  
30   Reports of the Board of Directors and the Board of Supervisors for the year 2021, Financial Report and Profit Distribution Plan for the year 2021, Remuneration of Directors and Supervisors, Duty Report of the Independent Directors for the year 2021, Report on the Overall Status of Connected Transactions for 2021 and Notice of Annual General Meeting      2022/4/13  
31  

Notice of Annual General Meeting

     2022/4/13  
32   Form of Proxy of Holders of H Shares for use at the Annual General Meeting of the Company to be held on Wednesday, 29 June 2022      2022/4/13  
33  

Reply Slip of H Share Shareholders

     2022/4/13  
34  

Notification Letter and Change Request Form to Registered Shareholders

     2022/4/13  
35  

Notification Letter and Request Form to Non-Registered Shareholders

     2022/4/13  
36  

2022 First Quarter Report

     2022/4/27  
37  

Announcement – Resolutions Passed at the First Extraordinary General Meeting 2022

     2022/4/27  
38  

Announcement – Change of Chairman of the Board

     2022/4/27  
39   Overseas Regulatory Announcement – China Life Insurance Company Limited – Announcement on Changes in Accounting Estimates      2022/4/27  
40  

Summary of Solvency Quarterly Report of Insurance Company (First Quarter of 2022)

     2022/4/28  
41  

Voluntary Announcement – Update on Status under Holding Foreign Companies Accountable Act

     2022/5/5  
42  

Announcement of Premium Income

     2022/5/13  
43  

Supplemental Notice of Annual General Meeting

     2022/5/25  
44   Supplemental Form of Proxy of Holders of H Shares for use at the Annual General Meeting of the Company to be held on Wednesday, 29 June 2022      2022/5/25  
45  

Notification Letter and Change Request Form to Registered Shareholders

     2022/5/25  
46  

Notification Letter and Request Form to Non-Registered Shareholders

     2022/5/25  
47  

Announcement – Change of Members of the Nomination and Remuneration Committee

     2022/5/25  
48   Announcement – Approval of Qualification as Chairman of the Board by the CBIRC and Resignation of Non-Executive Director      2022/6/2  
49  

Announcement of Premium Income

     2022/6/13  
50  

Announcement on Approval of the Amendments to the Articles of Association by the CBIRC

     2022/6/27  
51  

Articles of Association of China Life Insurance Company Limited

     2022/6/27  
52  

Announcement – Resolutions Passed at the Annual General Meeting and Distribution of Final Dividend

     2022/6/29  

 

56


DEFINITIONS AND MATERIAL RISK ALERT

In this report, unless the context otherwise requires, the following expressions have the following meanings:

 

China Life, the Company5    China Life Insurance Company Limited and its subsidiaries
CLIC    China Life Insurance (Group) Company, the controlling shareholder of the Company
AMC    China Life Asset Management Company Limited, a non-wholly owned subsidiary of the Company
Pension Company    China Life Pension Company Limited, a non-wholly owned subsidiary of the Company
AMP    China Life AMP Asset Management Company Limited, an indirect non-wholly owned subsidiary of the Company
CGB    China Guangfa Bank Co., Ltd., an associate of the Company
CLP&C    China Life Property and Casualty Insurance Company Limited, a non-wholly owned subsidiary of CLIC
CLI    China Life Investment Management Company Limited, a wholly-owned subsidiary of CLIC
China Life Capital    China Life Capital Investment Company, an indirect wholly-owned subsidiary of CLIC
CBIRC    China Banking and Insurance Regulatory Commission
CSRC    China Securities Regulatory Commission
HKSE    The Stock Exchange of Hong Kong Limited
SSE    Shanghai Stock Exchange
Company Law    Company Law of the People’s Republic of China
Insurance Law    Insurance Law of the People’s Republic of China
Securities Law    Securities Law of the People’s Republic of China
Articles of Association    Articles of Association of China Life Insurance Company Limited
C-ROSS (Phase II) Regulation    Solvency Regulatory Rules II for Insurance Companies
China or PRC    For the purpose of this report, “China” or “PRC” refers to the People’s Republic of China, excluding the Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan region
ESG    Environment, Social and Governance
RMB    Renminbi Yuan

Material Risk Alert:

The risks faced by the Company primarily include risks relating to macro trends, insurance risk, market risk, credit risk, operational risk, strategic risk, reputation risk, liquidity risk, information safety risk and ESG risk. The Company has adopted various measures to manage and control different risks effectively. The Company has stated in this report the details of its existing risks relating to macro trends and please refer to the “Future Prospect” in the section headed “Management Discussion and Analysis”. For other risk analysis, please refer to the “Internal Control and Risk Management” in the section headed “Corporate Governance” of the Annual Report 2021 of the Company. During the Reporting Period, there was no material change in the other risks mentioned above.

 

5 

Except for “the Company” referred to in the Interim Condensed Consolidated Financial Statements.

 

57


LOGO

 

58


Auditor’s Independent Review Report

 

LOGO

To the Board of Directors of China Life Insurance Company Limited

(incorporated in the People’s Republic of China with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 60 to 108, which comprises the interim condensed consolidated statement of financial position of China Life Insurance Company Limited (the “Company”) and its subsidiaries (together, the “Group”) as at 30 June 2022 and the interim condensed consolidated statement of comprehensive income, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six-month period then ended, and notes, comprising significant accounting policies and other explanatory information. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 “Interim Financial Reporting”. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 “Interim Financial Reporting”. Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 “Interim Financial Reporting”.

PricewaterhouseCoopers

Certified Public Accountants

Hong Kong, 25 August 2022

 

59


Interim Condensed Consolidated Statement of Financial Position

As at 30 June 2022

 

     Notes      Unaudited
As at

30 June
2022
RMB million
     Audited
As at 31
December
2021
RMB million
 

ASSETS

        

Property, plant and equipment

        53,567        54,398  

Right-of-use assets

        2,165        2,518  

Investment properties

        13,144        13,374  

Investments in associates and joint ventures

     6        269,621        257,953  

Held-to-maturity securities

     7.1        1,565,158        1,533,753  

Loans

     7.2        653,033        666,087  

Term deposits

     7.3        510,832        529,488  

Statutory deposits – restricted

        6,333        6,333  

Available-for-sale securities

     7.4        1,618,290        1,429,287  

Securities at fair value through profit or loss

     7.5        201,601        206,771  

Securities purchased under agreements to resell

        44,943        12,915  

Accrued investment income

        54,859        51,097  

Premiums receivable

        50,228        20,361  

Reinsurance assets

        7,560        6,630  

Other assets

        27,927        39,559  

Deferred tax assets

     14        136        121  

Cash and cash equivalents

        94,127        60,440  
     

 

 

    

 

 

 

Total assets

        5,173,524        4,891,085  
     

 

 

    

 

 

 

 

60


Interim Condensed Consolidated Statement of Financial Position (continued)

As at 30 June 2022

 

     Notes      Unaudited
As at
30 June 2022
RMB million
     Audited As
at 31
December
2021
RMB million
 

LIABILITIES AND EQUITY

        

Liabilities

        

Insurance contracts

     8        3,763,217        3,419,899  

Investment contracts

     9        348,375        313,594  

Policyholder dividends payable

        120,084        124,949  

Interest-bearing loans and borrowings

        18,965        18,686  

Lease liabilities

        1,931        2,182  

Bonds payable

        34,996        34,994  

Financial liabilities at fair value through profit or loss

        4,188        3,416  

Securities sold under agreements to repurchase

        175,450        239,446  

Annuity and other insurance balances payable

        60,339        56,818  

Premiums received in advance

        3,443        48,699  

Other liabilities

        149,734        133,676  

Deferred tax liabilities

     14        3,815        7,481  

Current income tax liabilities

        276        248  

Statutory insurance fund

        554        339  
     

 

 

    

 

 

 

Total liabilities

        4,685,367        4,404,427  
     

 

 

    

 

 

 

Equity

        

Share capital

     19        28,265        28,265  

Reserves

        248,346        249,055  

Retained earnings

        203,239        201,265  
     

 

 

    

 

 

 

Attributable to equity holders of the Company

        479,850        478,585  
     

 

 

    

 

 

 

Non-controlling interests

        8,307        8,073  
     

 

 

    

 

 

 

Total equity

        488,157        486,658  
     

 

 

    

 

 

 

Total liabilities and equity

        5,173,524        4,891,085  
     

 

 

    

 

 

 

Approved and authorised for issue by the Board of Directors on 25 August 2022.

 

Bai Tao

  

Huang Xiumei

Director

   Director

 

61


Interim Condensed Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2022

 

           

Unaudited

For the six months

ended 30 June

 
            2022     2021  
     Notes      RMB million     RMB million
(Restated
Note 18(a)(i))
 

REVENUES

       

Gross written premiums

        439,969       442,299  

Less: premiums ceded to reinsurers

        (4,458     (3,547
     

 

 

   

 

 

 

Net written premiums

        435,511       438,752  

Net change in unearned premium reserves

        (15,875     (16,110
     

 

 

   

 

 

 

Net premiums earned

        419,636       422,642  
     

 

 

   

 

 

 

Investment income

     10        91,196       82,046  

Net realised gains on financial assets

     11        6,662       22,571  

Net fair value gains through profit or loss

     12        (5,129     5,303  

Other income

        4,305       4,591  
     

 

 

   

 

 

 

Total revenues

        516,670       537,153  
     

 

 

   

 

 

 

BENEFITS, CLAIMS AND EXPENSES

       

Insurance benefits and claims expenses

       

Life insurance death and other benefits

        (66,505     (68,934

Accident and health claims and claim adjustment expenses

        (24,477     (26,829

Increase in insurance contract liabilities

        (324,716     (312,777

Investment contract benefits

        (6,631     (5,333

Policyholder dividends resulting from participation in profits

        (11,837     (15,483

Underwriting and policy acquisition costs

        (35,305     (42,132

Finance costs

        (2,610     (2,193

Administrative expenses

        (18,052     (18,142

Statutory insurance fund contribution

        (874     (861

Other expenses

        (6,429     (6,057
     

 

 

   

 

 

 

Total benefits, claims and expenses

        (497,436     (498,741
     

 

 

   

 

 

 

Net gains on investments of associates and joint ventures

        5,757       7,683  

Including: share of profit of associates and joint ventures

        5,757       7,683  
     

 

 

   

 

 

 

Profit before income tax

     13        24,991       46,095  

Income tax

     14        1,183       (4,372
     

 

 

   

 

 

 

Net profit

        26,174       41,723  
     

 

 

   

 

 

 

Attributable to:

       

– Equity holders of the Company

        25,416       40,968  

– Non-controlling interests

        758       755  

Basic and diluted earnings per share

     15        RMB0.90       RMB1.45  

 

62


Interim Condensed Consolidated Statement of Comprehensive Income (continued)

For the six months ended 30 June 2022

 

    

Unaudited

For the six months

ended 30 June

 
     2022
RMB million
    2021  
    RMB million
(Restated
Note 18(a)(i))
 

Other comprehensive income

    

Other comprehensive income that may be reclassified to profit or loss in subsequent periods:

    

Fair value gains/(losses) on available-for-sale securities

     (4,120     20,954  

Amount transferred to net profit from other comprehensive income

     (6,660     (22,583

Portion of fair value changes on available-for-sale securities attributable to policyholders equity

     3,787       (100

Share of other comprehensive income of associates and joint ventures under the equity method

     (171     13  

Exchange differences on translating foreign operations

     10       69  

Income tax relating to components of other comprehensive income

     1,771       (71
  

 

 

   

 

 

 

Other comprehensive income that may be reclassified to profit or loss in subsequent periods

     (5,383     (1,718
  

 

 

   

 

 

 

Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:

    

Share of other comprehensive loss of associates and joint ventures under the equity method

     (165     (227
  

 

 

   

 

 

 

Other comprehensive loss for the period, net of tax

     (5,548     (1,945
  

 

 

   

 

 

 

Total comprehensive income for the period, net of tax

     20,626       39,778  
  

 

 

   

 

 

 

Attributable to:

    

– Equity holders of the Company

     19,938       39,086  

– Non-controlling interests

     688       692  

The notes on pages 66 to 108 form an integral part of the interim condensed consolidated financial statements.

 

63


Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2022

 

     Unaudited
     Attributable to equity holders of the Company     Non-
controlling
interests
RMB million
    Total
    
RMB million
 
     Share capital
RMB million
     Reserves
RMB million
    Retained
earnings

RMB million
 

As at 1 January 2021

(Restated Note 18(a)(i))

     28,265        237,935       183,856       6,881       456,937  

Net profit

     —          —         40,968       755       41,723  

Other comprehensive income

     —          (1,882     —         (63     (1,945
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Total comprehensive income

     —          (1,882     40,968       692       39,778  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Transactions with shareholders

           

Appropriation to reserves

     —          5,033       (5,033     —         —    

Dividends declared

     —          —         (18,089     —         (18,089

Dividends to non-controlling interests

     —          —         —         (359     (359

Reserves to retained earnings

     —          68       (68     —         —    

Others

     —          394       —         —         394  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Total transactions with shareholders

     —          5,495       (23,190     (359     (18,054
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

As at 30 June 2021

     28,265        241,548       201,634       7,214       478,661  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

As at 1 January 2022

     28,265        249,055       201,265       8,073       486,658  

Net profit

     —          —         25,416       758       26,174  

Other comprehensive income

     —          (5,478     —         (70     (5,548
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Total comprehensive income

     —          (5,478     25,416       688       20,626  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Transactions with shareholders

           

Appropriation to reserves

     —          5,137       (5,137     —         —    

Dividends declared (Note 16)

     —          —         (18,372     —         (18,372

Dividends to non-controlling interests

     —          —         —         (454     (454

Reserves to retained earnings

     —          (67     67       —         —    

Others

     —          (301     —         —         (301
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Total transactions with shareholders

     —          4,769       (23,442     (454     (19,127
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

As at 30 June 2022

     28,265        248,346       203,239       8,307       488,157  
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

The notes on pages 66 to 108 form an integral part of the interim condensed consolidated financial statements.

 

64


Interim Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2022

 

     Unaudited  
     For the six months  
     ended 30 June  
           2021  
     2022
RMB million
    RMB million
(Restated
Note 18(a)(i))
 

Net cash inflow/(outflow) from operating activities

     242,684       198,320  
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

    

Disposals and maturities

     464,105       277,407  

Purchases

     (657,841     (546,075

Investments in associates and joint ventures

     (8,704     (4,950

Decrease/(Increase) in term deposits, net

     19,027       (7,628

Increase in securities purchased under agreements to resell, net

     (31,979     (1,352

Interest received

     75,573       67,529  

Dividends received

     12,379       9,225  

Increase in policy loans, net

     (9,251     (20,880
  

 

 

   

 

 

 

Net cash inflow/(outflow) from investing activities

     (136,691     (226,724
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

    

Increase/(Decrease) in securities sold under agreements to repurchase, net

     (64,186     47,676  

Interest paid

     (4,934     (4,280

Repayment of borrowings

     (69     —    

Dividends paid to non-controlling interests

     (313     (191

Payment of lease liabilities

     (620     (690

Capital injected into subsidiaries by non-controlling interests

     —         11,819  

Cash paid related to other financing activities

     (2,389     (750
  

 

 

   

 

 

 

Net cash inflow/(outflow) from financing activities

     (72,511     53,584  
  

 

 

   

 

 

 

Foreign exchange gains/(losses) on cash and cash equivalents

     205       (38
  

 

 

   

 

 

 

Net increase in cash and cash equivalents

     33,687       25,142  
  

 

 

   

 

 

 

Cash and cash equivalents

    

Beginning of period

     60,440       56,655  
  

 

 

   

 

 

 

End of period

     94,127       81,797  
  

 

 

   

 

 

 

Analysis of balances of cash and cash equivalents

    

Cash at banks and in hand

     94,103       81,669  

Short-term bank deposits

     24       128  

The notes on pages 66 to 108 form an integral part of the interim condensed consolidated financial statements.

 

65


Notes to the Interim Condensed Consolidated Financial Statements

For the six months ended 30 June 2022

 

1

ORGANISATION AND PRINCIPAL ACTIVITIES

China Life Insurance Company Limited (the “Company”) was established in the People’s Republic of China (“China” or the “PRC”) on 30 June 2003 as a joint stock company with limited liability as part of a group restructuring of China Life Insurance (Group) Company (“CLIC”, formerly China Life Insurance Company) and its subsidiaries. The Company and its subsidiaries are hereinafter collectively referred to as the “Group”. The Group’s principal activities are the writing of life, health, accident and other types of personal insurance business; reinsurance business for personal insurance business; fund management business permitted by national laws and regulations or approved by the State Council of the People’s Republic of China, etc.

The Company is a joint stock company incorporated in the PRC with limited liability. The address of its registered office is 16 Financial Street, Xicheng District, Beijing, the PRC. The Company is listed on the New York Stock Exchange(i), the Stock Exchange of Hong Kong Limited, and the Shanghai Stock Exchange.

These unaudited interim condensed consolidated financial statements are presented in millions of Renminbi (“RMB million”) unless otherwise stated. The interim condensed consolidated financial statements have been approved and authorised for issue by the Board of Directors of the Company on 25 August 2022.

 

  (i)

After 1 September 2022, the American depositary shares of the Company will no longer be listed and traded on the New York Stock Exchange.

 

2

BASIS OF PREPARATION

These interim condensed consolidated financial statements has been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting issued by the International Accounting Standards Board (“IASB”). The interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended 31 December 2021, which have been prepared in accordance with International Financial Reporting Standards (“IFRSs”).

Except for the standards and amendments described below, the accounting policies applied are consistent with those of the consolidated financial statements for the year ended 31 December 2021, as described in those financial statements.

 

  2.1

New accounting standards and amendments adopted by the Group for the first time for the financial year beginning on 1 January 2022

 

Standards/Amendments

  

Content

  

Effective for annual periods

beginning on or after

Amendments to IFRS 3

   Update Reference to the Conceptual Framework    1 January 2022

Amendments to IAS 16

   Property, Plant and Equipment: Proceeds before intended use    1 January 2022

Amendments to IAS 37

   Onerous Contracts – Cost of Fulfilling a Contract    1 January 2022

Annual improvements

  

Annual Improvements to IFRS Standards

2018-2020 Cycle

   1 January 2022

These amendments did not have any significant impact on the financial position and performance of the Group.

 

66


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

2

BASIS OF PREPARATION (continued)

 

  2.2

New accounting standards and amendments that are effective but temporary exemption is applied by the Group for the financial year beginning on 1 January 2022

 

Standards/Amendments

  

Content

  

Effective for annual periods
beginning on or after

IFRS 9

   Financial Instruments    1 January 2018

IFRS 9 Financial Instruments

In July 2014, the IASB issued the final version of IFRS 9, bringing together all phases of the financial instruments project to replace IAS 39 and all previous versions of IFRS 9. The standard introduces new requirements for classification and measurement, impairment, and hedge accounting. IFRS 9 is effective for annual periods beginning on or after 1 January 2018, with early adoption permitted. Based on the current assessment, the Group expects that the adoption of IFRS 9 will have a significant impact on the Group’s consolidated financial statements. The Group has adopted the temporary exemption permitted in the Amendments to IFRS 4 Applying IFRS 9 Financial Instruments with IFRS 4 Insurance Contracts (“IFRS 4 Amendment”) to apply IAS 39 rather than IFRS 9, until the effective date of IFRS 17. Refer to Note 17 for more details.

Classification and measurement

IFRS 9 requires that the Group classifies debt instruments based on the combined effect of application of business models (hold to collect contractual cash flows, hold to collect contractual cash flows and sell financial assets or other business models) and contractual cash flow characteristics (solely payments of principal and interest on the principal amount outstanding or not). Debt instruments not giving rise to cash flows that are solely payments of principal and interest on the principal amount outstanding would be measured at fair value through profit or loss. Other debt instruments giving rise to cash flows that are solely payments of principal and interest on the principal amount outstanding would be measured at amortised cost, fair value through other comprehensive income (“FVOCI”) or fair value through profit or loss, based on their respective business models. The Group analysed the contractual cash flow characteristics of financial assets as at 30 June 2022 and made relevant disclosures in Note 17.

Equity instruments would generally be measured at fair value through profit or loss unless the Group elects to measure at FVOCI for certain equity investments not held for trading. This will result in unrealised gains and losses on equity instruments currently classified as available-for-sale securities being recorded in income going forward. Currently, these unrealised gains and losses are recognised in other comprehensive income (“OCI”). If the Group elects to record equity investments at FVOCI, gains and losses would be recognised in retained earnings when the instruments be disposed, except for the received dividends which do not represent a recovery of part of the investment cost.

 

67


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

2

BASIS OF PREPARATION (continued)

 

  2.2

New accounting standards and amendments that are effective but temporary exemption is applied by the Group for the financial year beginning on 1 January 2022 (continued)

IFRS 9 – Financial Instruments (continued)

 

Impairment

IFRS 9 replaces the “incurred loss” model with the “expected credit loss” model which is designed to include forward-looking information. The Group is in the process of developing and testing the key models required under IFRS 9 and analysing the impact on the expected loss provision; the Group believes that the provision for debt instruments of the Group under the “expected credit loss” model would be larger than that under the previous “incurred loss” model.

Hedge accounting

The Group does not apply the hedge accounting currently, so the Group expects that the new hedge accounting model under IFRS 9 will have no impact on the Group’s consolidated financial statements.

 

  2.3

New accounting standards and amendments that are not yet effective and have not been early adopted by the Group for the financial year beginning on 1 January 2022

 

Standards/Amendments

  

Content

  

Effective for annual periods

beginning on or after

Amendments to IAS 1   

Classification of Liabilities as Current or Non-current

   1 January 2023
IFRS 17   

Insurance Contracts

   1 January 2023
Amendments to IAS 12   

Deferred Tax related to Assets and Liabilities arising from a Single Transaction

   1 January 2023
IFRS 10 and IAS 28 Amendments   

Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

   No mandatory effective date yet determined but available for adoption

The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

IFRS 17Insurance Contracts

In May 2017, the IASB issued IFRS 17 Insurance Contracts, a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure, which replaces IFRS 4 Insurance Contracts.

In contrast to the requirements in IFRS 4, which are largely based on grandfathering previous local accounting policies for measurement purposes, IFRS 17 provides a comprehensive model (the general model) for insurance contracts, supplemented by the variable fee approach for contracts with direct participation features and the premium allocation approach mainly for short-duration which typically applies to certain non-life insurance contracts.

 

68


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

2

BASIS OF PREPARATION (continued)

 

  2.3

New accounting standards and amendments that are effective but temporary exemption is applied by the Group for the financial year beginning on 1 January 2022 (continued)

IFRS 17 – Insurance Contracts (continued)

 

The main features of the new accounting model for insurance contracts are as follows:

 

   

The fulfilment cash flows including the expected present value of future cash flows and explicit risk adjustment, remeasured every reporting period;

 

   

A contractual service margin represents the unearned profitability of the insurance contracts and is recognised in profit or loss over the coverage period;

 

   

Certain changes in the expected present value of future cash flows are adjusted against the contractual service margin and thereby recognised in profit or loss over the remaining coverage period;

 

   

The effect of changes in discount rates will be reported in either profit or loss or OCI, determined by an accounting policy choice;

 

   

The recognition of insurance revenue and insurance service expenses in the statement of comprehensive income based on the concept of services provided during the period;

 

   

Amounts that the policyholder will always receive, regardless of whether an insured event happens (non-distinct investment components) are not presented in the statement of comprehensive income, but are recognised directly in the statement of financial position;

 

   

Insurance services results are presented separately from the insurance finance income or expense;

 

   

Extensive disclosures to provide information on the recognised amounts from insurance contracts and the nature and extent of risks arising from these contracts.

 

69


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

2

BASIS OF PREPARATION (continued)

 

  2.3

New accounting standards and amendments that are not yet effective and have not been early adopted by the Group for the financial year beginning on 1 January 2022 (continued)

IFRS 17 – Insurance Contracts (continued)

 

In June 2020, the IASB issued the amendments to IFRS 17 which include a deferral of the effective date of IFRS 17 to annual reporting periods beginning on or after 1 January 2023. Insurers qualifying for the deferral of IFRS 9 can apply both IFRS 17 and IFRS 9 for the first time to annual reporting periods beginning on or after 1 January 2023. In December 2021, the IASB issued the amendment to IFRS 17, which permit entities that first apply IFRS 17 and IFRS 9 at the same time to present comparative information about a financial asset as if the classification and measurement requirements of IFRS 9 had been applied to that financial asset before. The Group is currently assessing the impact of the implementation of the standard.

Except for IFRS 17, there are no other new accounting standards, amendments or IFRIC interpretations that are not yet effective but would be expected to have a significant impact on the financial position and performance of the Group.

 

3

CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING ACCOUNTING POLICIES

The preparation of the interim condensed consolidated financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

In preparing the interim condensed consolidated financial statements, the significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended 31 December 2021.

 

4

FINANCIAL RISK MANAGEMENT

The Group’s activities are exposed to a variety of financial risks. The key financial risk is that proceeds from the sale of financial assets will not be sufficient to fund the obligations arising from the Group’s insurance and investment contracts. The most important components of financial risk are market risk, credit risk and liquidity risk.

The interim condensed consolidated financial statements do not include all financial risk management information and disclosures required in the consolidated financial statements, and should be read in conjunction with the Group’s consolidated financial statements for the year ended 31 December 2021.

There have been no significant changes in the Group’s risk management processes or in any risk management policies since 31 December 2021.

 

70


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

4

FINANCIAL RISK MANAGEMENT (continued)

 

Fair value hierarchy

Level 1 fair value is based on quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can obtain at the measurement date.

Other than Level 1 quoted prices, Level 2 fair value is based on valuation techniques using significant inputs, that are observable for the asset being measured, either directly or indirectly, for substantially the full term of the asset through corroboration with observable market data. Observable inputs generally used to measure the fair value of securities classified as Level 2 include quoted market prices for similar assets in active markets; quoted market prices in markets that are not active for identical or similar assets and other market observable inputs. This level includes the debt securities for which quotations are available from pricing services providers. Fair values provided by pricing services providers are subject to a number of validation procedures by management. These procedures include a review of the valuation models utilised and the results of these models, as well as the recalculation of prices obtained from pricing services at the end of each reporting period.

Under certain conditions, the Group may not receive a price quote from independent third-party pricing services. In this instance, the Group’s valuation team may choose to apply an internally developed valuation method to the assets or liabilities being measured, determine the main inputs for valuation, and analyse the change of the valuation and report it to management. Key inputs involved in internal valuation services are not based on observable market data. They reflect assumptions made by management based on judgements and experiences. The assets or liabilities valued by this method are generally classified as Level 3.

As at 30 June 2022, assets classified as Level 1 accounted for 40.33% of assets measured at fair value on a recurring basis. Fair value measurements classified as Level 1 include certain debt securities, equity securities that are traded in an active exchange market or interbank market and open-ended funds with public market price quotations. The Group considers a combination of certain factors to determine whether a market for a financial instrument is active, including the occurrence of trades within the specific period, the respective trading volume, and the degree which the implied yields for a debt security for observed transactions differs from the Group’s understanding of the current relevant market rates and information. Trading prices from the Chinese interbank market are determined by both trading counterparties and can be observed publicly. The Group adopted this price of the debt securities traded on the Chinese interbank market at the reporting date as their fair market value and classified the investments as Level 1. Open-ended funds also have active markets. Fund management companies publish the net asset value of these funds on their websites on each trade date. Investors subscribe for and redeem units of these funds in accordance with the funds’ net asset value published by the fund management companies on each trade date. The Company adopted the unadjusted net asset value of the funds at the reporting date as their fair market value and classified the investments as Level 1.

 

71


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

4

FINANCIAL RISK MANAGEMENT (continued)

Fair value hierarchy (continued)

 

As at 30 June 2022, assets classified as Level 2 accounted for 39.46% of assets measured at fair value on a recurring basis. They primarily include certain debt securities and equity securities. Valuations are generally obtained from third party pricing services for identical or comparable assets, or through the use of valuation methodologies using observable market inputs, or recent trading prices. Valuation service providers typically gather, analyse and interpret information related to market transactions and other key valuation model inputs from multiple sources, and through the use of widely accepted internal valuation models, provide a theoretical quote on various securities. Debt securities are classified as Level 2 when they are valued at recent trading prices from the Chinese interbank market or from valuation service providers.

As at 30 June 2022, assets classified as Level 3 accounted for 20.21% of assets measured at fair value on a recurring basis. They primarily include unlisted equity securities and unlisted debt securities. Fair values are determined using valuation techniques, including discounted cash flow valuations, the comparable companies approach, etc. The determination of Level 3 is primarily based on the significance of certain unobservable inputs used to determine the fair value of those assets.

The following table presents the Group’s quantitative disclosures of the fair value measurement hierarchy for assets and liabilities measured at fair value as at 30 June 2022:

 

     Fair value measurement using         
     Quoted prices
in active
markets
Level 1
RMB million
     Significant
observable
inputs
Level 2
RMB million
     Significant
unobservable
inputs
Level 3
RMB million
     Total
RMB million
 

Assets measured at fair value

           

Available-for-sale securities

           

– Equity securities

           

Funds

     112,040        —          —          112,040  

Common stocks

     382,043        15,215        —          397,258  

Preferred stocks

     —          —          51,477        51,477  

Others

     45,366        32,129        148,859        226,354  

– Debt securities

           

Government bonds

     12,047        31,045        —          43,092  

Government agency bonds

     73,490        236,334        —          309,824  

Corporate bonds

     3,605        168,373        —          171,978  

Subordinated bonds

     40,801        85,069        —          125,870  

Others

     —          339        160,853        161,192  
Securities at fair value through profit or loss            

– Equity securities

           

Funds

     13,884        120        —          14,004  

Common stocks

     35,270        675        —          35,945  

Others

     5        294        —          299  

– Debt securities

           

Government bonds

     577        1,501        —          2,078  

Government agency bonds

     4,307        5,000        —          9,307  

Corporate bonds

     2,629        101,241        45        103,915  

Others

     201        33,101        2,751        36,053  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     726,265        710,436        363,985        1,800,686  
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities measured at fair value

           

Financial liabilities at fair value through profit or loss

     (4,188      —          —          (4,188

Investment contracts at fair value through profit or loss

     (8      —          —          (8
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     (4,196      —          —          (4,196
  

 

 

    

 

 

    

 

 

    

 

 

 

 

72


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

4

FINANCIAL RISK MANAGEMENT (continued)

Fair value hierarchy (continued)

 

The following table presents the changes in Level 3 assets and liabilities for the six months ended 30 June 2022:

 

     Available-for-sale securities     Securities at
fair value
through
profit or loss
     Total assets  
     Debt securities
RMB million
    Equity securities
RMB million
    Debt securities
RMB million
     RMB million  

Opening balance

     160,499       188,583       45        349,127  

Purchases

     12,203       16,075       2,670        30,948  

Transferred into Level 3

     —         —         —          —    

Transferred out of Level 3

     (10     —         —          (10

Total gains/(losses) recorded in profit or loss

     —         —         81        81  

Total gains/(losses) recorded in other comprehensive income

     (332     (49     —          (381

Disposals or exercises

     —         (4,273     —          (4,273

Maturity

     (11,507     —         —          (11,507
  

 

 

   

 

 

   

 

 

    

 

 

 

Closing balance

     160,853       200,336       2,796        363,985  
  

 

 

   

 

 

   

 

 

    

 

 

 

 

73


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

4

FINANCIAL RISK MANAGEMENT (continued)

Fair value hierarchy (continued)

 

The following table presents the Group’s quantitative disclosures of the fair value measurement hierarchy for assets and liabilities measured at fair value as at 31 December 2021:

 

     Fair value measurement using         
     Quoted
prices in active
markets
Level 1
RMB million
    Significant
observable
inputs
Level 2
RMB million
     Significant
unobservable
inputs
Level 3
RMB million
     Total
RMB million
 

Assets measured at fair value

          

Available-for-sale securities

          

– Equity securities

          

Funds

     94,895       —          —          94,895  

Common stocks

     233,347       23,094        —          256,441  

Preferred stocks

     —         —          52,127        52,127  

Others

     21,010       54,535        136,456        212,001  

– Debt securities

          

Government bonds

     9,208       49,353        —          58,561  

Government agency bonds

     31,464       228,289        —          259,753  

Corporate bonds

     4,705       198,442        —          203,147  

Subordinated bonds

     16,880       94,149        —          111,029  

Others

     —         555        160,499        161,054  

Securities at fair value through profit or loss

          

– Equity securities

          

Funds

     17,572       222        —          17,794  

Common stocks

     43,476       2,173        —          45,649  

Others

     5       266        —          271  

– Debt securities

          

Government bonds

     153       1,240        —          1,393  

Government agency bonds

     2,346       5,643        —          7,989  

Corporate bonds

     6,646       83,734        45        90,425  

Others

     100       43,150        —          43,250  
  

 

 

   

 

 

    

 

 

    

 

 

 

Total

     481,807       784,845        349,127        1,615,779  
  

 

 

   

 

 

    

 

 

    

 

 

 

Liabilities measured at fair value

          

Financial liabilities at fair value through profit or loss

     (3,416     —          —          (3,416

Investment contracts at fair value through profit or loss

     (9     —          —          (9
  

 

 

   

 

 

    

 

 

    

 

 

 

Total

     (3,425     —          —          (3,425
  

 

 

   

 

 

    

 

 

    

 

 

 

 

74


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

4

FINANCIAL RISK MANAGEMENT (continued)

Fair value hierarchy (continued)

 

The following table presents the changes in Level 3 assets and liabilities for the six months ended 30 June 2021:

 

     Available-for-sale securities     Securities at
fair value
through
profit or loss
     Total assets  
     Debt securities
RMB million
     Equity securities
RMB million
    Debt securities
RMB million
     Equity securities
RMB million
     RMB million  

Opening balance

     143,905        150,010       9        —          293,924  

Purchases

     16,498        9,823       —          130        26,451  

Transferred into Level 3

     —          —         36        —          36  

Transferred out of Level 3

     —          (6     —          —          (6

Total gains/(losses) recorded in profit or loss

     —          —         —          —          —    

Total gains/(losses) recorded in other comprehensive income

     950        2,376       —          —          3,326  

Disposals

     —          (1,231     —          —          (1,231
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

Closing balance

     161,353        160,972       45        130        322,500  
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

The assets and liabilities whose fair value measurements are classified under Level 3 above do not have material impact on the profit or loss of the Group.

For the assets and liabilities measured at fair value on a recurring basis, during the six months ended 30 June 2022, RMB15,181 million (for the six months ended 30 June 2021: RMB13,064 million) debt securities were transferred from Level 1 to Level 2 within the fair value hierarchy, whereas RMB27,990 million (for the six months ended 30 June 2021: RMB32,683 million) debt securities were transferred from Level 2 to Level 1. RMB2,725 million (for the six months ended 30 June 2021: RMB5,361) equity securities were transferred from Level 1 to Level 2 within the fair value hierarchy, whereas RMB31,483 million (for the six months ended 30 June 2021: RMB16,695 million) equity securities were transferred from Level 2 to Level 1.

For the six months ended 30 June 2022 and the six months ended 30 June 2021, there were no significant changes in the business or economic circumstances that affected the fair value of the Group’s financial assets and liabilities. There were also no reclassifications of financial assets.

As at 30 June 2022 and 31 December 2021, significant unobservable inputs such as discount rate and discounts for lack of marketability were used in the valuation of main assets and liabilities at fair value classified as Level 3. The fair value was not significantly sensitive to reasonable changes in these significant unobservable inputs.

 

75


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

4

FINANCIAL RISK MANAGEMENT (continued)

Fair value hierarchy (continued)

 

The table below presents information about the significant unobservable inputs used for main financial instruments at fair value classified as Level 3 as at 30 June 2022 and 31 December 2021:

 

    

Fair value

  

Valuation

techniques

  

Significant

unobservable inputs

  

Range

  

Relationships between fair

value and unobservable inputs

Equity securities

  

30 June 2022: 30,381

31 December 2021: 28,245

  

Comparable companies approach

  

Discounts for lack of marketability

  

30 June 2022:
12%–30%

31 December 2021:
11%–30%

  

The fair value is inversely related to the discounts for lack of marketability

  

30 June 2022: 45,206

31 December 2021: 36,556

  

Net asset value method

  

N/A

   N/A   

N/A

  

30 June 2022: 122,182

31 December 2021: 116,245

  

Discounted cash flow method

  

Discount rate

  

30 June 2022:
2.69%–9.91%

31 December 2021:
2.69%–9.93%

  

The fair value is inversely related to discount rate

Debt securities

  

30 June 2022: 163,604

31 December 2021: 160,499

  

Discounted cash flow method

  

Discount rate

  

30 June 2022:
3.11%–10.52%

31 December 2021:
3.21%–9.78%

  

The fair value is inversely related to discount rate

 

5

SEGMENT INFORMATION

 

  5.1

Operating segments

The Group operates in four operating segments:

 

  (i)

Life insurance business (Life)

Life insurance business relates primarily to the sale of life insurance policies, including those life insurance policies without significant insurance risk transferred.

 

  (ii)

Health insurance business (Health)

Health insurance business relates primarily to the sale of health insurance policies, including those health insurance policies without significant insurance risk transferred.

 

  (iii)

Accident insurance business (Accident)

Accident insurance business relates primarily to the sale of accident insurance policies.

 

  (iv)

Other businesses (Others)

Other businesses relate primarily to income and cost of the agency business in respect of transactions with CLIC, etc., as described in Note 18, net share of profit of associates and joint ventures, income and expenses of subsidiaries, and unallocated income and expenditure of the Group.

 

76


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

5

SEGMENT INFORMATION (continued)

 

  5.2

Allocation basis of income and expenses

 

Investment income, net realised gains on financial assets, net fair value gains through profit or loss and foreign exchange gains/(losses) within other expenses are allocated among segments in proportion to the respective segments’ average liabilities of insurance contracts and investment contracts at the beginning and end of the period. Administrative expenses are allocated among segments in proportion to the unit cost of respective products in the different segments. Unallocated other income and other expenses are presented in the “Others” segment directly. Income tax is not allocated.

 

           For the six months ended 30 June 2022  
     Life     Health     Accident     Others     Elimination     Total  
     RMB million  

Revenues

            

Gross written premiums

     356,528       75,284       8,157       —         —         439,969  

– Term life

     927       —         —         —         —            

– Whole life

     41,335       —         —         —         —        

– Endowment

     90,952       —         —         —         —        

– Annuity

     223,314       —         —         —         —            

Net premiums earned

     355,898       56,145       7,593       —         —         419,636  

Investment income

     81,296       5,560       223       4,117       —         91,196  

Net realised gains on financial assets

     6,091       410       17       144       —         6,662  

Net fair value gains through profit or loss

     (4,001     (270     (11     (847     —         (5,129

Other income

     558       34       —         5,317       (1,604     4,305  

Including: inter-segment revenue

     —         —         —         1,604       (1,604     —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment revenues

     439,842       61,879       7,822       8,731       (1,604     516,670  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Benefits, claims and expenses

            

Insurance benefits and claims expenses

            

Life insurance death and other benefits

     (62,998     (3,489     (18     —         —         (66,505

Accident and health claims and claim adjustment expenses

     —         (22,440     (2,037     —         —         (24,477

Increase in insurance contract liabilities

     (306,169     (18,389     (158     —         —         (324,716

Investment contract benefits

     (6,614     (17     —         —         —         (6,631

Policyholder dividends resulting from participation in profits

     (11,772     (65     —         —         —         (11,837

Underwriting and policy acquisition costs

     (26,593     (5,810     (2,195     (707     —         (35,305

Finance costs

     (2,115     (142     (6     (347     —         (2,610

Administrative expenses

     (10,187     (4,561     (1,275     (2,029     —         (18,052

Statutory insurance fund contribution

     (549     (256     (69     —         —         (874

Other expenses

     (3,469     (583     (125     (3,856     1,604       (6,429

Including: inter-segment expenses

     (1,499     (101     (4     —         1,604       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment benefits, claims and expenses

     (430,466     (55,752     (5,883     (6,939     1,604       (497,436
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net gains on investments of associates and joint ventures

     —         —         —         5,757       —         5,757  

Including: share of profit of associates and joint ventures

     —         —         —         5,757       —         5,757  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment results

     9,376       6,127       1,939       7,549       —         24,991  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income tax

               1,183  
            

 

 

 

Net profit

               26,174  
            

 

 

 

Attributable to

            

– Equity holders of the Company

               25,416  

– Non-controlling interests

               758  

Other comprehensive income attributable to equity holders of the Company

     (5,101     (344     (14     (19     —         (5,478

Depreciation and amortisation

     1,424       663       180       414       —         2,681  

 

77


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

5

SEGMENT INFORMATION (continued)

 

  5.2

Allocation basis of income and expenses (continued)

 

           For the six months ended 30 June 2021  
     Life     Health     Accident     Others     Elimination     Total  
     RMB million  

Revenues

            

Gross written premiums

     356,897       76,372       9,030       —         —         442,299  

– Term life

     1,168       —         —         —         —            

– Whole life

     36,285       —         —         —         —        

– Endowment

     54,403       —         —         —         —        

– Annuity

     265,041       —         —         —         —            

Net premiums earned

     356,304       58,085       8,253       —         —         422,642  

Investment income

     74,070       4,965       244       2,767       —         82,046  

Net realised gains on financial assets

     20,840       1,389       69       273       —         22,571  

Net fair value gains through profit or loss

     3,116       208       10       1,969       —         5,303  

Other income

     553       42       —         5,530       (1,534     4,591  

Including: inter-segment revenue

     —         —         —         1,534       (1,534     —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment revenues

     454,883       64,689       8,576       10,539       (1,534     537,153  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Benefits, claims and expenses

            

Insurance benefits and claims expenses

            

Life insurance death and other benefits

     (65,763     (3,151     (20     —         —         (68,934

Accident and health claims and claim adjustment expenses

     —         (23,122     (3,707     —         —         (26,829

Increase in insurance contract liabilities

     (295,974     (16,699     (104     —         —         (312,777

Investment contract benefits

     (5,326     (7     —         —         —         (5,333

Policyholder dividends resulting from participation in profits

     (15,405     (78     —         —         —         (15,483

Underwriting and policy acquisition costs

     (28,311     (10,612     (2,459     (750     —         (42,132

Finance costs

     (1,737     (116     (6     (334     —         (2,193

Administrative expenses

     (11,106     (4,217     (1,244     (1,575     —         (18,142

Statutory insurance fund contribution

     (584     (211     (66     —         —         (861

Other expenses

     (4,072     (419     (80     (3,020     1,534       (6,057

Including: inter-segment expenses

     (1,433     (96     (5     —         1,534       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment benefits, claims and expenses

     (428,278     (58,632     (7,686     (5,679     1,534       (498,741
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net gains on investments of associates and joint ventures

     —         —         —         7,683       —         7,683  

Including: share of profit of associates and joint ventures

     —         —         —         7,683       —         7,683  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment results

     26,605       6,057       890       12,543       —         46,095  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income tax

               (4,372
            

 

 

 

Net profit

               41,723  
            

 

 

 

Attributable to

            

– Equity holders of the Company

               40,968  

– Non-controlling interests

               755  

Other comprehensive income attributable to equity holders of the Company

     (1,344     (90     (4     (444     —         (1,882

Depreciation and amortisation

     1,570       569       178       344       —         2,661  

 

78


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

6

INVESTMENTS IN ASSOCIATES AND JOINT VENTURES

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

As at 1 January

     257,953        239,584  

Change of the cost

     8,635        8,269  

Share of profit or loss

     5,757        7,683  

Other equity movements

     (660      257  

Dividends declared (i)

     (2,064      (1,890
  

 

 

    

 

 

 

As at 30 June

     269,621        253,903  
  

 

 

    

 

 

 

 

  (i)

The 2021 final dividend of RMB0.0813 in cash per ordinary share was approved and declared in the Annual General Meeting of China Guangfa Bank Company Limited (“CGB”) on 24 June 2022, and the Company’s cash dividend receivable is RMB774 million.

The 2021 final dividend of HKD0.032 in cash per ordinary share was approved and declared in the Annual General Meeting of Sino-Ocean Group Holding Limited (“Sino-Ocean”) on 20 May 2022. The Company received a cash dividend equivalent to RMB61 million during the period.

The 2021 final dividend of RMB0.0391 in cash per ordinary share was approved and declared in the Annual General Meeting of China United Network Communications Limited (“China Unicom”) on 10 May 2022. The Company received a cash dividend of RMB125 million during the period.

On 30 June 2022, the Hong Kong stock price of Sino-Ocean was HKD1.33 per share. As at 31 December 2021, cumulative impairment loss of RMB3,217 million for the investment in Sino-Ocean had been recognised by the Group. The Group performed an impairment test to this investment valued using the discounted future cash flow method on 30 June 2022 and no further impairment loss should be made. The impairment test involved significant assumptions including selling prices of properties under development, rental prices of investment properties and discount rates, and the Group used 10% as the discount rate of cash flow for properties under development and investment properties (As at 31 December 2021: 10% for properties under development and investment properties).

 

7

FINANCIAL ASSETS

 

  7.1

Held-to-maturity securities

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Debt securities

     

Government bonds

     349,484        349,370  

Government agency bonds

     968,793        911,451  

Corporate bonds

     192,922        209,627  

Subordinated bonds

     53,959        63,305  
  

 

 

    

 

 

 

Total

     1,565,158        1,533,753  
  

 

 

    

 

 

 

Debt securities

     

Listed in Mainland, PRC

     236,707        246,134  

Listed in Hong Kong, PRC

     151        87  

Listed overseas

     46        44  

Unlisted (i)

     1,328,254        1,287,488  
  

 

 

    

 

 

 

Total

     1,565,158        1,533,753  
  

 

 

    

 

 

 

 

  (i)

Unlisted debt securities are those traded on the Chinese interbank market.

 

79


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

7

FINANCIAL ASSETS (continued)

 

  7.1

Held-to-maturity securities (continued)

 

The valuation method used to determine the fair value of held-to-maturity securities is the same as debt securities which are measured at fair value. Please refer to Note 4. As at 30 June 2022, there is no provision for the investment of held-to-maturity securities (as at 31 December 2021: nil).

 

     As at 30 June 2022      As at 31 December 2021  
     Level 1      Level 2      Total      Level 1      Level 2      Total  

Debt securities – Fair value hierarchy

   RMB million      RMB million      RMB million      RMB million      RMB million      RMB million  

Government bonds

     24,085        360,834        384,919        68,300        314,113        382,413  

Government agency bonds

     82,100        955,153        1,037,253        74,241        895,343        969,584  

Corporate bonds

     865        202,386        203,251        7,911        211,882        219,793  

Subordinated bonds

     —          56,764        56,764        —          66,481        66,481  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     107,050        1,575,137        1,682,187        150,452        1,487,819        1,638,271  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

Debt securities – Contractual maturity schedule

   As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Maturing:

     

Within one year

     42,174        55,370  

After one year but within five years

     162,201        147,786  

After five years but within ten years

     130,614        163,479  

After ten years

     1,230,169        1,167,118  
  

 

 

    

 

 

 

Total

     1,565,158        1,533,753  
  

 

 

    

 

 

 

 

80


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

7

FINANCIAL ASSETS (continued)

 

  7.2

Loans

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Policy loans (i)

     245,460        236,209  

Other loans

     411,392        433,697  
  

 

 

    

 

 

 

Total

     656,852        669,906  
  

 

 

    

 

 

 

Impairment

     (3,819      (3,819
  

 

 

    

 

 

 

Net value

     653,033        666,087  
  

 

 

    

 

 

 

Fair value

     665,302        686,005  
  

 

 

    

 

 

 
     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Maturing:

     

Within one year

     361,981        348,940  

After one year but within five years

     167,596        182,493  

After five years but within ten years

     105,112        106,319  

After ten years

     22,163        32,154  
  

 

 

    

 

 

 

Total

     656,852        669,906  
  

 

 

    

 

 

 

Impairment

     (3,819      (3,819
  

 

 

    

 

 

 

Net value

     653,033        666,087  
  

 

 

    

 

 

 

 

  (i)

The Group’s policy loans are pledged by the policyholders’ policy, and the loan amount is limited to the cash value of the policyholders’ policy. As at 30 June 2022, maturities of policy loans were within 6 months (as at 31 December 2021: same), and their fair values approximated to their carrying amounts.

 

81


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

7

FINANCIAL ASSETS (continued)

 

  7.3

Term deposits

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Maturing:

     

Within one year

     167,972        135,301  

After one year but within five years

     342,860        394,187  
  

 

 

    

 

 

 

Total

     510,832        529,488  
  

 

 

    

 

 

 

As at 30 June 2022, the Group’s term deposits of RMB2,668 million (as at 31 December 2021: RMB2,641 million) were deposited in banks for risk reserves of enterprise annuity fund investments, risk reserves of personal endowment security management business and backing overseas borrowings, which are restricted to use.

 

  7.4

Available-for-sale securities

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Available-for-sale securities, at fair value

     

Debt securities

     

Government bonds

     43,092        58,561  

Government agency bonds

     309,824        259,753  

Corporate bonds

     171,978        203,147  

Subordinated bonds

     125,870        111,029  

Others (i)

     161,192        161,054  
  

 

 

    

 

 

 

Subtotal

     811,956        793,544  

Equity securities

     

Funds

     112,040        94,895  

Common stocks

     397,258        256,441  

Preferred stocks

     51,477        52,127  

Others (i)

     226,354        212,001  

Subtotal

     787,129        615,464  

Available-for-sale securities, at cost

     

Equity securities

     

Others (i)

     19,205        20,279  
  

 

 

    

 

 

 

Total

     1,618,290        1,429,287  
  

 

 

    

 

 

 

 

  (i)

Other available-for-sale securities mainly include unlisted equity investments, private equity funds, trust schemes and perpetual bonds.

 

82


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

7

FINANCIAL ASSETS (continued)

 

  7.4

Available-for-sale securities (continued)

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Debt securities

     

Listed in Mainland, PRC

     79,576        86,145  

Listed in Hong Kong

     136        —    

Unlisted

     732,244        707,399  
  

 

 

    

 

 

 

Subtotal

     811,956        793,544  
  

 

 

    

 

 

 

Equity securities

     

Listed in Mainland, PRC

     392,055        238,155  

Listed in Hong Kong, PRC

     71,386        75,694  

Listed overseas

     —          28  

Unlisted

     342,893        321,866  
  

 

 

    

 

 

 

Subtotal

     806,334        635,743  
  

 

 

    

 

 

 

Total

     1,618,290        1,429,287  
  

 

 

    

 

 

 

Unlisted debt securities are those traded on the Chinese interbank market and those not publicly traded. Unlisted equity securities are those not traded on stock exchanges, which are mainly open-ended funds with public market price quotations, wealth management products and private equity funds.

 

Debt securities – Contractual maturity schedule

   As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Maturing:

     

Within one year

     79,480        36,597  

After one year but within five years

     182,969        179,476  

After five years but within ten years

     270,715        318,992  

After ten years

     278,792        258,479  
  

 

 

    

 

 

 

Total

     811,956        793,544  
  

 

 

    

 

 

 

 

83


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

7

FINANCIAL ASSETS (continued)

 

  7.5

Securities at fair value through profit or loss

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Debt securities

     

Government bonds

     2,078        1,393  

Government agency bonds

     9,307        7,989  

Corporate bonds

     103,915        90,425  

Others (i)

     36,053        43,250  
  

 

 

    

 

 

 

Subtotal

     151,353        143,057  
  

 

 

    

 

 

 

Equity securities

     

Funds

     14,004        17,794  

Common stocks

     35,945        45,649  

Others

     299        271  
  

 

 

    

 

 

 

Subtotal

     50,248        63,714  
  

 

 

    

 

 

 

Total

     201,601        206,771  
  

 

 

    

 

 

 

Debt securities

     

Listed in Mainland, PRC

     29,797        29,934  

Listed in Hong Kong, PRC

     58        23  

Listed overseas

     285        273  

Unlisted

     121,213        112,827  
  

 

 

    

 

 

 

Subtotal

     151,353        143,057  
  

 

 

    

 

 

 

Equity securities

     

Listed in Mainland, PRC

     33,449        45,817  

Listed in Hong Kong, PRC

     788        736  

Listed overseas

     3,919        4,849  

Unlisted

     12,092        12,312  
  

 

 

    

 

 

 

Subtotal

     50,248        63,714  
  

 

 

    

 

 

 

Total

     201,601        206,771  
  

 

 

    

 

 

 

 

  (i)

Other debt securities at fair value through profit or loss mainly include interbank negotiable certificates of deposit.

Unlisted debt securities consist of those traded on the Chinese interbank market and those not publicly traded. Unlisted equity securities consist of those not traded on stock exchanges, which are mainly open-ended funds with public market price quotations.

 

84


 

Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

8

INSURANCE CONTRACTS

 

  (a)

Process used to decide on assumptions

 

  (i)

For the insurance contracts of which future insurance benefits are affected by investment yields of the corresponding investment portfolios, the discount rate assumption is based on expected investment returns of the asset portfolio backing these liabilities, considering the impacts of time value on reserves.

In developing the discount rate assumptions, the Group considers investment experience, the current investment portfolio and the trend of the relevant yield curves. The assumed discount rates reflect the future economic outlook as well as the Group’s investment strategy. The assumed discount rates with risk margin are as follows:

 

    

Discount rate assumptions

 

As at 30 June 2022

     4.85%  

As at 31 December 2021

     4.85%  

As at 30 June 2021

     4.85%  

For the insurance contracts of which future insurance benefits are not affected by investment yields of the corresponding investment portfolios, the discount rate assumption is based on the “Yield curve of reserve computation benchmark for insurance contracts”, published on the “China Bond” website with consideration of liquidity spreads, taxation and other relevant factors. The assumed spot discount rates with risk margin are as follows:

 

    

Discount rate assumptions

 

As at 30 June 2022

     2.79%~4.80%  

As at 31 December 2021

     2.88%~4.80%  

As at 30 June 2021

     2.96%~4.80%  

There is uncertainty on the discount rate assumption, which is affected by factors such as future macro-economy, monetary and foreign exchange policies, capital market and availability of investment channels of insurance funds. The Group determines the discount rate assumption based on the information available at the end of each reporting period, including the consideration of risk margin.

 

85


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

8

INSURANCE CONTRACTS (continued)

 

  (a)

Process used to decide on assumptions (continued)

 

  (ii)

The mortality and morbidity assumptions are based on the Group’s historical mortality and morbidity experience. The assumed mortality rates and morbidity rates vary with the age of the insured and contract type.

The Group bases its mortality assumptions on China Life Insurance Mortality Table (2010-2013), adjusted where appropriate to reflect the Group’s recent historical mortality experience. The main source of uncertainty with life insurance contracts is that epidemics and wide-ranging lifestyle changes could result in deterioration in future mortality experience, thus leading to an inadequate reserving of liability. Similarly, improvements in longevity due to continuing advancements in medical care and social conditions may expose the Group to longevity risk.

The Group bases its morbidity assumptions for critical illness products on analysis of historical experience and expectations of future developments. There are two main sources of uncertainty. Firstly, wide-ranging lifestyle changes could result in future deterioration in morbidity experience. Secondly, future development of medical technologies and improved coverage of medical facilities available to policyholders may bring forward the timing of diagnosing critical illness, which demands earlier payment of the critical illness benefits. Both could ultimately result in an inadequate reserving of liability if current morbidity assumptions do not properly reflect such trends.

Risk margin is considered in the Group’s mortality and morbidity assumptions.

 

  (iii)

Expense assumptions are based on expected unit costs with the consideration of previous expense studies and future trends. Expense assumptions are affected by certain factors such as future inflation and market competition which bring uncertainty to these assumptions. The Group determines expense assumptions based on information available at the end of each reporting period and risk margin. Components of expense assumptions include the cost per policy and percentage of premium as follows:

 

     Individual life      Group life  
     RMB Per Policy      % of Premium      RMB Per Policy      % of Premium  

As at 30 June 2022

     45        0.85%~0.90%        25        0.90%  

As at 31 December 2021

     45        0.85%~0.90%        25        0.90%  

As at 30 June 2021

     45        0.85%~0.90%        25        0.90%  

 

  (iv)

The lapse rates and other assumptions are affected by certain factors, such as future macro-economy, availability of financial substitutions, and market competition, which bring uncertainty to these assumptions. The lapse rates and other assumptions are determined with reference to creditable past experience, current conditions, future expectations and other information.

 

  (v)

The Group applies a consistent method to determine risk margin. The Group considers risk margin for the discount rate, mortality and morbidity and expense assumptions to compensate for the uncertain amount and timing of future cash flows. When determining risk margin, the Group considers historical experience, future expectations and other factors. The Group determines the risk margin level by itself as the regulations have not imposed any specific requirement on it.

 

  (vi)

The policy dividend assumption has uncertainty and is affected by factors such as the expected investment returns, the Group’s dividend policy, and the reasonable expectations of policyholders. The Group is obliged to pay 70% or a higher percentage as agreed in the insurance policy of the cumulative distributable income to the participating insurance policyholders.

 

86


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

8

INSURANCE CONTRACTS (continued)

 

  (b)

Net liabilities of insurance contracts

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Gross

     

Long-term insurance contracts

     3,704,462        3,379,603  

Short-term insurance contracts

     

– Claims and claim adjustment expenses

     28,390        26,234  

– Unearned premiums

     30,365        14,062  
  

 

 

    

 

 

 

Total, gross

     3,763,217        3,419,899  
  

 

 

    

 

 

 

Recoverable from reinsurers

     

Long-term insurance contracts

     (5,042      (4,910

Short-term insurance contracts

     

– Claims and claim adjustment expenses

     (530      (412

– Unearned premiums

     (1,251      (823
  

 

 

    

 

 

 

Total, ceded

     (6,823      (6,145
  

 

 

    

 

 

 

Net

     

Long-term insurance contracts

     3,699,420        3,374,693  

Short-term insurance contracts

     

– Claims and claim adjustment expenses

     27,860        25,822  

– Unearned premiums

     29,114        13,239  
  

 

 

    

 

 

 

Total, net

     3,756,394        3,413,754  
  

 

 

    

 

 

 

 

87


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

8

INSURANCE CONTRACTS (continued)

 

  (c)

Movements in liabilities of short-term insurance contracts

The table below presents movements in the claims and claim adjustment expenses reserves:

 

     For the six months ended 30 June  
     2022
RMB million
     2021
RMB million
 

Notified claims

     4,197        4,319  

Incurred but not reported

     22,037        17,672  
  

 

 

    

 

 

 

Total as at 1 January – gross

     26,234        21,991  
  

 

 

    

 

 

 

Cash paid for claims settled in period

     

– Cash paid for current period’s claims

     (7,887      (10,261

– Cash paid for prior periods’ claims

     (15,362      (14,602

Claims incurred in period

     

– Claims arising in current period

     25,566        26,986  

– Claims arising in prior periods

     (161      365  
  

 

 

    

 

 

 

Total as at 30 June – gross

     28,390        24,479  
  

 

 

    

 

 

 

Notified claims

     3,264        3,401  

Incurred but not reported

     25,126        21,078  
  

 

 

    

 

 

 

Total as at 30 June – gross

     28,390        24,479  
  

 

 

    

 

 

 

The table below presents movements in unearned premium reserves:

 

     For the six months ended 30 June  
           2022                 2021        
     Gross     RMB million
Ceded
    Net     Gross     RMB million
Ceded
    Net  

As at 1 January

     14,062       (823     13,239       14,701       (523     14,178  

Increase

     30,365       (1,251     29,114       30,892       (604     30,288  

Release

     (14,062     823       (13,239     (14,701     523       (14,178
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

As at 30 June

     30,365       (1,251     29,114       30,892       (604     30,288  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

88


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

8

INSURANCE CONTRACTS (continued)

 

  (d)

Movements in liabilities of long-term insurance contracts

The table below presents movements in the liabilities of long-term insurance contracts:

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

As at 1 January

     3,379,603        2,936,533  

Premiums

     387,102        389,951  

Release of liabilities (i)

     (157,739      (162,512

Accretion of interest

     81,424        72,610  

Change in assumptions

     

– Change in discount rates

     14,129        13,288  

Other movements

     (57      1  
  

 

 

    

 

 

 

As at 30 June

     3,704,462        3,249,871  
  

 

 

    

 

 

 

 

  (i)

The release of liabilities mainly consists of release due to death or other termination and related expenses, amortization of residual margin and change of reserves for claims and claim adjustment expenses.

 

9

INVESTMENT CONTRACTS

 

    

As at

30 June

2022

    

As at

31 December
2021

 
     RMB million      RMB million  

Investment contracts with discretionary participating features (“DPF”) at amortised cost

     70,964        68,544  

Investment contracts without DPF

     

– At amortised cost

     277,403        245,041  

– At fair value through profit or loss

     8        9  
  

 

 

    

 

 

 

Total

     348,375        313,594  
  

 

 

    

 

 

 

 

89


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

9

INVESTMENT CONTRACTS (continued)

 

The table below presents movements of investment contracts with DPF:

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

As at 1 January

     68,544        64,950  

Deposits received

     2,816        3,238  

Deposits withdrawn, payments on death and other benefits

     (1,147      (993

Interest credited

     751        716  
  

 

 

    

 

 

 

As at 30 June

     70,964        67,911  
  

 

 

    

 

 

 

The fair value of investment contracts at fair value through profit or loss was classified as Level 1. As at 30 June 2022, the fair value of investment contracts at amortised cost was RMB332,630 million (as at 31 December 2021: RMB299,718 million), which was classified as Level 3.

 

10

INVESTMENT INCOME

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

Debt securities

     

– held-to-maturity securities

     31,039        26,295  

– available-for-sale securities

     15,474        13,901  

– at fair value through profit or loss

     2,399        1,893  

Equity securities

     

– available-for-sale securities

     12,678        10,100  

– at fair value through profit or loss

     350        412  

Bank deposits

     12,797        13,050  

Loans

     16,102        16,240  

Securities purchased under agreements to resell

     357        155  
  

 

 

    

 

 

 

Total

     91,196        82,046  
  

 

 

    

 

 

 

For the six months ended 30 June 2022, the interest income calculated using the effective interest method in investment income was RMB75,769 million (for the six months ended 30 June 2021: RMB71,659 million).

 

90


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

11

NET REALISED GAINS ON FINANCIAL ASSETS

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

Debt securities

     

Realised gains/(losses) (i)

     4,977        (55

Impairment (ii)

     —          —    
  

 

 

    

 

 

 

Subtotal

     4,977        (55
  

 

 

    

 

 

 

Equity securities

     

Realised gains (i)

     7,363        30,230  

Impairment (ii)

     (5,678      (7,604
  

 

 

    

 

 

 

Subtotal

     1,685        22,626  
  

 

 

    

 

 

 

Total

     6,662        22,571  
  

 

 

    

 

 

 

 

  (i)

Realised gains were generated mainly from available-for-sale securities.

  (ii)

During the six months ended 30 June 2022, the Group recognised an impairment charge of RMB263 million (for the six months ended 30 June 2021: RMB8 million) of available-for-sale funds, an impairment charge of RMB5,415 million (for the six months ended 30 June 2021: RMB7,596 million) of available-for-sale stock securities, for which the Group determined that objective evidence of impairment existed.

 

12

NET FAIR VALUE GAINS THROUGH PROFIT OR LOSS

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

Debt securities

     264        405  

Equity securities

     (5,514      4,700  

Stock appreciation rights

     (53      83  

Financial liabilities at fair value through profit or loss

     174        115  
  

 

 

    

 

 

 

Total

     (5,129      5,303  
  

 

 

    

 

 

 

 

91


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

13

PROFIT BEFORE INCOME TAX

Profit before income tax is stated after charging/(crediting) the following:

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

Employee salaries and welfare costs

     9,050        9,060  

Housing benefits

     714        688  

Contribution to the defined contribution pension plan

     1,720        1,353  

Depreciation and amortisation

     2,681        2,661  

Foreign exchange gains

     (219      (240

 

14

TAXATION

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income tax relates to the same tax authority.

 

  (a)

The amount of taxation charged to net profit represents:

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

Current taxation – Enterprise income tax

     720        5,503  

Deferred taxation

     (1,903      (1,131
  

 

 

    

 

 

 

Taxation charges

     (1,183      4,372  
  

 

 

    

 

 

 

 

92


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

14

TAXATION (continued)

 

  (b)

The reconciliation between the Group’s effective tax rate and the statutory tax rate of 25% in the PRC (for the six months ended 30 June 2021: same) is as follows:

 

     For the six months ended 30 June  
     2022      2021  
     RMB million      RMB million  

Profit before income tax

     24,991        46,095  

Tax computed at the statutory tax rate

     6,248        11,524  

Adjustment on current income tax of previous period

     (245      (412

Non-taxable income (i)

     (7,385      (6,778

Expenses not deductible for tax purposes (i)

     123        81  

Unused tax losses

     13        15  

Others

     63        (58
  

 

 

    

 

 

 

Income tax at the effective tax rate

     (1,183      4,372  
  

 

 

    

 

 

 

 

  (i)

Non-taxable income mainly includes interest income from government bonds, dividend income from applicable equity securities, etc. Expenses not deductible for tax purposes mainly include donations and other expenses that do not meet the criteria for deduction according to the relevant tax regulations.

 

  (c)

As at 30 June 2022 and 31 December 2021, the amounts of deferred tax assets and liabilities were as follows:

 

    

As at

30 June

2022

    

As at

31 December

2021

 
     RMB million      RMB million  

Deferred tax assets

     22,216        22,354  

Deferred tax liabilities

     (25,895      (29,714
  

 

 

    

 

 

 

Net deferred tax assets

     136        121  

Net deferred tax liabilities

     (3,815      (7,481
  

 

 

    

 

 

 

 

93


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

14

TAXATION (continued)

 

  (c)

As at 30 June 2022 and 31 December 2021, the amounts of deferred tax assets and liabilities were as follows (continued):

As at 30 June 2022 and 31 December 2021, deferred tax was calculated in full on temporary differences under the balance sheet liability method using the principal tax rate of 25%. The movements in net deferred income tax assets and liabilities during the period were as follows:

Net deferred tax assets/(liabilities)

 

     Insurance      Investments      Others      Total  
     RMB million      RMB million      RMB million      RMB million  
     (i)      (ii)      (iii)     

 

 

As at 1 January 2021

     4,334        (22,386      2,853        (15,199

Credited/(Charged) to net profit

     842        776        (487      1,131  

Credited/(Charged) to other comprehensive income

           

– Available-for-sale securities

     —          (80      —          (80

– Portion of fair value changes on available-for-sale securities attributable to participating policyholders

     25        —          —          25  

– Others

     —          (18      —          (18
  

 

 

    

 

 

    

 

 

    

 

 

 

As at 30 June 2021

     5,201        (21,708      2,366        (14,141
  

 

 

    

 

 

    

 

 

    

 

 

 

As at 1 January 2022

     7,644        (18,202      3,198        (7,360

Credited/(Charged) to net profit

     1,022        89        792        1,903  

Credited/(Charged) to other comprehensive income

           

– Available-for-sale securities

     —          2,694        —          2,694  

– Portion of fair value changes on available-for-sale securities attributable to participating policyholders

     (946      —          —          (946

– Others

     —          30        —          30  
  

 

 

    

 

 

    

 

 

    

 

 

 

As at 30 June 2022

     7,720        (15,389      3,990        (3,679
  

 

 

    

 

 

    

 

 

    

 

 

 
                      

  (i)

The deferred tax liabilities arising from the insurance category are mainly related to the change of long-term insurance contract liabilities at 31 December 2008 as a result of the first time adoption of IFRSs in 2009, and the deferred tax assets are mainly related to temporary differences of short-term insurance contract liabilities and policyholder dividends payable.

  (ii)

The deferred tax arising from the investments category is mainly related to the temporary differences of unrealised gains/(losses) on available-for-sale securities, securities at fair value through profit or loss, and others.

  (iii)

The deferred tax arising from the others category is mainly related to the temporary differences of employee salaries and welfare costs payable.

Unrecognised deductible tax losses of the Group amounted to RMB3,194 million as at 30 June 2022 (as at 31 December 2021: RMB3,173 million). Unrecognised deductible temporary differences of the Group amounted to RMB1 million as at 30 June 2022 (as at 31 December 2021: RMB1 million).

 

94


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

14

TAXATION (continued)

 

  (d)

The analysis of net deferred tax assets and deferred tax liabilities is as follows:

 

    

As at

30 June 2022

    

As at

31 December 2021

 
     RMB million      RMB million  

Deferred tax assets:

     

– deferred tax assets to be recovered after 12 months

     12,856        14,695  

– deferred tax assets to be recovered within 12 months

     9,360        7,659  
  

 

 

    

 

 

 

Subtotal

     22,216        22,354  
  

 

 

    

 

 

 

Deferred tax liabilities:

     

– deferred tax liabilities to be settled after 12 months

     (23,750      (26,850

– deferred tax liabilities to be settled within 12 months

     (2,145      (2,864
  

 

 

    

 

 

 

Subtotal

     (25,895      (29,714
  

 

 

    

 

 

 

Net deferred tax liabilities

     (3,679      (7,360
  

 

 

    

 

 

 

 

15

EARNINGS PER SHARE

There is no difference between the basic and diluted earnings per share. The basic and diluted earnings per share for the six months ended 30 June 2022 are calculated based on the net profit for the period attributable to ordinary equity holders of the Company and the weighted average of 28,264,705,000 ordinary shares (for the six months ended 30 June 2021: same).

 

16

DIVIDENDS

A dividend in respect of 2021 of RMB0.65 (inclusive of tax) per ordinary share, totalling RMB18,372 million, was approved at the Annual General Meeting on 29 June 2022.

 

95


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

17

DISCLOSURES ABOUT THE TEMPORARY EXEMPTION FROM IFRS 9

According to IFRS 4 Amendments, the Company made the assessment based on the Group’s financial position of 31 December 2015, concluding that the carrying amount of the Group’s liabilities arising from contracts within the scope of IFRS 4, which includes any deposit components or embedded derivatives unbundled from insurance contracts, was significant compared to the total carrying amount of all its liabilities. The percentage of the total carrying amount of its liabilities connected with insurance relative to the total carrying amount of all its liabilities is greater than 90 percent. There had been no significant change in the activities of the Group since then that requires reassessment. Therefore, the Group’s activities are predominantly connected with insurance, meeting the criteria to apply temporary exemption from IFRS 9.

Sino-Ocean, China Unicom, CGB and certain associates of the Group, have adopted IFRS 9. According to IFRS 4 Amendments, the Group elected not to apply uniform accounting policies when using the equity method for these associates.

 

  (a)

The tables below present the fair value of the following groups of financial assets(i) under IFRS 9 as at 30 June 2022 and 31 December 2021 and fair value changes for the six months ended 30 June 2022 and 30 June 2021:

 

     Fair value as at
30 June 2022
RMB million
     Fair value as at
31 December 2021
RMB million
 

Held for trading financial assets

     201,601        206,771  

Financial assets that are managed and whose performance are evaluated on a fair value basis

     —          —    

Other financial assets

     

– Financial assets with contractual terms that give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding (“SPPI”)

     2,579,663        2,559,014  

– Financial assets with contractual terms that do not give rise to SPPI

     1,140,656        958,340  
  

 

 

    

 

 

 

Total

     3,921,920        3,724,125  
  

 

 

    

 

 

 
    

Fair value changes

for the six months ended 30 June

 
     2022      2021  
     RMB million      RMB million  

Held for trading financial assets

     (5,252      5,104  

Financial assets that are managed and whose performance are evaluated on a fair value basis

     —          —    

Other financial assets

     

– Financial assets with contractual terms that give rise to SPPI

     7,369        20,067  

– Financial assets with contractual terms that do not give rise to SPPI

     4,129        22,751  
  

 

 

    

 

 

 

Total

     6,246        47,922  
  

 

 

    

 

 

 

 

(i)

Only including securities at fair value through profit or loss, loans (excluding policy loans), available-for-sale securities and held-to-maturity securities.

 

96


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

17

DISCLOSURES ABOUT THE TEMPORARY EXEMPTION FROM IFRS 9 (continued)

 

  (b)

The table below presents the credit risk exposure (ii) for aforementioned financial assets with contractual terms that give rise to SPPI:

 

     Carrying
amount (iii)
As at
30 June 2022
RMB million
     Carrying
amount (iii)
As at
31 December 2021
RMB million
 

Domestic

     

Rating not required (iv)

     832,242        832,127  

AAA

     1,609,337        1,592,582  

AA+

     4,749        6,551  

AA

     30        80  

AA–

     3,000        3,000  
  

 

 

    

 

 

 

Subtotal

     2,449,358        2,434,340  
  

 

 

    

 

 

 

Overseas

     

A+

     757        427  

A

     4,446        4,331  

A–

     13        13  

BBB+

     81        75  

BBB

     1        —    

BBB–

     149        —    
  

 

 

    

 

 

 

Subtotal

     5,447        4,846  
  

 

 

    

 

 

 

Total

     2,454,805        2,439,186  
  

 

 

    

 

 

 

 

  (c)

The table below presents financial assets without low credit risk for aforementioned financial assets with contractual terms that give rise to SPPI:

 

     As at 30 June 2022  
     Carrying
amount (iii)
RMB million
     Fair value
RMB million
 

Domestic

     7,779        5,469  

Overseas

     —          —    
  

 

 

    

 

 

 

Total

     7,779        5,469  
  

 

 

    

 

 

 
     As at 31 December 2021  
     Carrying
amount (iii)
RMB million
     Fair value
RMB million
 

Domestic

     9,631        7,274  

Overseas

     —          —    
  

 

 

    

 

 

 

Total

     9,631        7,274  
  

 

 

    

 

 

 

 

(ii)

Credit risk ratings for domestic assets are provided by domestic qualified external rating agencies and credit risk ratings for overseas assets are provided by overseas qualified external rating agencies.

(iii)

For financial assets measured at amortised cost, the carrying amount before adjusting impairment allowance is disclosed here.

(iv)

Mainly including government bonds and policy financial bonds.

 

97


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS

 

  (a)

Related parties

The table set forth below summarises the names of significant related parties and the nature of relationship with the Company as at 30 June 2022:

 

Significant related parties

  

Relationship with the Company

CLIC    Immediate and ultimate holding company

China Life Asset Management Company Limited (“AMC”)

   A subsidiary of the Company

China Life Pension Company Limited (“Pension Company”)

   A subsidiary of the Company

China Life (Suzhou) Pension and Retirement Investment Company Limited (“Suzhou Pension Company”)

   A subsidiary of the Company

Golden Phoenix Tree Limited

   A subsidiary of the Company

Shanghai Rui Chong Investment Co., Limited (“Rui Chong Company”)

   A subsidiary of the Company

New Aldgate Limited

   A subsidiary of the Company

Glorious Fortune Forever Limited

   A subsidiary of the Company

CL Hotel Investor, L.P.

   A subsidiary of the Company

Golden Bamboo Limited

   A subsidiary of the Company

Sunny Bamboo Limited

   A subsidiary of the Company

Fortune Bamboo Limited

   A subsidiary of the Company

China Life (Beijing) Health Management Co., Limited

   A subsidiary of the Company

Ningbo Meishan Bonded Port Area Guo Yang Guo Sheng Investment Partnership (Limited Partnership)

   A subsidiary of the Company

Ningbo Meishan Bonded Port Area Bai Ning Investment Partnership (Limited Partnership)

   A subsidiary of the Company

Shanghai Yuan Shu Yuan Pin Investment Management Partnership (Limited Partnership)

   A subsidiary of the Company

Shanghai Yuan Shu Yuan Jiu Investment Management Partnership (Limited Partnership)

   A subsidiary of the Company

Shanghai Wansheng Industry Partnership (Limited Partnership) (“Shanghai Wansheng”)

   A subsidiary of the Company

Wuhu Yuanxiang Tianfu Investment Management Partnership (Limited Partnership) (“Yuanxiang Tianfu”)

   A subsidiary of the Company

Wuhu Yuanxiang Tianyi Investment Management Partnership (Limited Partnership) (“Yuanxiang Tianyi”)

   A subsidiary of the Company

CBRE Global Investors U.S. Investments I, LLC (“CG Investments”)

   A subsidiary of the Company

China Life Guang De (Tianjin) Equity Investment Fund Partnership (Limited Partnership) (“CL Guang De”)

   A subsidiary of the Company

Beijing China Life Pension Industry Investment Fund (Limited Partnership) (“CL Pension Industry”)

   A subsidiary of the Company

China Life Qihang Phase I (Tianjin) Equity Investment Fund Partnership (Limited Partnership) (“China Life Qihang Fund I”)

   A subsidiary of the Company

China Life Insurance Sales Company Limited (“CL Sales”)(i)

   A subsidiary of the Company

China Life Franklin Asset Management Company Limited (“AMC HK”)

   An indirect subsidiary of the Company

China Life AMP Asset Management Co., Limited

   An indirect subsidiary of the Company

King Phoenix Tree Limited

   An indirect subsidiary of the Company

China Life Wealth Management Co., Limited

   An indirect subsidiary of the Company

China Century Core Fund Limited

   An indirect subsidiary of the Company

 

98


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (a)

Related parties (continued)

The table set forth below summarises the names of significant related parties and the nature of relationship with the Company as at 30 June 2022 (continued):

 

Significant related parties

  

Relationship with the Company

China Life Franklin (Shenzhen) Equity Investment Fund Management Co., Limited    An indirect subsidiary of the Company

New Fortune Wisdom Limited

   An indirect subsidiary of the Company

New Capital Wisdom Limited

   An indirect subsidiary of the Company

Wisdom Forever Limited Partnership

   An indirect subsidiary of the Company

Dalian Hope Building Company Ltd.

   An indirect subsidiary of the Company

Xi’an Shengyi Jingsheng Real Estate Co., Ltd.

   An indirect subsidiary of the Company

China Life Xing Wan (Tianjin) Enterprise Management Partnership (Limited Partnership)

   An indirect subsidiary of the Company

China Life (Hangzhou) Hotel Company Limited (“CL Hangzhou Hotel”)

   An indirect subsidiary of the Company

China Life Jiayuan (Xiamen) Health Management Company Limited (“CL Jiayuan”)

   An indirect subsidiary of the Company

Sino-Ocean

   An associate of the Company

CGB

   An associate of the Company

China Life Property & Casualty Insurance Company Limited (“CLP&C”)

   An associate of the Company

COFCO Futures Company Limited

   An associate of the Company

China Pipe Group Sichuan to East China Gas Pipeline Co., Ltd.

   An associate of the Company

China Unicom

   An associate of the Company

Joy City Commercial Property Fund L.P.

   A joint venture of a subsidiary of the Company

Mapleleaf Century Limited

   A joint venture of subsidiaries of the Company

China Life Real Estate Co., Limited (“CLRE”)

   Under common control of CLIC

China Life Insurance (Overseas) Company Limited (“CL Overseas”)

   Under common control of CLIC

China Life Investment Management Company Limited (Formerly known as “China Life Investment Holding Company Limited”)(“CLI”)

   Under common control of CLIC

China Life Ecommerce Company Limited (“CL Ecommerce”)

   Under common control of CLIC
China Life Healthcare Investment company limited (“CLHI”)    Under common control of CLIC
China Life Insurance (Group) Enterprise Annuity Fund (“EAP”)    A pension fund jointly set up by the Company and others

 

(i)

For the year ended 31 December 2021, the Group acquired the CL Sales by a business combination under common control. Therefore, the financial statements of the Group were restated for the six months ended 30 June 2021.

 

99


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (a)

Related parties (continued)

The table set forth below summarises the names of significant related parties and the nature of relationship with the Company as at 30 June 2022 (continued):

 

Significant related parties

  

Relationship with the Company

CL AMC-Yuanliu No.1 Insurance Asset Management Product   

A directly and indirectly held consolidated structured entity of the Company

CLI-China Eastern Airlines Group Equity Investment Scheme   

A directly held consolidated structured entity of the Company

China Life-China Hua Neng Debt-to-Equity Swap Investment Scheme   

A directly held consolidated structured entity of the Company

Shan Guo Tou • Jing Tou Corporate Trust Loan Collective Funds Trust Scheme   

A directly held consolidated structured entity of the Company

Jiao Yin Guo Xin • CL China Aluminium Co., Ltd. Supply-side Reform Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

Jian Xin Trust • CL Guo Xin Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

Guang Da • Hui Ying No. 8 Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

Bai Rui Heng Yi No.817 Collective Fund Trust Scheme (Zhong Guo Guo Xin)

  

A directly and indirectly held consolidated structured entity of the Company

Chongqing Trust Fund • Guo Rong No.4 Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

Jiao Yin Guo Xin • Jing Tou Corporate Collective Funds Trust Scheme

  

A directly held consolidated structured entity of the Company

China Life-Yanzhou Coal Mining Co., Ltd. Debt Investment Scheme

  

A directly held consolidated structured entity of the Company

Zhong Hang Trust Fund • Tian Qi [2020] No.372 China Eastern Airlines Equity Instrument Investment Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

Shang Xin-Ningbo Wu Lu Si Qiao PPP Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

Zhong Hang Trust Fund • Tian Qi No.21A155 Perpetual Bond Equity Instrument Investment Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

Kun Lun Trust-China Metallurgical No.1 Collective Fund

  

A directly held consolidated structured entity of the Company

Jiang Su Trust-Xin Bao Sheng No.144 (Jing Tou) Collective Fund Trust Scheme

  

A directly held consolidated structured entity of the Company

China Life-Reform and Development Yunnan State-Owned Enterprises Equity Investment Scheme (Phase I)

  

A directly held consolidated structured entity of the Company

 

100


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (b)

Transactions with significant related parties

 

            For the six months ended 30 June  
     Notes      2022
RMB million
     2021
RMB million
 

Transactions with CLIC and its subsidiaries

        

CLIC

        

Distribution of dividends from the Company and AMC to CLIC

        12,941        12,663  

Policy management fee received from CLIC

     (i) (vii      211        276  

Asset management fee received from CLIC

     (ii.a      70        80  

CLP&C

        

Agency fee received from CLP&C

     (iii) (vii      719        776  

Dividends from CLP&C

        75         

Rental and a service fee received from CLP&C

        46        27  

Asset management fee received from CLP&C

     (ii.c      17        16  

CLI

        

Payment of asset management fee to CLI

     (ii.d) (vii      290        292  

CLHI

        

Payment of a operation management service fee to CLHI

     (vi      48        54  

CL Overseas

        

Asset management fee received from CL Overseas

     (ii.b      39        33  

Transactions with associates and joint ventures

        

CGB

        

Interest received from CGB

        1,415        1,519  

Dividends from CGB (Note 6)

        774        662  

Commission expenses charged by CGB

     (iv      150        130  

Rental received from Pension Company

        88        74  

Insurance premium received from CGB

        85        85  

Sino-Ocean

        

Dividends from Sino-Ocean (Note 6)

        61        168  

Interest of corporate bonds received from Sino-Ocean

        7        8  

Transaction between other associates and joint ventures and the Group

        

Dividends from other associates and joint ventures (Note 6)

        1,154        1,060  

Transaction between EAP and the Group

        

Contribution to EAP

        704        371  

 

101


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (b)

Transactions with significant related parties (continued)

 

            For the six months ended 30 June  
     Notes      2022
RMB million
     2021
RMB million
 

Transactions between other subsidiaries and the Company

        

Payment of an asset management fee

        

Payment of an asset management fee to AMC

     (ii.e) (vii      1,426        1,406  

Payment of an asset management fee to AMC HK

     (ii.f      10        8  

Dividends from subsidiaries

        

Dividends from AMC

        549        432  

Dividends from Pension Company

        241        127  

Dividends from other subsidiaries

        25        —    

Agency fee received

        

Agency fee received from Pension Company for entrusted sales of annuity funds and other businesses

     (v      20        22  

Rental received

        

Rental received from Pension Company

        39        36  

Capital increase in subsidiaries

        

Capital contribution to China Life Qihang Fund I

        2,255        6,364  

CL Guang De

        94         

Capital contribution to Shanghai Wansheng

        12        12  

Capital reduction in subsidiaries

        

Capital reduction from Yuanxiang Tianfu

        35         

Capital reduction from Yuanxiang Tianyi

        35         

Transactions between the consolidated structured entities and the Company

        

Distribution of profits from the consolidated structured entities to the Company

        7,614        7,498  

 

Notes:

 

(i)

On 31 December 2021, the Company and CLIC renewed an insurance agency agreement, effective from 1 January 2022 to 31 December 2024. The Company performs its duties as insurance agent in accordance with the agreement, but does not acquire any rights and profits or assume any obligations, losses and risks as an insurer of the non-transferable policies. The policy management fee was payable annually, and is equal to the sum of (1) the number of policies in force as at the last day of the period, multiplied by RMB14 per policy and (2) 2.5% of the actual premiums and deposits received during the period, in respect of such policies. The policy management fee income is included in other income in the interim condensed consolidated statement of comprehensive income.

 

102


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (b)

Transactions with significant related parties (continued)

Notes (continued):

 

  (ii.a)

In December 2018, CLIC renewed an asset management agreement with AMC, entrusting AMC to manage and make investments for its insurance funds. The agreement is effective from 1 January 2019 to 31 December 2021. In July 2020, CLIC revised the asset management agreement with AMC, effective from 1 July 2020 to 31 December 2022. In accordance with the agreement and the revision, CLIC paid AMC a basic service fee at the rate of 0.08% per annum for the management of insurance funds. The service fee was calculated on a monthly basis and payable on a quarterly basis, by multiplying the average book value of the assets under management (after deducting the funds and interests of positive repurchase transactions and deducting the principal and interests of debt and equity investment schemes, project asset-backed schemes and customised non-standard products) at the beginning and the end of any given month by the rate of 0.08%, divided by 12. According to specific projects, debt investment schemes, equity investment plans, project asset-backed plans, and customised non-standard products are based on the contractual agreed rate, without paying for an extra management fee. At the end of each year, CLIC assessed the investment performance of the assets managed by AMC, compared the actual results against benchmark returns and made adjustment to the basic service fee.

  (ii.b)

In 2018, CL Overseas renewed an investment management agreement with AMC HK, effective from 1 January 2018 to 31 December 2022. In accordance with the agreement, CL Overseas entrusted AMC HK to manage and make investments for its insurance funds and paid AMC HK a basic investment management fee and an investment performance fee. The basic investment management fee was accrued by multiplying the weighted average total funds by the basic fee rate. The investment performance fee was calculated based on the difference between the total actual annual yields and predetermined net realised yield. The basic investment management fee was calculated and payable on a semi-annual basis. The investment performance fee was payable according to the total actual annual yield at the end of each year.

  (ii.c)

On 10 February 2021, CLP&C renewed an agreement for the management of insurance funds with AMC, entrusting AMC to manage and make investments for its insurance funds, effective from 1 January 2021 to 31 December 2023. In accordance with the agreement, CLP&C paid AMC a fixed service fee and a variable service fee. The fixed service fee was calculated on a monthly basis and payable on an annual basis, by multiplying the average net asset value of assets of each category under management at the beginning and the end of any given month by the responding annual investment management fee rate, divided by 12. The variable service fee was payable on an annual basis, and linked to investment performance.

  (ii.d)

On 27 December 2021, the Company and CLI renewed an operation and management agreement of alternative investment of insurance funds, effective from 1 January 2022 to 31 December 2023. The agreement shall be automatically renewed for one year unless either party gives written notice to the other party not to renew it 90 business days prior to the expiration of this agreement. In accordance with the agreement, the Company entrusted CLI to engage in investment, operation and management of non-standard financial products and securitised financial products under the instructions of the annual guidelines. The Company paid CLI an asset management fee, product management fee and a performance related bonus based on the agreement. For existing projects, the management fee rate depended on the rate determined previously; for newly signed projects, the management fee rate was determined by both sides based on market and management pattern, and the maximum rate shall not exceed 0.6%. The performance-related bonus is based on the internal return rate by the Company upon expiry of the project. In addition, the Company adjusts the investment management fees for fixed-income projects and non-fixed-income projects based on the annual evaluation results on CLI’s performance. The adjustment (variable management fee) ranges from negative 2% to positive 2% of the investment management fee in the current period.

  (ii.e)

On 28 December 2018, the Company and AMC renewed the agreement for the management of insurance funds, effective from 1 January 2019 to 31 December 2021. On 1 July 2020, the Company and AMC revised the agreement for the management of insurance funds, effective from 1 July 2020 to 31 December 2022. In accordance with the agreement and the revision, the Company entrusted AMC to manage and make investments for its insurance funds and paid AMC a fixed investment management service fee and a variable investment management service fee. The daily accrued fixed service fee was calculated and payable on a quarterly basis, by multiplying the net value of the total investment assets on the day by the variety-based annual investment management fee rate divided by 360; the variable investment management service fee was payable annually, based on the results of performance evaluation, at 20% of the fixed service fee per annum. Asset management fees charged to the Company by AMC are eliminated in the interim condensed consolidated statement of comprehensive income.

 

103


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (b)

Transactions with significant related parties (continued)

Notes (continued):

 

  (ii.f)

On 29 December 2021, the Company and AMC HK renewed the management agreement of insurance funds investment, which is effective from 1 January 2022 to 31 December 2024. In accordance with the agreement, the Company entrusted AMC HK to manage and make investments for its insurance funds and paid AMC HK an asset management fee on a semi-annual basis. The management fee is determined by market-oriented pricing, and the maximum investment management fee paid annually is RMB30 million. Asset management fees charged to the Company by AMC HK are eliminated in the interim condensed consolidated statement of comprehensive income.

  (iii)

On 31 January 2018, the Company and CLP&C signed an insurance agency framework agreement, whereby CLP&C entrusted the Company to act as an agent to sell designated CLP&C insurance products in certain authorised jurisdictions. The agency fee was determined based on cost (tax included) plus a margin. The agreement is effective for three years, from 8 March 2018 to 7 March 2021. On 20 February 2021, CLP&C and the Company renewed the agreement, effective for two years, from 8 March 2021 to 7 March 2023. CLP&C and CL Sales signed the Strategic Cooperation Agreement on 22 July 2019. According to the agreement, CL Sales, as an agent of insurance products, provides intermediary services for CLP&C. The two parties determine the specific commissions and the standard of sales management fee through fair negotiation, based on the local market price and the paid-in premium which exclude value-added tax and deduct the premium from batch reduction. This agreement is valid for three years, from 22 July 2019 to 21 July 2022.

  (iv)

On 19 October 2018, the Company and CGB renewed an insurance agency agreement to distribute insurance products. All individual insurance products suitable for distribution through bancassurance channels are included in the agreement. CGB provides agency services, including the sale of insurance products, collecting premiums and paying benefits. The Company paid the agency commission by multiplying the net amount of total premiums received from the sale of each category individual insurance products after deducting the surrender premiums in the hesitation period, by the responding fixed commission rate. The commission rates for various insurance products sold by CGB are agreed based on arm’s length transactions. The commissions are payable on a monthly basis. The agreement was effective from the signing date to 16 August 2020. On 22 August 2020, the Company and CGB renewed an insurance agency agreement to distribute insurance products, effective from the signing date to 22 August 2022. On 27 December 2021, the Company and CGB renewed another insurance agency agreement to distribute corporate group insurance products. The corporate group insurance products suitable for distribution through bancassurance channels are included in the agreement. The Company paid the agency commission by multiplying the net amount of total premiums received from the sale of each category group insurance product after deducting the surrender premiums, by the responding fixed commission rate. The commission rates for various insurance products sold by CGB are agreed by reference to comparable market prices of independent third-parties. The commissions are paid on a monthly basis. The agreement is effective for one year from 1 January 2022, with an automatic one-year renewal, no more than twice, if no objections were raised by either party upon expiry.

  (v)

On 29 December 2021, the Company and Pension Company renewed an entrusted sales service agreement for pension business acted by life business. The agreement is effective from 1 January 2022 to 31 December 2024. The business means that Pension Company entrusted the Company to cooperate in selling enterprise annuity funds, pension security business, occupational pension business and the third-pillar pension financial business. According to the agreement, the commissions for the cooperative service of enterprise annuity fund management, which is the core business of Pension Company, are calculated at 50% to 70% of the annual entrusting management fee revenues, depending on the duration of the agreement. The commissions for cooperative account management service are calculated at 60% of the first year’s account management fee and were only charged for the first year, regardless of the duration of the agreement. The commissions for cooperative investment management services, in accordance with the duration of the agreement, are calculated at 35% to 60% of the annual investment management fee (excluding risk reserves for investment). For pension security business, the commissions of the group pension plan are, in accordance with the duration of the contracts, calculated at 50% to 3% of the annual investment management fee, decreasing annually; the commissions of the personal pension plan are calculated at 30% to 50% of the annual investment management fee according to the various rates of the daily management fee applied to the various individual pension management products in all of the management years; the cooperative commissions of occupation annuity and third-pillar pension financial business should be determined by both parties on a separate occasion. The commissions charged to Pension Company by the Company are eliminated in the interim condensed consolidated statement of comprehensive income of the Group.

  (vi)

On 31 December 2021, the Company and CLHI renewed an aged-care projects management service agreement, effective from 1 January 2022 to 31 December 2022. In accordance with the agreement, the Company entrusted CLHI to operate and manage existed aged-care projects and paid CLHI a management service fee. The management service fee was calculated and payable on a quarterly basis, by multiplying the total amount of the investments under management (based on the daily weighted average investment amount) by the annual rate of 2.2%.

  (vii)

These transactions constitute continuing connected transactions which are subject to reporting and announcement requirements but are exempt from independent shareholders’ approval requirements under Chapter 14A of the Listing Rules. The Company has complied with the disclosure requirements in accordance with Chapter 14A of the Listing Rules.

 

104


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (c)

Amounts due from/to significant related parties

The following table summarises the balances due from and to significant related parties. The balances of the Group are all unsecured. The Balances of the Group are non-interest-bearing and have no fixed repayment dates except for deposits with CGB, wealth management products and other securities of CGB, and corporate bonds issued by Sino-Ocean.

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

The resulting balances due from and to significant related parties of the Group

     

Amount due from CLIC

     267        342  

Amount due from CL Overseas

     99        59  

Amount due from CLP&C

     207        258  

Amount due to CLP&C

     25        17  

Amount due from CLI

     25        51  

Amount due to CLI

     426        445  

Amount due from CLRE

     —          2  

Amount due to CLHI

     35        40  

Amount deposited with CGB

     61,141        69,148  

Wealth management products and other financial instruments of CGB

     8,139        8,384  

Amount due from CGB

     1,798        9,138  

Amount due to CGB

     82        80  

Corporate bonds of Sino-Ocean

     408        356  

Amount due from Sino-Ocean

     7        7  

Amount due from CL Ecommerce

     3        3  

Amount due to CL Ecommerce

     5        15  

The resulting balances due from and to subsidiaries of the Company

     

Amount due to AMC

     723        717  

Amount due to AMC HK

     10        8  

Amount due from Pension Company

     80        46  

Amount due to Pension Company

     80        114  

Amount due from Rui Chong Company

     500        604  

 

105


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

18

SIGNIFICANT RELATED PARTY TRANSACTIONS (continued)

 

  (d)

Key management personnel compensation

 

     For the six months ended 30 June  
     2022
RMB million
     2021
RMB million
 

Salaries and other benefits

     10        7  
  

 

 

    

 

 

 

The total compensation package for the Company’s key management personnel has not yet been finalised in accordance with regulations of the relevant PRC authorities. The compensation listed above is the tentative payment.

 

  (e)

Transactions with state-owned enterprises

Under IAS 24 Related Party Disclosures (“IAS 24”), business transactions between state-owned enterprises controlled by the PRC government are within the scope of related party transactions. CLIC, the ultimate holding company of the Group, is a state-owned enterprise. The Group’s key business is insurance and investment related and therefore the business transactions with other state-owned enterprises are primarily related to insurance and investment activities. The related party transactions with other state-owned enterprises were conducted in the ordinary course of business. Due to the complex ownership structure, the PRC government may hold indirect interests in many companies. Some of these interests may, in themselves or when combined with other indirect interests, be controlling interests which may not be known to the Group. Nevertheless, the Group believes that the following captures the material related parties and has applied IAS 24 exemption and disclosed only qualitative information.

As at 30 June 2022, most of the bank deposits of the Group were with state-owned banks; the issuers of corporate bonds and subordinated bonds held by the Group were mainly state-owned enterprises. For the six months ended 30 June 2022, a large portion of group insurance business of the Group were with state-owned enterprises; the majority of bancassurance commission charges were paid to state-owned banks and postal offices; and the majority of the reinsurance agreements of the Group were entered into with a state-owned reinsurance company.

 

19

SHARE CAPITAL

 

     As at 30 June 2022      As at 31 December 2021  
     No. of shares      RMB million      No. of shares      RMB million  

Registered, authorised, issued and fully paid

           

Ordinary shares of RMB1 each

     28,264,705,000        28,265        28,264,705,000        28,265  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

106


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

19

SHARE CAPITAL (continued)

 

As at 30 June 2022, the Company’s share capital was as follows:

 

     As at 30 June 2022  
     No. of shares      RMB million  

Owned by CLIC (i)

     19,323,530,000        19,324  

Owned by other equity holders

     8,941,175,000        8,941  

Including: Domestic listed

     1,500,000,000        1,500  

  Overseas listed (ii)

     7,441,175,000        7,441  
       

 

 

    

 

 

 

Total

     28,264,705,000        28,265  
  

 

 

    

 

 

 

 

  (i)

All shares owned by CLIC are domestic listed shares.

  (ii)

Overseas listed shares are traded on the Stock Exchange of Hong Kong Limited and the New York Stock Exchange.

 

20

PROVISIONS AND CONTINGENCIES

The following is a summary of the significant contingent liabilities:

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Pending lawsuits

     557        506  
  

 

 

    

 

 

 

The Group involves in certain lawsuits arising from the ordinary course of business. In order to accurately disclose the contingent liabilities for pending lawsuits, the Group analysed all pending lawsuits case by case at the end of each interim and annual reporting period. Provision will only be recognised if management determines, based on third-party legal advice, that the Group has present obligations and the settlement of which is expected to result in an outflow of the Group’s resources embodying economic benefits, and the amount of such obligations could be reasonably estimated. Otherwise, the Group will disclose the pending lawsuits as contingent liabilities. As at 30 June 2022 and 31 December 2021, the Group had other contingent liabilities but disclosure of such was not practical because the amounts of liabilities could not be reliably estimated and were not material in aggregate.

 

107


Notes to the Interim Condensed Consolidated Financial Statements (continued)

For the six months ended 30 June 2022

 

21

COMMITMENTS

 

  (a)

Capital commitments

The Group had the following capital commitments relating to property development projects and investments:

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Contracted, but not provided for

     

Investments

     92,729        94,770  

Property, plant and equipment

     1,692        1,528  
  

 

 

    

 

 

 

Total

     94,421        96,298  
  

 

 

    

 

 

 

 

  (b)

Operating lease commitments—as lessor

The future minimum rentals receivable under non-cancellable operating leases are as follows:

 

     As at
30 June 2022
RMB million
     As at
31 December 2021
RMB million
 

Not later than one year

     833        781  

Later than one year but not later than five years

     1,333        1,296  

Later than five years

     122        142  
  

 

 

    

 

 

 

Total

     2,288        2,219  
  

 

 

    

 

 

 

 

108


LOGO


LOGO